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The Effect of Psilocybin on Personality 
By  
Ravital Segal LaBua 
Chair: Paul Wachtel, Ph.D. 
As classic psychedelics are increasingly legalized and reintroduced into the 
psychotherapeutic frame, a deeper understanding of their effect on personality and overall 
wellbeing - as well as their clinical contraindications and potential pitfalls - will prove essential.  
As a result, this study represents a preliminary investigation into the effect of psilocybin 
exposure on a range of personality constructs. 
Methods: Data was collected through a collaboration with The Psychedelic Society, an 
organization that legally administers psilocybin truffles in the Netherlands to self-selecting 
retreat attendees who have been screened for mental health disorders in accordance with Johnson 
et al.’s (2008) widely accepted safety guidelines.  Participants completed the following measures 
via online questionnaire the day before psilocybin exposure, two days after psilocybin exposure, 
and at a one-month follow-up: Brief Symptom Inventory (BSI), Experiences in Close 
Relationships-Revised (ECR-R), Mentalization Scale (MentS), Inventory of Personality 
Organization (IPO), Pathological Narcissism Inventory (PNI), Pro-Environmental Behavior 
(PEB) and the Ryff Scale of Psychological Well-Being (Ryff).  As rigorous double-blind clinical 
studies have linked psychedelic-occasioned mystical experiences to sustained improvement in 
personality-related domains (Maclean et al., 2011; Griffiths et al., 2006; Griffiths et al., 2008, 
Griffiths et al., 2011), the Mystical Experience Questionnaire (MEQ) was also administered.  
 
 v 
Lastly, participants provided self-report responses to open-ended questions regarding subjective 
experiences following psilocybin exposure.  
Results: Due to the Covid-19 pandemic, data collection was prematurely cut short, and only 
preliminary conclusions can be drawn.  Those provisional conclusions include significantly 
improved overall symptomatology (BSI GSI), identity diffusion (IPO-ID) and reality testing 
(IPO-RT) following psilocybin exposure.  Significant interactions were also identified for 
primitive defenses (IPO-PD) and narcissistic grandiosity (PNI-G), with the non-mystical 
experience group trending toward improvement, and the mystical-experience group remaining 
largely unchanged over time.  Due to methodological constraints encountered, these findings 
remain preliminary.  Nevertheless, the presence of multiple significant findings (however 
nascent) within the context of so few participants suggests the possibility of more robust findings 
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“The future may teach us to exercise a direct influence, by means of particular chemical 
substances, on the amounts of energy and their distribution in the mental apparatus. It may be 
that there are other still undreamt-of possibilities of therapy,” -Sigmund Freud, 1940 
 
Classic (serotonergic) psychedelics1 are a group of psychoactive drugs that alter 
consciousness through agonism action at the cortical 5-HT2A (serotonin) receptor (Aixala, dos 
Santos, Hallak, & Bouso, 2018; Bouso, dos Santos, Alcázar-Córcoles, & Hallak, 2018).  
Throughout human history, indigenous peoples have ritually used these substances for medicinal, 
spiritual and therapeutic purposes, including ayahuasca in the Amazonian basin, iboga root in 
West Africa, psychedelic mushrooms in southwestern Mexico and peyote cactus in the western 
United States (Aixala et al., 2018; Furst, 1976; Grinspoon & Doblin, 2001; Nichols, 2016; Sessa, 
2012).   
Industrialized society encountered its own psychedelic when, in 1938, Albert Hoffman 
synthesized lysergic acid diethylamide (LSD) in a Swiss laboratory, inspiring a flurry of clinical 
and scientific interest (Shroder, 2014).  LSD was quickly enlisted as a psychotherapeutic aid for 
patients suffering from a panoply of mental health difficulties, ranging from depression, 
neuroticism and refractory psychoanalytic treatments, to schizophrenia, substance dependence 
 
1 The term ‘hallucinogen’ is considered a misnomer by many, as true hallucinations are not a common feature of the 
substances in question (Carhart-Harris & Goodwin, 2017; Chandler & Hartman, 1960; Ditman & Bailey, 1967; 
Domínguez-Clavé, Soler, Elices, Pascual, Álvarez, De La Fuente Revenga, Friedlander, Feilding & Riba, 2016).  
This text therefore uses the more accurate term ‘psychedelic,’ which combines the Greek words psychē (ψ υ χ ή, 
‘soul’) and dēloun (δ η λ ο ῦ ν, ‘to make visible, to reveal’) to denote ‘mind-revealing’ (Carhart-Harris & Goodwin, 
2017).  The origins of this term can be found in Osmond’s (1957) paper on the topic:  
“I have tried to find an appropriate name for the agents under discussion: a name that will include the 
concepts of enriching the mind and enlarging the vision. Some possibilities are: psychephoric, mind-
moving; psychehormic, mind-rousing;  and psycheplastic, mind-molding.  Psychezymic, mind-fermenting, 
is indeed appropriate. Psycherhexic, mind bursting forth, though difficult, is memorable. Psychelytic, mind-
releasing, is satisfactory. My choice, because it is clear, euphonious, and uncontaminated by other 




and end-of-life anxiety (Johnson, Richards, & Griffiths, 2008; Schmiege, 1963).  By the mid 
1960s, over 1000 peer-reviewed clinical papers had been published on the topic, tracking 
approximately 40,000 patients (Shroder, 2014), detailing notably promising findings (Abramson, 
1967; Ditman, 1968; Passie, 1997) and identifying very few, if any, negative side effects in the 
context of controlled settings (Ditman & Bailey, 1967; Grinspoon & Bakalar, 1979; Grof, 1967; 
Pahnke, Kurland, Unger, Savage & Grof, 1970; Schmiege, 1963).   
Nevertheless, growing socio-political opposition was beginning to cloud this clinical and 
scientific promise.  According to psychedelic historian, Tom Shroder (2014),  
“The release of LSD into the public consciousness coincided suggestively with widening 
fault lines of a culture that would soon be at war with itself. Feminism, 
environmentalism, antimilitarism, anticorporatism, secularism, and the civil rights 
movement all underlined a growing discontent with the status quo, a status quo most 
notably guarded by a white, male elite…It was hard to avoid seeing a connection.” (p. 48)  
 
Indeed, society’s old guard was justified in fearing LSD’s influence on the counterculture, as 
research has since suggested a relationship between the use of classic psychedelics and decreased 
materialism (Grof, 1970; Savage, Fadiman, Mogar, & Allen, 1966), social status strivings 
(Savage et al., 1966) and authoritarian political views (Grof, 1970; Lyons, Taylor, & Carhart-
Harris, 2018; Nour, Evans, & Carhart-Harris, 2017), as well as increased environmentalism 
(Doblin, 1991; Forstmann & Sagioglou, 2017; Grof, 1970; Lyons et al., 2018; Nour et al., 2017; 
Watts, Day, Krzanowski, Nutt, Carhart-Harris, Bossis, & Grob, 2017), progressive politics (Nour 
et al., 2017) and political activism (Doblin, 1991).   
 Simultaneously serving as both a cause - as well as a reflection - of mounting social 
anxiety, the mid-1960s saw an alarmist media campaign (Carhart-Harris & Goodwin, 2017; 
Ditman, 1968) detailing sensational, anecdotal and often unsourced stories, with lurid headlines 
linking LSD to a range of horrors, including gangrene, blindness, narcotic addiction, leukemia, 
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birth defects, chromosomal damage, psychosis, suicide, crime and murder (Baumeister & 
Placidi, 1983; Johnson et al., 2008; Shroder, 2014).  In 1966, two clinical researchers, Walter 
Pahnke and William Richards (1966), issued a prescient warning:   
“We are confronted by the very real possibility that the known and unknown uses of 
these drugs that could prove to be legitimate and beneficial for individual persons and 
society may be suppressed until some future century when investigation will be permitted 
to proceed unhampered by popular hysteria and over-restrictive legislation. In the United 
States, interested and capable scientists are hesitating to investigate this field because of 
the abundance of unfavorable publicity and the threat of condemnation…Paradoxically, a 
significant danger confronting our society may lie in losing out on the values that the 
responsible use of these drugs may offer.” (p. 176) 
 
Strikingly, history has revealed Walter Pahnke to be both capable of prophecy as well as 
hypocrisy.  In 1991, Rick Doblin conducted a long-term follow-up of Pahnke’s famous 1962 
Marsh Chapel Experiment (during which Harvard divinity students ingested psilocybin while 
attending a Good Friday church service) and unexpectedly uncovered Pahnke’s own bias, as the 
published findings “significantly underemphasized the difficult psychological struggles 
experienced by most of the psilocybin subjects,” (p. 24).  Doblin (1991) surmises: 
“With some proponents of psychedelics exaggerating the benefits and minimizing the 
risks, a backlash against these substances was predictable. With the intriguing connection 
reported by several psilocybin subjects between mystical experiences and political action, 
the backlash in retrospect may have been inevitable.” (p. 24) 
 
Ultimately, following a moral outcry without scientific basis (Nutt, King & Nichols, 
2013; Winkelman, Roberts & Thomas, 2007), Congress passed the United States Controlled 
Substances Act of 1970, which classified serotonergic psychedelics as a Schedule 1 drug and 
effectively halted academic research for over thirty years (Johnson et al., 2008; Shroder, 2014).  
In order to receive a Schedule 1 classification, a drug must: 1) lack safety under medical 
supervision, 2) carry high abuse potential, and 3) have no accepted medicinal value (Nutt et al., 
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2013).  As Winkelman and colleagues (2007) point out, (and as the following discussion 
explores), with regard to classic psychedelics, “none of these statements are defensible,” (p. 85). 
The effects of classic psychedelics are directly linked to “set and setting,” (Grof, 1967; 
Johnson et al., 2008; Mogar, Savage, Gendlin, & Eugene, 1964; Pahnke, 1969; Savage, Terrill, 
& Jackson, 1962; Schmiege, 1963; Sherwood, Stolaroff & Harmon, 1968; Studerus, Gamma, 
Kometer, & Vollenweider, 2012), a phrase first coined by the (in)famous psychedelic researcher, 
Timothy Leary (Leary, Litwin & Metzner, 1963, p. 572).  Instead of narrowly addressing a 
specific symptom formation, classic psychedelics instead operate as “powerful catalysts,” 
(Metzner, 1998, p. 340), “unspecific amplifiers,” (Grof, 1979, p. 52) and “microscopes” (Watts, 
1962, p. 15) that “[strip] off the protective barriers of the ego,” (Savage et al., 1962, p. 430), 
release unconscious material (Chandler & Hartman, 1960; Cutner, 1959; Grof, 1970; Majić, 
Schmidt & Gallinat, 2015; Pahnke & Richards, 1966; Savage et al., 1962; Savage, Savage, 
Fadiman & Hartman, 1964; Sherwood et al., 1968; Studerus, Kometer, Hasler & Vollenweider, 
2011; Tenenbaum, 1961; Unger, 1963; Winkelman et al., 2007) and magnify both internal and 
external inputs, regardless of valence (Savage et al., 1962).  Thus, the psychedelic encounter 
varies widely as a function ‘set’ (intrapsychic factors, such as personal expectations, mood, and 
ability to surrender to the experience) and ‘setting’ (environmental context, such as experimenter 
expectations, availability of support and cultural milieu) (Johnson et al., 2008; Leary et al., 1963; 
Pahnke, 1969; Sherwood et al., 1968; Studerus et al., 2012).  Put another way, 
“[The psychedelic experience is] the result of a complex set of determinants, only one of 
which is the ingestion of a particular chemical agent. The significance of contradictory 
results obtained with LSD therapy have often been obscured by the persistent search for 
‘drug specific’ reactions.  Inconsistent findings become more understandable if the 
response to LSD is viewed as the resultant of complex transactions between the patient, 
the therapist, set or expectation, and the setting. In short, the administration of LSD is 




With proper preparation and support, classic psychedelics may potentiate a therapeutic 
encounter; absent such conditions, the very same substance may precipitate anxiety, depression, 
and even acute or chronic psychosis (Ditman, 1968).  As Doblin (1991) points out, “Some of the 
backlash that swept psychedelics out of the research labs and out of the hands of physicians and 
therapists can be traced in part to the thousands of cases of people who took psychedelics in non-
research settings, were unprepared for the frightening aspects of their psychedelic experiences 
and ended up in hospital emergency rooms,” (p. 24).  
In a recreational context, where contraindications may be poorly understood, classic 
psychedelics are not risk-free (Cohen, 1960; McGlothlin & Arnold, 1971; Strassman, 1984; 
Winkelman et al., 2007).  No matter how rare, these risks can prove serious and therefore 
necessitate clear-eyed consideration.  Most concerningly, classic psychedelics have precipitated 
prolonged psychoses in individuals who are genetically loaded for psychotic disorders (Cohen, 
1960; Johnson et al., 2008; Schmiege, 1963; Winkelman et al., 2007).  As Johnson et al. (2008) 
point out, it is unknown whether psychosis represents an inevitable reality for such individuals, 
or whether a psychotic break could have been avoided in the absence of drug exposure. As a 
result of these findings, current safety guidelines exclude individuals who either meet criteria (or 
have first- or second-degree relatives who meet criteria) for bipolar or psychotic disorders 
(Johnson et al., 2008).  Research studies that exclude such participants consistently report no 
evidence of psychotic sequelae in their subject pools (Gasser, 1996; Studerus et al., 2011).  
Classic psychedelics have also been linked to flashback phenomena, whereby individuals 
re-experience perceptual irregularities initially encountered while under the influence, such as 
seeing flashes of color (Winkelman et al., 2007).  Although these experiences are often 
characterized as pleasurable, thought-provoking, benign and short-lived (Frecska & Luna, 2006; 
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Lerner, Gelkopf, Skladman, Oyffe, Finkel, Sigal et al., 2002; Strassman, 1984; Winkelman et al., 
2007), they are occasionally (albeit rarely) associated with clinical distress and impaired 
functioning (Baggott, Erowid, Erowd, Robertson, 2006; Cohen, 1960; Halpern & Pope, 2003; 
Lerner et al., 2002; McGlothlin & Arnold, 1971).  In such instances, a diagnosis of Hallucinogen 
Persisting Perception Disorder (HPPD) may be warranted (American Psychiatric Association, 
2013).  Although the incidence of HPPD is currently unknown, it is considered “very 
uncommon,” (Halpern, Lerner, & Passie, 2016; Johnson et al., 2008, p. 608; Linszen, Kleijer, & 
Sommer, 2017).  Notably, reports of HPPD are higher in uncontrolled settings (where polydrug 
use2 and unscreened psychiatric disorders likely represent confounding variables) and lower in 
clinical research settings with carefully screened subject pools (Cohen, 1960; Halpern & Pope, 
2003; McGlothlin & Arnold, 1971; Strassman, 1984). 
As classic psychedelics are known to activate unconscious material (Chandler & 
Hartman, 1960; Cutner, 1959; Majić et al., 2015; Savage et al., 1962; Savage et al., 1964; 
Studerus et al., 2011; Tenenbaum, 1961; Unger, 1963; Winkelman et al., 2007), individuals may 
also encounter challenging emotions while under the influence, as well as in the days and weeks 
that follow (Carhart-Harris, Kaelen, Bolstridge, Williams, Williams, Underwood, & Nutt, 2016; 
Cohen & Eisner, 1958; Grof, 1967; Johnson et al., 2008).  As Savage et al. (1962) point out,  
“Once we open Pandora’s box, we cannot always control what flies out. The 
[psychedelic] experience may strip the patient of his capacity for lies and rationalization; 
he may see himself in all his psychological nakedness. To expose him so violently and 
suddenly to his shortcomings may only increase his guilt to an intolerable degree…the 
intervention of the therapist makes the difference between a helpful and a damaging 
experience.” (p. 429)  
 
 
2 Current safety guidelines exclude individuals who are taking tricyclic antidepressants, lithium, serotonin reuptake 
inhibitors (SSRIs) and haloperidol, as these drugs potentiate psychedelic effects (Johnson et al., 2008).  
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Thus, psychotherapeutic supports are at times necessary in order to help individuals successfully 
process and integrate new psychological landscapes (Johnson et al., 2008; Pahnke et al., 1970; 
Studerus et al., 2011).  As Pahnke & Richards (1966) further clarify,  
“[Challenging psychedelic] experiences may be useful in facilitating psychotherapy if a 
competent therapist is available both at the time these experiences occur and in the 
following weeks to help the patient integrate feelings and insights.  Without competent 
psychiatric supervision, such experiences may, at best, remain frightening memories and, 
at worst, cause a person to decompensate under the stress.” (p. 187) 
 
In particularly unsupportive, over-stimulating or stressful environments, classic 
psychedelics may also precipitate overwhelming anxiety in the form of transient 
psychotomimetic (psychotic-like) experiences (Carhart-Harris et al., 2016; Cohen & Eisner, 
1958; Ditman, 1968; Savage et al., 1962).  As a result, early investigators initially administered 
classic psychedelics in a misguided attempt to create and then study model psychoses (Belleville, 
1956; Savage et al, 1962).  This practice quickly fell out of favor once the psychotomimetic 
experience was understood to be a reflection of the disturbing context within which drug 
administration occurred and not an inherent quality of the psychedelic experience itself (Savage 
et al., 1962; Unger, 1963).  As Pahnke & Richards (1966) contend,  
“When subjects were given a psychedelic drug without knowing what to expect or how to 
respond, often being left alone in a dark room or threatened by unfamiliar researchers 
demanding cooperation in psychological testing, it is easy to understand why many 
experiences quickly became psychotic. If nonpsychotic experiences are desired, subjects 
must be prepared, must feel secure in a friendly environment, and above all must be 
willing and able to trust reality greater than themselves.” (p. 188) 
 
Although extremely rare, individuals under the influence of classic psychedelics have 
also acted violently toward others, as well as toward themselves (Johnson et al., 2008; Keeler & 
Reifler, 1967; O’Brien, 2006; Reitman & Vasilakis, 2004; Reynolds & Jindrich, 1985).  These 
incidents almost exclusively occur in the context of hazardous and unsupervised settings, carried 
out by individuals with severe pre-existing psychopathology (Cohen, 1960; Winkelman et al., 
 
 8 
2007).  Cohen’s (1960) study, which synthesized data from 5,000 individuals (and approximately 
25,000 psychedelic exposures), found 0 attempts or completed suicides by (healthier) research 
participants following drug exposure, and 1.2 attempts and .4 completed suicides per 1000 
patients (suffering from pre-existing psychopathology).  According to Cohen, the majority of 
these suicides could not be definitively and causally linked to the psychedelic experience.  Of 
note, other investigators have since reported similar findings (Gasser, 1996; Malleson, 1971).  
Nevertheless, according to Johnson et al.’s (2008) widely accepted safety guidelines:3  
“Even under unsupervised and unprepared conditions, reactions to hallucinogens 
involving violence and self-destructive behavior are rare, and our intention is not to 
create an unrealistic account of the dangers of hallucinogens.  Nonetheless, even 
infrequent reports of such dangers require that investigators take seriously such risks and 
take steps to avoid their occurrence.” (p. 607) 
 
Importantly, once researchers and clinicians recognized the profound impact of set and 
setting on the psychedelic experience, the frequency of adverse reactions dropped precipitously 
(Johnson et al., 2008).  In the context of controlled and supportive settings, and with the 
implementation of relevant exclusion criteria, classic psychedelics demonstrate safety and 
tolerability in both the short- and long-term (Dos Santos, R., Osório, F., Crippa, J., Riba, J., 
Zuardi, A., & Hallak, J. 2016; Pahnke et al., 1970; Schmiege, 1963; Strassman, 1984; Studerus et 
al., 2011; Winkelman et al., 2007).  Within the discipline of psychopharmacology, acute drug 
toxicity is traditionally measured with what’s called the therapeutic index: a ratio of the lethal 
dose for 50% of subjects (LD50) to the effective dose for 50% of subjects (ED50) (Winkelman et 
al., 2007).  With higher numbers reflecting safer profiles, classic psychedelics have therapeutic 
indices above 600, compared to aspirin’s index of 199 and nicotine’s of 21 (Winkelman et al., 
2007).  Indeed, normal functioning is almost completely restored within 24 hours after drug 
 
3 Johnson et al.’s (2008) safety guidelines are written for “high-dose hallucinogen research” (e.g. ≥ 25 mg psilocybin 
or 200 mcg LSD) (p. 604) 
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administration (Studerus et al., 2011) and complications are both rare and unimpressive (Aixalà, 
et al., 2018; Ditman & Bailey, 1967; Grof, 1967; Studerus et al., 2011), most often including 
headache, fatigue and mild somatic discomfort (Johnson et al., 2008; Studerus et al., 2011).  
Additionally, classic psychedelics are not associated with increased psychopathology (Bouso, 
Palhano-Fontes, Rodriguez-Fornells, Ribeiro, Sanches, Crippa, & Riba, 2015; Dos Santos, 
Osório, Crippa, & Hallak, 2016; Johansen & Krebs, 2015; Krebs & Johansen, 2013), 
neurocognitive decline (Barbosa, Strassman, Da Silveira, Areco, Hoy, Pommy, Thoma, & 
Bogenschutz, 2016; Bouso et al., 2015; Dos Santos et al., 2016b; Halpern & Pope, 1999; 
Halpern, Sherwood, Hudson, Yurgelun-Todd & Pope, 2005), organ impairment (Gable, 1993; 
Gable, 2004; Nichols, 2004; Strassman, 1984) or chromosomal damage - as was falsely 
contended by an anti-LSD, government-funded media campaign in the late 1960s (Johnson et al., 
2008).  To the contrary, classic psychedelics carry a positive side-effect profile (Carhart-Harris 
& Goodwin, 2017), as they are associated with lower rates of suicidality and psychopathology 
(Hendricks, Johnson & Griffiths, 2015; Johansen & Krebs, 2015; Krebs & Johansen, 2013), and 
preliminarily linked to strengthened neurocognitive capacity (Bouso et al., 2015). 
Additionally, although classic psychedelics evidence a tolerance effect (and therefore 
require increasingly higher doses to produce similar effects over time) (Winkelman et al., 2007), 
they are not physiologically addictive and are therefore not associated with compulsive drug 
seeking or withdrawal symptoms (Johnson et al., 2008; McGlothlin & Arnold, 1971; National 
Institute on Drug Abuse [NIDA], 2001; NIDA, 2006; O’Brien, 2006; Pahnke et al., 1970; 
Studerus et al., 2011; Winkelman et al., 2007).  Quite the opposite, classic psychedelics may 
have antiaddictive effects and have been successfully employed in the treatment of substance 
dependence (Barbosa et al., 2016; Dos Santos et al., 2016b; Mascher, 1967). 
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 Overall, when viewed through the lens of the scientific literature, the Schedule 1 
categorization of classic psychedelics is unjustified, as these substances are neither addictive, 
lacking in medicinal value, nor unsafe in the context of controlled settings.  Nevertheless, as a 
function of socio-political pressure, the first wave of classic psychedelic research came to an end 
in the early 1970s (Carhart-Harris & Goodwin, 2017; Johnson et al., 2008; Nutt et al., 2013; 
Strassman, 1991).  As Johnson et al. (2008) point out, “the decades-long virtual dormancy of 
human hallucinogen research stands as a unique case in the history of modern clinical 
pharmacology,” (p. 604).  Importantly, we are currently in the midst of “an intriguing new 
zeitgeist in modern psychiatry,” (Watts et al., 2017, p. 521), as classic psychedelics are 
experiencing a renaissance (Carhart-Harris & Goodwin, 2017).  Indeed, the second wave of 
research into classic psychedelics, which tentatively began in the early 1990s, is currently 
cresting, with a 2017 academic conference representing the largest to date, with over 3000 





















Personality change constitutes an important area of investigation within both the first and 
second wave of classic psychedelic research.  Although clinicians and researchers have long 
viewed personality as a potent predictor of physical, emotional and relational health (Borghans, 
Duckworth, Heckman & Ter Weel, 2008; Ozer & Benet-Martínez, 2006; Roberts, 2006; Roberts, 
Kuncel, Shiner, Caspi & Goldberg, 2007), a widespread and discouraging consensus also casts 
personality as an entity that changes only incrementally and over a time horizon of many years 
(Erritzoe, Roseman, Nour, Maclean, Kaelen, Nutt & Carhart-Harris, 2018; Roberts, 2006).  It’s 
therefore striking to note that preliminary research links psychedelic exposure to accelerated 
rates of personality change (Aixalà et al., 2018; Chandler & Hartman, 1960; Erritzoe et al., 2018; 
Savage et al., 1966; Tenenbaum, 1961).   
In order to map the territory already traversed by psychedelic researchers on the topic of 
personality, a literature review was conducted with the following search strategy.  First, an 
electronic search was performed in the Academic Search Complete database (1887-2019) using 
the following search terms: (psychedelic OR hallucinogen OR mescaline OR psilocybin OR 
lysergic acid diethylamide OR dimethyltryptamine OR ayahuasca) AND (personality*).  Next, in 
light of the fact that first-wave publications from the mid-twentieth century are not widely 
accessible online, all reference lists were then manually reviewed for additional studies and 
downloaded from the Multidisciplinary Association for Psychedelics Studies (1931-1995) 
Psychedelic Bibliography (MAPS, 2018). 
 In keeping with convention, this literature review only included classic (serotonergic) 
psychedelics and excluded similar substances with a different mechanism of action, such as 
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empathogens (e.g., MDMA) and dissociative anesthetics (e.g., ketamine) (Bouso et al., 2018; 
Johnson et al., 2008).  Classic psychedelics are distinguished by their agonism action at the 
cortical 5-HT2A serotonin receptor and include substances such as mescaline, psilocybin, 
dimethyltryptamine (DMT) and lysergic acid diethylamide (LSD) (Aixalà et al., 2018).  In 
addition to a shared biochemical interaction, serotonergic psychedelics also create a similar 
profile of subjective effects (Unger, 1963), as well as a unique constellation of therapeutic 
benefits.  According to Carhart-Harris & Goodwin (2017), with proper preparation and support, 
classic psychedelics encourage individuals to “address rather than suppress or side-step aversive 
memories and emotions,” which may distinguish this class of drugs from “alternative, largely 
‘palliative’ [pharmacological] treatment options,” (p. 2107).  Additionally, classic psychedelics 
are notable for their physiological non-addictiveness (Johnson et al., 2008; McGlothlin & 
Arnold, 1971; NIDA, 2001; NIDA, 2006; O’Brien, 2006; Pahnke et al., 1970; Studerus et al., 
2011; Winkelman et al., 2007).   
This literature review yielded 27 articles on the topic of personality from the first wave of 
psychedelic research (published between 1956 and 1980) and 27 articles from the second wave 
(published between 1991 and 2018).  In order to cast a wide net and avoid a priori assumptions 
regarding the definitional parameters of personality, articles were included that discuss mood, 
behavior, attitudes, values, neurocognitive capacity and self/ego structure.   
First-wave articles almost exclusively share a psychoanalytic orientation and include 17 
research studies (Belleville, 1956; Bottrill, 1969; Cohen & Eisner, 1958; Cohen, 1969; Chandler 
& Hartman, 1960; Cwynar & Rydyznski, 1966; Ditman & Bailey, 1967; Hartung, Jurgen & 
Skorka, 1980; Keeler & Reifler, 1967; McGlothlin & Arnold, 1971; Mogar et al., 1964; Rinkel, 
DiMascio, Robey & Atwell, 1961; Savage et al., 1964; Savage et al., 1966; Savage, Hughes & 
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Mogar, 1968; Tenenbaum, 1961; Von Felsinger, Lasagna & Beecher, 1956), 6 theoretical pieces 
(Cutner, 1959; Grof, 1967; Grof, 1970; Osmond, 1957; Savage et al., 1962; Unger, 1963), 2 case 
reports (Schoen, 1964; Sherwood, Stolaroff & Harman, 1962) and 1 systematic review (Mascher, 
1967).  With regard to first-wave research, the most studied psychedelic is LSD (14 studies), 
followed by psilocybin (3 studies), and the most common outcome measure is the Minnesota 
Multiphasic Personality Inventory (MMPI) (9 out of 17 studies), followed by therapist 
assessment of diagnostic change (3 studies).  Additionally, first-wave investigators most 
frequently studied classic psychedelics through the lens of psycholytic psychotherapy, where 
psychedelic exposure was repeated over the course of months to years, embedded within the 
context of long-term psychotherapeutic treatment (Ditman, 1968; Grof, 1970; Majic et al., 2015; 
Pahnke, 1969; Pahnke et al., 1970).  As a result, first-wave subject pools span the diagnostic 
spectrum, skew toward severe pathology, and include mood disturbances, substance addiction, 
personality pathology and psychosis.   
Second-wave articles include 24 research studies (Barbosa, Ribeiro, Cazorla, Giglio & 
Strassman, 2009; Barbosa et al., 2016; Barrett, Johnson & Griffiths, 2017; Borg, Andrée, 
Soderstrom & Farde, 2003; Bouso, González, Fondevila, Cutchet & Fernández, Barbosa, 
Alcazar-Córcoles, Araújo, Barbanoj, Fábregas & Riba, 2012; Bouso et al., 2015; Carhart-Harris 
et al., 2016; Doblin, 1991; Erritzoe et al., 2018; Forstmann & Sagioglou, 2017; Griffiths, 
Richards, McCann & Jesse, 2006; Griffiths, Richards, Johnson, McCann & Jesse, 2008; 
Griffiths, Johnson, Richards, Richards, McCann & Jesse, 2011; Kavenská, Simonová, Kavenská 
& Simonová, 2015; Lebedev, Kaelen, Lövdén, Nilsson, Feilding, Nutt & Carhart‐Harris, 2016; 
Lerner & Lyvers, 2006; Lyons & Carhart-Harris, 2018; Maclean, Johnson & Griffiths, 2011; 
Nour et al., 2017; Schmid & Liechti, 2018; Studerus et al., 2011; Studerus et al., 2012; 
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Tagliazucchi, Roseman, Kaelen, Orban, Muthukumaraswamy, Murphy, Laufs, Leech, 
Mcgonigle, Crossley, Bullmore, Williams, Bolstridge, Feilding, Nutt & Carhart-Harris, 2016; 
Watts et al., 2017), 3 systematic reviews (Bouso et al., 2018; Rucker, Jelen, Flynn, Frowde & 
Young, 2016; Dos Santos, Osório, Crippa & Hallak, 2016) and 1 literature review (Domínguez-
Clavé et al., 2016).  Among second-wave research, the most studied psychedelic is psilocybin 
(11 studies), followed by ayahuasca (5 studies) and LSD (4 studies).  Additionally, second-wave 
research most commonly utilizes trait-based (e.g., Five-Factor Model) outcome measures from 
the discipline of personality psychology, such as the NEO Personality Inventory-Revised (NEO 
PI-R) (5 out of 24 studies), the Temperament and Character Inventory (TCI) (4 studies), the Big 
Five Inventory (BFI) (2 studies), Freiburg Personality Inventory (FPI) (2 studies) and the Ten 
Item Personality Inventory (TIPI) (2 studies).  On the whole, and in contrast to first-wave 
research, second-wave methodologies do not investigate classic psychedelics in the context of 
long-term psychotherapeutic treatment but, instead, administer 1-2 psychedelic doses in a 
supportive setting, with the possibility of follow-up psychotherapeutic supports when necessary.  
Drawing an additional comparison to first-wave subject pools, second-wave research participants 
skew in a diagnostically healthier direction, as contemporary safety guidelines exclude psychotic 
and bipolar disorders (Johnson et al., 2008), with a subset of investigators also excluding 
personality disorders, substance dependence and neuroticism (Bouso et al., 2018; Winkelman et 
al., 2007).   
First-wave studies are often critiqued for failing to meet modern-day methodological 
standards (Studerus et al., 2012).  This scrutiny is undeniably warranted, as early findings often 
rely on anecdotal clinical accounts (Johnson et al., 2008) and research designs that lack adequate 
sample sizes (Bouso et al., 2018; Mogar et al., 1964; Winkelman et al., 2007), standardized 
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clinical interventions (Winkelman et al., 2007), control groups with random assignment (Carhart-
Harris & Goodwin, 2017; Mogar et al., 1964; Winkelman et al., 2007), psychometrically reliable 
outcome measures (Bouso et al., 2018; Mogar et al., 1964) and blind raters (Winkelman et al., 
2007).  Even still, the first-wave research included in this literature review collectively details 
psychedelic-assisted psychotherapeutic work with thousands of patients.  It would therefore 
prove intellectually imprudent to disregard the (albeit preliminary) clinical insights on offer. 
Although second-wave research has adopted notably more stringent standards with regard 
to experimental design and outcome measures (Carhart-Harris & Goodwin, 2017), psychedelic 
research nevertheless continues to face methodological challenges.  Promising drug liberalization 
efforts notwithstanding, the illegal status of classic psychedelics continues to compromise 
research, as investigators are not infrequently obliged to implement observational and 
correlational designs, which, in turn, undermine causal claims (Bouso et al., 2018; Kavenská et 
al., 2015; McGlothlin & Arnold, 1971; Nour et al., 2017).  Of course, this arrangement supports 
a circular logic, whereby classic psychedelics are frequently disregarded by the mainstream due 
to a lack of sound data.  Even for those few institutions that successfully clear the formidable 
regulatory, legal and financial hurdles, the double-blind standard remains difficult to achieve, as 
it’s often obvious when a psychedelic has been administered (Doblin, 1991; Grinspoon & 
Doblin, 2001).   
Most relevant to the topic of this literature review, what the second wave gained in 
methodological rigor, it also lost in clinical nuance.  Though psychometrically sound, second-
wave outcome measures reflect the Five-Factor Model’s trait-based taxonomy of personality, 
which reduces personality to five constructs (also known as the Big Five personality traits): 
extraversion, neuroticism, conscientiousness, agreeableness and openness.  As Funder (2001) 
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points out, “this lack of comprehensiveness becomes a problem when researchers, seduced by 
convenience and seeming consensus, act as if they can obtain a complete portrait of personality 
by grabbing five quick ratings,” (p. 201).  Conversely, while first-wave research is 
methodologically messy, its psychoanalytic paradigm renders a much more nuanced and 
phenomenological exploration of personality.  As a result, this literature review integrates first- 
and second-wave data in order to present a complete picture of what is currently known 
regarding the relationship between classic psychedelics and personality.   
Overall, this literature review preliminarily links psychedelic exposure (in the context of 
supportive and supervised settings) to shifts in the following (interdependent and overlapping) 
personality-related domains: 1) Personality Traits, 2) Neurocognitive Capacity, 3) Mood and 
Emotional Repertoire, 4) Personality Pathology and Psychosis, 5) Relationship to Self and the 
Interpersonal Other, 6) Relationship to the Collective Other, and 7) Spirituality and Relationship 
to the Universal Whole. 
Personality Traits 
Representing one of the most widely documented findings of second wave (personality-related) 
research, increased openness constitutes a reliable mid- to long-term effect of psychedelic 
exposure (Barbosa et al., 2016; Carhart-Harris et al., 2016; Erritzoe et al., 2018; Maclean et al., 
2011; Nour et al., 2017).  Within the Five-Factor taxonomy of personality, this trait encompasses 
openness to ideas, actions, feelings, values, fantasy and aesthetics (McCrae & Costa, 2010).  
Though identified far less frequently, psychedelic exposure is also preliminarily linked to 
decreased neuroticism (anxiety, insecurity, emotionality) (Erritzoe et al., 2018), increased 
extraversion (sociability, optimism, loquaciousness) (Erritzoe, 2018; Kavenská et al., 2015), and 
increased agreeableness (pro-social tendencies and altruism) (Barbosa et al., 2016).  It is perhaps 
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relevant to note that no Five-Factor data yet exists linking psychedelic exposure to increased 
conscientiousness (self-discipline, efficiency, impulse control).  Although first-wave research 
does not assess personality through the Five-Factor lens, it nevertheless provides support for 
similar trait-based change, with evidence linking psychedelic exposure to increased open-
mindedness (Savage et al., 1966), aesthetic appreciation (Ditman & Bailey, 1967; Savage et al., 
1962), creativity (Hartung et al., 1980), imaginative fantasy (Hartung et al., 1980), optimism 
(Grof, 1970), and empathy (Ditman & Bailey, 1967; Grof, 1970; Hartung et al., 1980). 
Neurocognitive Capacity  
This literature review identifies a nascent connection between classic psychedelics and 
improved neurocognitive capacity.  According to Bouso et al.’s (2012) study, when compared to 
controls, 127 ritual ayahuasca users (with a minimum of two ayahuasca ceremonies per month 
for at least 15 years) performed better on neurocognitive tasks, such as the Stroop test (which 
measures processing speed, selective attention and automaticity), the Wisconsin Card Sorting 
Test (attention, working memory and visual processing) and the Letter-Number Sequencing task 
from the Wechsler Adult Intelligence Scale III (working memory).  Preliminary research also 
links acute and long-term ayahuasca exposure to improved planning and inhibitory control (Dos 
Santos et al., 2016c).  Perhaps most strikingly, classic psychedelics anecdotally generate 
“creative insights into complex problems” (Friedman, 2013, p. 354), with two Nobel Prize 
winners, Francis Crick and Kary Mullis, partially crediting experiences with LSD for their 
respective prize-winning discoveries of DNA’s double helical structure and molecular biology’s 





Mood and Emotional Repertoire 
Both first- and second-wave research link psychedelic exposure to decreased guilt (Grof, 
1970), anxiety (Dos Santos et al., 2016a; Grof, 1970; Mascher, 1967; Savage et al., 1962; Savage 
et al., 1964; Savage et al., 1968), and depression (Barbosa et al., 2016; Dos Santos et al., 2016a; 
Grof, 1970; Lyons et al., 2018; Mascher, 1967; Rucker et al., 2016).  According to Rucker et 
al.’s (2016) meta-analysis, which synthesizes data from 19 first-wave studies examining the 
therapeutic use of psychedelics in the treatment of unipolar mood disorders (and which includes 
diagnoses such as contemporary depressive disorder with co-morbid anxiety, as well as more 
antiquated classifications, such as ‘neurotic’ and ‘psychoneurotic’ disorders), 79.2% of patients 
(335 out of 423) evidenced “clinician-judged improvement” (p. 1220) following psychedelic-
assisted treatment.  Correspondingly, classic psychedelics are also associated with improved 
mood (Dos Santos et al., 2016a; Griffiths et al., 2011; Schmid & Liechti, 2018), increased 
equanimity (Doblin, 1991; Griffiths et al., 2008; Grof, 1970; Kavenská et al., 2015; Watts et al., 
2017), a more positive outlook on life (Carhart-Harris et al., 2016; Griffiths et al., 2011; Grof, 
1970; Kavenská et al., 2015; Schmid & Liechti, 2018), and an expanded emotional repertoire 
(Savage et al., 1962; Watts et al., 2017).  According to 6-month follow-up interviews with three 
separate subjects who had participated in Watts et al.’s (2017) open-label trial of psilocybin for 
treatment-resistant depression: “I used to get angry about having anxiety, now I think I can have 
the anxiety, I can just feel it and it will go, I don’t have to have the fear or run away,” (p. 541).  
“I used to just put [bad things in the back of my mind].  After [the psilocybin experience], I 
[allow] myself to experience everything – even if it is sadness.  Now I know how to deal with my 
feelings rather than repress them,” (p. 541).  “I have a felt sense of acceptance; more acceptance 
of agony, boredom, loneliness, and also appreciation of the wonderful times.  [A] willingness to 
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try to accept the negative times,” (p. 541).  Perhaps due to a lessened need for maladaptive 
coping strategies, psychedelic exposure is also associated with reduced substance use (Barbosa et 
al., 2016; Dos Santos et al., 2016a; Krebs & Johansen, 2013; Mascher, 1967).   
Personality Pathology and Psychosis 
Although second-wave investigators have failed to pick up this thread, first-wave 
research explores psychedelic-assisted psychotherapy as a potential treatment modality for 
personality pathology (Belleville, 1956; Bottrill, 1969; Chandler & Hartman, 1960; Cohen & 
Eisner, 1958; Cutner, 1959; Cwynar & Rydzynski, 1966; Grof, 1967; Grof, 1970; Mascher, 
1967; Mogar et al., 1964; Pahnke & Richards, 1966; Savage et al., 1962; Savage, Stolaroff, 
Harman, & Fadiman, 1963; Savage et al., 1964; Savage et al., 1966; Savage et al., 1968; 
Schmiege, 1963; Schoen, 1964; Sherwood et al., 1968; Tenenbaum, 1961; Unger, 1963).  
According to Chandler & Hartman (1960):  
“With LSD as an aid, it has been possible to ‘reach’ and work with patients who are 
otherwise unresponsive to psychotherapy.  This includes…severe characterological 
defense systems of the obsessive compulsive and acting-out types, as well as several of 
the overly inhibited schizoid types.” (p. 74)  
 
The following success rates are identified by Mascher’s (1967) systematic review, which 
analyzes data from 42 papers (1953-1965) and includes psychedelic-assisted treatment with 1603 
patients, grouped by the following anachronistic diagnostic categories (many of which overlap 
with contemporary personality disorder classifications): anxiety neuroses (9 papers, 70% 
success), depressive reactions (4 papers, 62% success), character neuroses and sociopaths (10 
papers, 61% success), borderline cases (4 papers, 53% success), obsessive-compulsive neuroses 
(10 papers, 42% success), and hysteria and conversion symptoms (2 papers, 31.5% success)4.  
 
4 Mascher’s (1967) systematic review also reports “good results” for 50% of all “sexual perverts and prevailing 




By way of example, Savage et al.’s (1966) study administered the Minnesota Multiphasic 
Personality Inventory (MMPI) to assess personality in 77 long-term psychotherapy patients 
before and after one high-dose of LSD, as well as at two-, six-, and twelve-month follow-ups.  
According to their findings, borderline psychotic personalities significantly improved at two 
months, but lost ground by six months:  
“Their dystonic defensive structure has been restored, but they have less depression, 
anxiety, and guilt. It would appear that they have insufficient ego resources to capitalize 
on the significant characterological changes noted at two months. One would conclude 
that additional therapy is required to supplement personal resources which are inadequate 
to instrument newly-acquired insights.” (p. 245)   
 
Hysterical personalities followed a similar trajectory, with improvement at two months, followed 
by a regression at six months:  
“This group is characterized clinically by passive-dependency, lack of a sense of personal 
responsibility, and poor reality testing which contribute to their inability to integrate the 
LSD experience into their self-system and life circumstances. This group tends to retain 
some degree of magical or unrealistic expectations with regard to outcome. They sit back 
passively and wait for the drug to transform them. They bask in the greatly expanded 
sense of well-being and take no steps to translate their insights into living reality…A 
longer period of preparation might lead to more realistic expectations. Another alternative 
might be to repeat the psychedelic experience after six months.” (p. 245)   
 
All other diagnostic categories, which include subjects characterized by “cyclothymic impulsive 
trends, anxiety and tension states, obsessive compulsive symptoms, reactive depressions and 
passive-aggressive tendencies,” demonstrated,  
“Stable, positive changes throughout the follow-up period…[Although] these groups 
tended to display less spectacular shifts in mood shortly after LSD, [they] continued to 
show positive changes in character structure at the six-month follow-up… [At one year] 
these groups not only sustain improvement but continue to realize potentialities 
discovered under LSD.” (p. 245-6)  
 
With regard to characterologically “normal” individuals, who tend to suffer from “philosophical 
neuroses” due to difficulty finding “identity and meaning” in the context of “modern man’s deep 
sense of alienation,” Savage et al. (1966) argue that “these subjects benefit considerably from the 
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psychedelic experience along the lines of self-actualization, richer creative experience, and 
enhancement of special abilities and aptitudes,” (p. 250).  Savage et al. (1966) conclude: 
“With regard to the nature of changes characterizing different personality types, shifts 
tend to occur consistent with the symptoms and defense patterns of a given group. Thus 
anxiety neurotics are less anxious, compulsive and withdrawn, while close object 
relations are more gratifying. In contrast, impulsive, hyperactive subjects lead a more 
orderly, less hectic existence and display greater impulse control.” (p. 246)   
 
Although not mentioned in this particular study, first-wave investigators also warn that classic 
psychedelics may exacerbate grandiose tendencies if proper therapeutic supports are not in place 
(Chandler & Hartman, 1960; Cohen & Eisner, 1958; Savage et al., 1962).  According to 
Chandler & Hartman (1960), 
“[Psychedelic exposure may cause an individual] to feel that he has discovered the 
answer to everything, that he has acquired philosophical insights into the meaning of life, 
the nature of the universe, etc. If utilized in the proper manner during regular 
psychotherapy…these philosophical understandings can be a valuable part of the person’s 
growth, but they will prove harmful to him if he…uses them as a defensive means of 
supporting neurotic delusions of superiority.” (p. 75) 
 
 With regard to psychosis, contemporary safety guidelines prohibit the use of classic 
psychedelics with individuals who meet criteria (or have first- or second-degree relatives who 
meet criteria) for bipolar or psychotic disorders (Cohen, 1960; Johnson et al., 2008; Schmiege, 
1963; Winkelman et al., 2007).  It’s nevertheless worth noting that Stanislav Grof M.D. Ph.D., a 
preeminent psychedelic psychiatrist and researcher, holds a divergent (albeit minority) view.  In 
Beyond Psychoanalysis: Implications of LSD Research for Understanding Dimensions of Human 
Personality, Grof (1970) details psycholytic psychotherapy with 50 patients at the Psychiatric 
Research Institute of Prague over the course of seven years (1960-1967).  With regard to 
psychosis, Grof details a case report of a woman who initially presented with psychosis but who, 
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after 90 LSD dosing sessions, no longer suffered from psychotic symptomatology and instead 
presented with a “completely restructured personality,” (p. 72).  According to Grof (1970),  
“She had a new zest for life, appreciation for nature and art, a purified attitude to her 
children and could completely give up her unrealistic ambitions and fantasies. She was 
able to resume her job, accomplish divorce from her husband and care for her children in 
a very independent way. Three years after discontinuation of treatment, and at the time of 
the last follow-up feedback session, the condition was even more stabilized.” (p. 72) 
 
Relationship to Self and the Interpersonal Other 
Research preliminarily suggests that classic psychedelics may support the healing of 
one’s relationship to self and other.  More specifically, psychedelic exposure is associated with 
improved introspection (Savage et al., 1966; Savage et al., 1968), self-compassion (Grof, 1970; 
Watts et al., 2017), physical and psychological self-care (Griffiths et al., 2011), self-esteem 
(Griffiths et al., 2011; Savage et al., 1964; Savage et al., 1968), self-acceptance (Kavenská et al., 
2015) and self-actualization (Doblin, 1991; Savage et al., 1964).  Psychedelic exposure is also 
associated with healthier interpersonal relationships (Griffiths et al., 2011; Kavenská et al., 2015; 
Savage et al., 1964), characterized by stronger communication (Savage et al., 1966; Savage et 
al., 1968), fewer arguments (Savage et al., 1966; Watts et al., 2017), and deeper emotional bonds 
(Ditman & Bailey, 1967; Watts et al., 2017).  Notably, individuals also report feeling increased 
compassion in the wake of psychedelic experiences, even toward those individuals who have 
abused and wronged them (Ditman & Bailey, 1967; Watts et al., 2017).  According to one 
research subject, who had participated in an open-label psilocybin trial, and who had been 
severely abused by his mother during childhood,  
“When I was being toilet trained, my mother lost it with me and drowned me in my own 
human waste and throughout my life, I tend to replay that. [During the dosing session], I 
realized that my mother was out on a ledge, we were two people out on a ledge, she too 
was completely unconnected, disconnected. I felt some compassion for her…a different 
perspective, that it wasn’t an all-powerful world and universe against me, my mother too 




Relationship to the Collective Other 
This literature review suggests a link between classic psychedelics and an individual’s 
relationship to the collective other.  With regard to values, psychedelic exposure is associated 
with decreased materialism (Savage et al., 1966), social status strivings (Grof, 1970; Savage et 
al., 1966), and authoritarian political views (Grof, 1970; Lyons & Carhart-Harris, 2018; Nour et 
al., 2017).  Additionally, psychedelic exposure is also associated with increased liberal politics 
(Nour et al., 2017), nature relatedness (defined as self-identification with nature) (Doblin, 1991; 
Forstmann & Sagioglou, 2017; Grof, 1970; Lyons & Carhart-Harris, 2018; Nour et al., 2017) and 
vegan/vegetarianism, with anecdotal reports of research participants receiving “lessons” 
regarding the importance of eating plants instead of animals during dosing sessions (Watts et al., 
2017, p. 532).   
Preliminary evidence also suggests that classic psychedelics may influence an 
individual’s behavior toward the collective other.  For example, psychedelic exposure may be 
associated with pro-environmental behavior (Forstmann & Sagioglou, 2017), increased altruism 
(Griffiths et al., 2011; Grof, 1970; Schmid & Liechti, 2018) and political activism (Doblin, 
1991).  During a follow-up interview approximately twenty years after psilocybin administration, 
a research participant reflected on how psychedelic-assisted insights regarding the nature of 
death ultimately influenced his political activism:  
“When you get a clear vision of what [death] is and have sort of been there, and have left 
the self, left the body, you know, self leaving the body, or soul leaving the body, or 
whatever you want to call it, you would also know that marching in the Civil Rights 
Movement or against the Vietnam War in Washington [is less scary]…In a sense [it takes 
away the fear of dying]…because you've already been there. You know what it's about. 
When people approaching death have an out-of-body experience…[you] say, ‘I know 
what you're talking about. I've been there. Been there and come back. And it's not 




Spirituality and Relationship to the Universal Whole 
As Chandler & Hartman (1960) point out, reports of psychedelic-assisted spiritual 
insights are “just as frequent among scientifically and intellectually sophisticated patients with 
strictly materialistic orientations,” (p. 72).  Indeed, classic psychedelics are associated with self-
reported mystical experiences (Ditman & Bailey, 1967; Doblin, 1991; Griffiths et al., 2008; 
Grof, 1970; Kurland, Unger, Savage, Olsson, & Pahnke, 1968; Lerner & Lyvers, 2006; Maclean 
et al., 2011; Pahnke et al., 1970; Unger, 1963), euphoria (Ditman & Bailey, 1967; Doblin, 1991; 
Savage et al., 1962; Watts et al., 2017), reduced fear of death (Doblin, 1991; Grob, Danforth, 
Chopra, et al., 2011; Ross, Bossis, Guss, Agin-Liebes, Malone, Cohen, et al., 2016), greater 
purpose and meaning in life (Ditman & Bailey, 1967; Savage et al., 1966), increased 
commitment to spiritual lifestyles (Dos Santos et al., 2016c; Griffiths et al., 2011; Winkelman et 
al., 2007), and a changed relationship to time (Grof, 1970; Savage et al., 1962).  Grof (1970) 
explains, “the obsessive dwelling in the past alternating with indulgence in unrealistic 
daydreaming and building of wind castles in the future [is] considerably reduced [following the 
psychedelic experience] and replaced by an enhanced emotional emphasis on the here and now,” 
(p. 68).  Additionally, psychedelic exposure is preliminarily associated with increased self-
transcendence (Bouso et al., 2012; Bouso et al., 2015; Doblin, 1991).  According to the 
Temperament and Character Inventory (TCI), self-transcendence refers to,  
“Identification with everything conceived as essential and consequential parts of a unified 
whole. This involves a state of ‘unitive consciousness’ in which everything is part of one 
totality. In unitive consciousness, there is no individual self because there is no 
meaningful distinction between self and other—the person is simply aware of being an 
integral part of the evolution of the cosmos. This unitive perspective may be described as 
acceptance, identification, or spiritual union with nature and its source.” (Cloninger, 




Importantly, a number of researchers have not only identified personality change directly 
following one (or a few) psychedelic doses (Aixalà et al., 2018; Bouso et al., 2018; Carhart-
Harris & Goodwin, 2017; Erritzoe et al., 2018; Savage et al., 1966), but have also successfully 
tracked the stability of personality change in longitudinal studies of up to one year (Bouso et al., 
2018; Griffiths et al., 2011; Lyons et al., 2018; Maclean et al., 2011; Savage et al., 1966; Savage 
et al., 1968; Schmid & Liechti, 2018).  Perhaps most notably, at a 14-month follow-up, 67% of 
Griffiths et al.’s (2006) research participants rated their encounter with psilocybin as among the 
five most personally meaningful and spiritually significant experiences of their lives, similar to 
the birth of a child or the death of a parent (Griffiths et al., 2008).  
Proposed Mechanisms 
Classic psychedelics may inspire a paradigm shift with regard to both 
psychopharmacology and psychotherapy, as this drug class does not narrowly address a specific 
set of symptoms (Grof, 1970), but is instead thought to promote a nonordinary state of 
consciousness that may transform personality through the accelerated emergence of unconscious 
material (Chandler & Hartman, 1960; Cutner, 1959; Majić et al., 2015; Savage et al., 1962; 
Savage et al., 1964; Studerus et al., 2011; Tenenbaum, 1961; Unger, 1963; Winkelman et al., 
2007).  According to the literature, to describe this “therapeutically useful state of 
consciousness” (Majić et al., 2015, p. 241) is to “communicate a quality of experience [that] 
borders on the incommunicable,” (Sherwood et al., 1968, p. 108).  Ineffability notwithstanding, 
the psychedelic encounter has been described as a “catalyzer” (Grof, 1970, p. 73) that “enlarges 
the psychic horizon” (Savage et al., 1964, p. 119), “broadens perception” (Winkelman et al., 
2007, p. 55), “expands consciousness” (Sherwood et al., 1968, p. 96), and creates a “four 
dimensional” sensory experience (Watts et al., 2017, p. 530).  According to Unger (1963), “the 
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personality is touched to its core and is led into provinces of psychic life otherwise unexplored; 
light is shed on boundaries otherwise dark and unrevealed,” (p. 115).  It’s certainly intriguing 
that observer and participant alike have invoked similar language to characterize the psychedelic 
experience.  According to one team of clinical researchers, classic psychedelics provide “a 
dramatic freeing…from [the self’s] habitual ways of viewing the world, an opportunity to see 
clearly without distortion, without a defensive structure [that] limits and filters perception,” 
(Savage et al., 1964, p. 119).  Likewise, a research participant from an open-label psilocybin trial 
reflected on his experience in related terms: “[During the dosing session], I could see [my 
relationships] clearly, almost as if for the first time.  I had fresh insight…It was as if suddenly the 
scales dropped from my eyes, I could see things as they really are,” (Watts et al., 2017, p. 532).   
The literature suggests that individuals may need to psychologically surrender to the 
psychedelic experience and “work cooperatively with the drug” (Chandler & Hartman, 1960, p. 
67) in order to maximize therapeutic benefit (Savage et al., 1962; Sherwood et al., 1968; Watts et 
al., 2017).  As Savage et al. (1962) warn, “[if a subject is unwilling or unable] to give himself up 
to the effects of the drug…[or] if [he] is very concerned about maintaining control…the 
experience can [become] frightening, sometimes terrifying,” (p. 427).  Indeed, in Watts et al.’s 
(2017) open-label psilocybin trial for treatment-resistant depression, “the two patients who 
showed less marked improvement in symptoms posttreatment described not being able to ‘let 
go,’ implying that ‘letting-go’ may be a key factor in lasting responses,” (p. 538).   
For individuals who are able to surrender to the experience, the literature suggests that 
classic psychedelics may foster greater acceptance and non-defensiveness in the face of 
potentially painful insights (Cohen & Eisner, 1958; Savage et al., 1962; Tenenbaum, 1961; Watts 
et al., 2017; Winkelman et al., 2007).  According to Tenenbaum (1961), “ego-alien unconscious 
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material is able to come forth without decompensation,” (p. 460-1).  In this context, it is perhaps 
relevant to note that classic psychedelics are associated with decreased activation in the brain’s 
anxiety and fear networks (Dos Santos et al., 2016b; Soler, Elices, Franquesa, Barker, 
Friedlander, Feilding, Pascual, Riba, 2016; Winkelman et al., 2007).  Additionally, in the context 
of proper set and setting, the literature also preliminarily suggests that individuals may maintain 
a capacity for intact reality testing while under the influence, as well as an ability to recall the 
psychedelic experience after the fact (Chandler & Hartman, 1960; Studerus et al., 2011).  
Chandler & Hartman (1960) define this capacity for reality testing in the following way: 
“The drug does not appear to produce any serious or marked impairment in the major ego 
functions when used in proper dosage and in an active therapeutic relationship. The 
patient remains oriented [to] person, place and time. He does not appear to lose contact 
with everyday reality but, rather, seems to gain contact with other levels of his own 
psyche and to be freer to direct his attention to the emotions and projections of his 
unconscious.” (p. 68) 
 
In sum, with proper preparation and support, and for those individuals who are able to 
release into the experience, the literature preliminarily suggests that classic psychedelics may 
facilitate a nonordinary state of consciousness that expands awareness to include previously 
unconscious material and nurtures non-defensiveness in the face of potentially painful insights, 
all while maintaining ego function integrity.  In the context of this potent psychological state, the 
literature links shifts in personality to the following mechanisms: 1) Free Association, 2) Defense 
Mechanisms Revealed, 3) Emotional Insight, 4) Psychosomatic Healing, 5) Traumatic Reliving, 
6) Symbolic Insight, 7) Integration, 8) Neurobiology, 9) Mystical Encounters, and 10) Therapist 
Intervention.  At this juncture, a caveat may prove prudent, as this list of proposed mechanisms 
likely reflects the theoretical orientation of this literature - as well as that of this writer - in ways 
as yet not fully understood.  As Savage et al. (1962) warn:  
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Galileo’s contemporaries refused to look at the moons of Jupiter through his new 
telescope. And some of our contemporaries refuse to contemplate the intricacies of the 
LSD experience, or having contemplated them are unable to process the new 
data…Instead of marveling: ‘My God, I’ve never been in this land before,’ they explain, 
interpret and deny all in terms of their conventional framework…they cling desperately 
to the old familiar terminology; they maintain a death grip on their ‘cathexes’ and 
‘repressions’; and clinging to the old, they cannot let go and be intrigued by the new. 
Acute discomfort is their lot, if they cannot hammer their data onto the cross (chi-square) 
of their old methodology.” (p. 433) 
 
Free Association 
The psychedelic encounter is thought to strengthen cognitive dexterity, along with a 
concomitant capacity for free association (Cohen & Eisner, 1958; Pahnke & Richards, 1966; 
Savage et al., 1962).  According to Pahnke & Richards (1966), “[While under the influence], one 
[may feel] capable of thinking unusually sharply, quickly, and clearly…Further, one [may 
become] conscious of the presuppositions underlying one's thoughts and of the interrelations 
between different ideas. Chain reactions of associations and inferences may occur, and one may 
feel as though one is able to think on several different levels of discourse all at once,” (p. 188-9).  
From a psychotherapeutic perspective, and with regard to mechanisms that may undergird 
personality change, “the [heightened] ability of the patient to follow his own 
associations…permits a dramatic opportunity to trace [an intrapsychic] problem to its origin,” 
(Cohen & Eisner, 1958, p. 537). 
Defense Mechanisms Revealed 
The psychedelic experience is also linked to increased awareness of previously 
unconscious defense mechanisms (Chandler & Hartman, 1960; Grinspoon & Doblin, 2001; 
Savage et al., 1962; Savage et al., 1966; Schmiege, 1963; Watts et al., 2017).  While under the 
influence, one “[may] literally ‘see’ [themselves] resisting, rationalizing, denying, [and] 
isolating,” (Chandler, 1960, p. 74) or “[catch] [themselves] in the act of using [an ego defense, 
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such as projection, denial or displacement],” (Grinspoon & Doblin, 2001, p. 680).  According to 
Savage et al. (1966), “the maladaptive defenses, found by the subjects to be anachronistic, often 
[crumble] away over a short period of time. Thus, rapid personality changes do occur,” (p. 253). 
Emotional Insight 
Classic psychedelics are also associated with a deepened felt sense (Cutner, 1959; Pahnke 
et al., 1969; Sherwood et al., 1968; Watts et al., 2017) and, in turn, reduced intellectualization 
(Cutner, 1959; Schmiege, 1963; Sherwood et al., 1968; Tenenbaum, 1961), increased feelings of 
connection (to self, other and the world) and a shift from avoidance to acceptance (Watts et al., 
2017).  According to Watts et al.’s (2017) phenomenological analysis of psilocybin exposure:  
“People described that during the dosing session, unlike in their daily lives, they 
[couldn’t just] avoid or hide from negative [emotions]. [They were] too overwhelming.  
And they found that when they finally surrendered after years of trying to avoid or fight 
these feelings, the feelings would swell and then diminish.” (p. 538) 
 
According to one study participant,  
“There was a lot of sadness, really really deep sadness: the loss, the grief, it was love and 
sadness together, and letting go, I could feel the grief and then let it go because holding 
onto it was hurting me, holding me back. It was a process of unblocking.” (p. 538) 
 
Another study participant described her experience in the following terms, “Once I went into the 
anger, it went ‘pouf’ and evaporated.  I got the lesson that you need to go into the scary 
basement, once you get into it, there is no scary basement to go into [anymore],” (p. 538).  
Similarly, according to Pahnke & Richards (1966), “the unexpected confrontation [with] 
guilt…may be strongly therapeutic,” (p. 187).  Indeed, one research participant “who had been 
seriously neglecting his wife and children,” described his LSD dosing session in the following 
way: 
“There seemed to be in front of [me]…many veils…I pushed each veil aside one by 
one…And finally the last veil was pulled aside and there were my three children crying 
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for their father…Before me was all of the selfish feelings – all of the selfish attitudes that 
I had had throughout my entire married life.” (p. 187) 
 
Often, study participants describe the experience of catharsis following emotional insight: 
“[Before the dosing session] I had lost my ability to grieve and cry. [During the dosing session] I 
cried and that was a cathartic experience for me, a very welcoming sweet experience,” (Watts et 
al., 2017, p. 540).  “I was weeping, tears were flowing out of me, it wasn’t a painful crying, it 
was like turning on the taps, like a washing, a washing out,” (Watts et al., 2017, p. 540). 
Psychosomatic Healing 
The literature also includes references to psychedelic-assisted psychosomatic healing 
(Chandler & Hartman, 1960; Cohen & Eisner, 1958; Schmiege, 1963; Watts et al., 2017).  
According to Chandler & Hartman (1960),  
“Pain is of frequent occurrence…It is an expression of a repressed affect, at times 
associated with the memory of some trauma…The patient is always encouraged to go 
along with the pain and let it become more intense, until the fantasy with which it is 
associated breaks through into awareness.  When this occurs, the pain usually disappears 
immediately.” (p. 70) 
 
According to Cohen & Eisner (1958), “With the uncovering of critical problems varying degrees 
of somatic discomfort…are felt…The word most commonly used by the patient after an 
experience of this sort is that he feels ‘purged,’” (p. 533).  Watts et al.’s (2017) examination of 
psilocybin exposure supports this conclusion: “Some [research participants] also reported 
specific physical sensations, [which] they interpreted as emotions that had manifested as somatic 
symptoms because they had not been expressed,” (p. 540).  In the words of one such participant:  
“The dose helped me realize why I felt the pain in my chest, I saw it visually and felt it 
emotionally, then I felt so much lighter, like something had been released. It was an 







Representing a controversial contention in the context of what we know regarding the 
malleability of memory (Gonsalves & Paller, 2002; Loftus, 2004; Loftus, 2005; Roediger & 
McDermott, 1995), the literature links psychedelic exposure to the reappearance of allegedly 
repressed, traumatic memory (Chandler & Hartman, 1960; Cohen & Eisner, 1958; Cutner, 1959; 
Grof, 1967; Schmiege, 1963; Tenenbaum, 1961; Watts et al., 2017; Winkelman et al., 2007), 
dating back as early as infancy (Cutner, 1959; Pahnke, 1969; Watts et al., 2017) and possibly 
including genuine prenatal and birth traumata (Cutner, 1959; Grof, 1979).  According to 
Chandler & Hartman (1960), “Several patients who had almost complete amnesia for childhood 
events before 10 or 11 years of age uncovered a great wealth of material which proved of 
tremendous therapeutic benefit,” (p. 74).  The literature suggests that these memories are not just 
recalled, but in fact “relived,” (Chandler & Hartman, 1960, p. 71; Cohen & Eisner, 1958, p. 530; 
Grof, 1967, p. 165; Pahnke, 1969, p. 150; Tenenbaum, 1961, p. 460; Watts et al., p. 539).  
Chandler & Hartman (1960) describe the phenomenon of reliving in the following way:  
“The term ‘reliving’ describes the more intense experiences better than the term ‘recall.’  
Scenes may be pictured with great vividness of color and other detail, and the patient 
feels himself to be back in the situation and experiences the affects in all the original 
intensity.  Some patients describe it by saying that it is as though a 3-D film tape [is] 
being run off in the visual field.” (p. 71) 
 
Put another way, “Unconscious memories [are not only] recovered easily, but…relived [with 
extreme realism] …frequently accompanied by changes in the body image, so that the patient 
[feels as if] he [is] the physical size and age [as] when the traumatic experience occurred,” 
(Pahnke, 1969, p. 186-7).  According to Watts et al. (2017), one research participant reported 
reliving, “from the perspective of himself as an infant, a pillow held over his face by a caregiver, 
and felt a deep fear of annihilation,” (p. 539).  In the words of another participant,  
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“[I] became myself at age 7, after my [grandparent] had died. I totally was back there, so 
vivid, so real, I had the emotions that I would have felt at the time: fearful, why did this 
happen, the naivety, the shock and confusion. I was getting overly upset and my parents 
were saying ‘boys don’t cry.’” (p. 539)  
 
It may prove consequential that memories are said to be relived through the child’s experience, 
while simultaneously reexamined through the adult’s eyes:  
“The recalled and relived experiences are reformulated on a grown-up level and 
rationally integrated into the ego…The patient can oscillate between…experiencing the 
present grown-up level and a deeply regressive infantile one. A very important factor 
seems to be the patient’s ability to relive fully and with an intense emotional charge the 
infantile traumatic material and at the same time to evaluate its relevancy from the point 
of view of a grown person. This means an opportunity for rational mastering and for 
mature and adequate judging of the significance of these experiences.” (Grof, 1967, p. 
179)   
 
As a function of traumatic reliving, clinical researchers have theorized that deep shifts occur on 
the object relational plane (Savage et al., 1964): “A reorientation of object relationships can take 
place on a level more archaic than that of language,” (Cutner, 1959, p. 723), as “the infantile 
core, fully recalled and relived, loses its dominant position in the experiential field, and is 
replaced by a new one,” (Grof, 1967, p. 177).  Intriguingly, the literature anecdotally reports 
incidents whereby patients later corroborate memories first uncovered during the psychedelic 
encounter (Ditman, 1968; Frederking, 1955; Grof, 1967; Newland, 1962; Sandison & Whitelam, 
1957).  For example, 
“A woman under LSD felt herself to become tiny.  [In her words], ‘a helpless 
baby…feeling very cold and hungry…seeing nothing but white, white tile…’ Several 
weeks after this LSD experience, the woman learned from her mother, to her complete 
amazement, that she had been placed in an incubator for several days directly after her 
birth – a fact which she had not consciously known for all of her life.” (Ditman, 1968, p. 
49) 
 
As Ditman (1968) points out,  
“It has been debated whether these early, repressed incidents which are recovered in the 
LSD experience are in fact truly, realities relived; or whether they are fantasies evoked 
for the sake of the therapist through the disinhibiting effects of the LSD 
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experience…Whether such vivid upsurges of psychic material are based on actual events 
or, rather, are symbolic representations of conflict-laden areas does not seem of much 
relevance when, as a result of such LSD-induced fantasies, the patient achieves greater 
insight and ability to resolve the problems which have been crippling his day-to-day 
living.” (p. 48-50) 
 
Symbolic Insight 
The literature also suggests that psychological insight may be conveyed symbolically 
(Ditman, 1968; Schmiege, 1963; Sherwood et al., 1962; Watts et al., 2017).  According to 
Pahnke & Richards (1966),  
“Visions of objects not present may suddenly appear.  At times, in a dreamlike state, one 
may enter one’s visions and seem to be walking through gardens, art museums, medieval 
castles, futuristic cities…Archetypal imagery may appear, and one [may find] oneself 
encountering mythological characters such as angels, demons, dragons, and Grecian 
gods.” (p. 185) 
 
Sherwood (1962) further explains, 
“The unconscious mind employs visual and other symbolic representations with 
seemingly endless variety to convey insights to the conscious mind. They may represent 
to the individual some aspect of his own picture of himself, or some characteristic of his 
approach to life…Through [these] processes, the subject constantly works off repressed 
material and unreality structures, false concepts, ideas, and attitudes, which have been 
accumulated through his life experiences.  Thus a form of psychological cleansing seems 
to accompany the subjective imagery. This results in considerable ventilation and release 
almost independent of intellectual clarification.” (p. 98) 
 
As self-consciousness is thought to remain intact, this state may be compared to a lucid dream, 
whereby an individual is empowered to interact with psychological conflicts symbolically.  As 
one research participant recounted, “There was this huge terrifying creature with a rifle, and 
instead of running away, I looked at it, and it wasn’t as scary as it had seemed.  [My] fear 
subsided, it suddenly seemed ridiculous, I started laughing. If I had avoided it, it would have got 






In what Cohen & Eisner (1958) term the “integrative effect,” (p. 537), classic 
psychedelics may also meld fissures in the personality structure (Cohen & Eisner, 1958; Grof, 
1967; Grof, 1970).  According to Grof (1967), “A very typical occurrence is the resolution of 
ambivalent attitudes with a successive narrowing of the oscillation spectrum of contradictory 
tendencies and a sort of mutual neutralization…the boundaries between controversial 
components of various ambivalent attitudes melt,” (p. 177-9).  According to Cohen & Eisner 
(1958), “In our sample this integrative aspect appeared to occur in conjunction with resolution of 
conflicts,” (p. 537).  It may be theorized that an expansion of consciousness allows for an 
encounter between previously split off parts of the self.  With such a bridging in place, 
psychological conflicts underlying personality chasms may resolve and, in turn, facilitate a more 
integrated personality structure. 
Neurobiology 
Dos Santos et al. (2016b) conducted a systematic review of neuroimaging research and 
identified 25 studies that met their four-pronged inclusion criteria: 1) investigation of acute and 
non-acute effects of classic psychedelics on the human brain, 2) via observational or 
interventional study design, 3) and the application of structural, functional or neurochemical 
neuroimaging techniques, 4) with findings published in a peer-reviewed journal.  When 
considered in aggregate, the results of this systematic review preliminarily link classic 
psychedelics to increased neuroplasticity, neurogenesis and integration of disparate cortical 
regions, as well as increased activation of brain structures implicated in cognitive processes, 
memory, interoception and mood regulation.  Simultaneously, these findings also preliminarily 
link psychedelic exposure to decreased activation of brain structures required for anxiety and 
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fear processing, as well as rumination.  Dos Santos et al.’s (2016b) systematic review also 
identifies neural correlates for the psychedelic-assisted experience of ego dissolution, which 
intriguingly resembles the brain’s state during deep meditation. 
In this context, it is relevant to note that all neuroscientific literature, including the 
aforementioned, may rest on “unquestioned but highly questionable foundations,” (Noë, 2010, p. 
3).  This critique is explored in The Manifesto for a Post-Materialist Science (2014), a mission 
statement co-authored by an internationally diverse group of scientists (spanning the fields of 
biology, neuroscience, medicine, psychiatry and psychology) at a 2014 summit co-organized by 
the University of Arizona’s Gary E. Schwartz, Ph.D. and Mario Beauregard, Ph.D. and Columbia 
University’s Lisa Miller, Ph.D.  Of note, this summit was not specific to psychedelic research, 
but instead a more universal meeting of the minds regarding the state of contemporary science: 
“The modern scientific worldview is predominantly predicated on assumptions that are 
closely associated with classical physics. Materialism—the idea that matter is the only 
reality—is one of these assumptions. A related assumption is reductionism, the notion 
that complex things can be understood by reducing them to the interactions of their parts, 
or to simpler or more fundamental things such as tiny material particles. During the 19th 
century, these assumptions narrowed, turned into dogmas, and coalesced into an 
ideological belief system that came to be known as ‘scientific materialism.’ This belief 
system implies that the mind is nothing but the physical activity of the brain, and that our 
thoughts cannot have any effect upon our brains and bodies, our actions, and the physical 
world.” (p. 1)  
 
Similarly, as renowned neuroscientist Alva Noë, Ph.D. (2010) contends,  
 
“The idea that the only genuinely scientific study of consciousness would be one that 
identifies consciousness with events in the nervous system is a bit of outdated 
reductionism…To move forward in our understanding of consciousness, we need to give 
up the internal, neural microfocus…It is striking that the majority of scientists working 
on consciousness don’t even notice there is an overlooked theoretical possibility here.  
They tend to think that consciousness, whatever its ultimate explanation, must be 
something that happens somewhere and sometime in the human brain, just as digestion 




With regard to the mechanistic underpinnings of personality change, the assumption that 
neurobiological events cause revelatory psychological events is just that – an assumption.  It’s 
just as plausible to conjecture that experiences of consciousness occur – and are then reflected on 
the neurobiological plane.   
Mystical Encounters 
According to Pahnke & Richards (1966), classic psychedelics facilitate two qualitatively 
different types of nonordinary states: the mystical and the non-mystical.  In the context of non-
mystical states, which have been discussed up until this point, “the empirical ego generally exists 
as the subject viewing objects of a visionary nature, or pondering objects of a cognitive nature,” 
(p. 183).  In mystical (and some psychotic)5 states, however, “the subject-object dichotomy is 
transcended and the empirical ego extinguished,” (p. 184).   
Mystical consciousness fits less neatly into the traditional psychotherapeutic paradigm 
and therefore occasions more skepticism: 
“Of all the varieties of psychedelic experiences, the type that has elicited the most 
enthusiastic interest as well as the most indignant rebuttal from both psychiatric and 
theological spokesmen is the mystical experience. The claim that spontaneous mystical 
experiences are similar to, if not identical with…drug-facilitated mystical consciousness 
has caused considerable apprehension and dismay among some religious professionals, 
and the possible therapeutic potential…has been somewhat embarrassing to those 
therapists who pride themselves on their scientific objectivity and lack of religious 
involvement.” (Pahnke & Richards, 1966, p. 190) 
 
 
5 Although a full reckoning of the psychotic versus mystical states is outside the scope of this paper, Ken Wilber’s 
theory of the pre/trans fallacy may prove relevant.  According to Wilber’s theoretical model, there are three broad 
developmental stages of consciousness: the pre-personal (pre-egoic, such as the infantile or psychotic), the personal 
(egoic, such as that of the healthy adult) and the trans-personal (trans-egoic, such as that of the mystic).  According 
to the pre/trans fallacy, non-rational stages of consciousness (which include the pre and trans stages) share certain 
similarities (such as egolessness) and are therefore often confused for one another.  For example, trans-rational 
states (e.g. mystical experiences) are often conflated with pre-rational states (e.g. psychotic breaks), and vice versa.  
According to Wilber, both Freud and Jung committed versions of the pre/trans fallacy: Freud erroneously reduced 
the mystical experience to a regressed and infantile oceanic state, whereas Jung erroneously elevated pre-rational 




Taboo notwithstanding, mystical experiences (also known as peak, cosmic and transcendental) 
are one of the most potent predictors of post-psychedelic personality change (Doblin, 1991; 
Griffiths et al., 2008; Grof, 1970; Kurland et al., 1968; Lebedev et al., 2016; Maclean et al., 
2011; Maslow, 1959; Pahnke, 1969; Pahnke et al., 1970; Savage et al., 1962; Unger, 1963).  
Indeed, rigorous double-blind clinical studies have linked psilocybin-occasioned mystical 
experiences to sustained improvement in the domains of openness (Maclean et al., 2011), 
personal well-being, life satisfaction, and positive behavioral change (Griffiths et al., 2006; 
Griffiths et al., 2008, Griffiths et al., 2011).  Of note, not all individuals who ingest a psychedelic 
will encounter a mystical experience: “a relatively high dosage is a necessary, but not sufficient, 
condition,” (Pahnke & Richards, 1966, p. 199). 
In an effort to experimentally operationalize mystical consciousness, Pahnke (1963) 
content analyzed historical reports of spontaneous mysticism and identified the following nine 
interrelated criteria (with subsequent investigators having since identified similar definitional 
parameters, see reviews in: Hood, 2003; Hood, Hill & Spilka, 2009):6 1) Unity, 2) 
Transcendence of Time and Space, 3) Deeply Felt Positive Mood, 4) Sense of Sacredness, 5) 
Noetic Quality, 6) Paradoxicality, 7) Ineffability, 8) Transiency, and 9) Persisting Positive 
Changes in Attitude and Behavior.  In an attempt to illuminate this opaque construct, each 
criterion will be defined in turn. 
Unity: According to Pahnke & Richards (1966), the hallmark of mystical consciousness 
is “undifferentiated unity,” (p. 177), which may be experienced either internally (ego dissolution) 
 
6 Studies included in this literature review administered the following measures in order to experimentally capture 
mystical phenomena: Mystical Experience Questionnaire (created by Pahnke), States of Consciousness 




or externally (transcendence of the subject-object dichotomy).  By way of clarification, Pahnke 
& Richards describe internal unity in the following terms: 
“Awareness of all normal sense impressions (visual, auditory, cutaneous, olfactory, 
gustatory, and kinesthetic) ceases, and the empirical ego (i.e., the usual sense of 
individuality) seems to die or fade away while pure consciousness of what is being 
experienced paradoxically remains and seems to expand as a vast inner world is 
encountered…Internal unity occurs when consciousness merges with [the ground of 
being] beyond all empirical distinctions.  Although awareness of one’s empirical ego has 
ceased, one does not become unconscious.” (Pahnke & Richards, 1966, p. 177) 
 
Notably, neuroimaging studies have identified neurobiological correlates for this phenomenon 
(Carhart-Harris et al., 2012; Lebedev et al., 2015; Tagliazucchi et al., 2016).  For example, 
Lebedev et al. (2016) acquired functional MRI scans of 15 healthy subjects during active 
psilocybin exposure (as well as during a placebo condition) and identified an association 
between psilocybin-induced ego-dissolution and decreased functional connectivity between the 
medial temporal lobe and high-level cortical regions, as well as reduced interhemispheric 
communication and a disintegration of the salience network (Lebedev et al., 2016, p. 3137).  The 
authors of this study conclude, “[These findings] suggest that the maintenance of ‘self’ or ‘ego,’ 
as a perceptual phenomenon, may rest on the normal functioning of these systems,” (Lebedev et 
al., 2016, p. 3137).  Of course, it’s just as reasonable to conjecture that such neurobiological 
shifts are a reflection – and not a cause – of ego dissolution.   
With regard to external unity, Pahnke & Richards (1966) describe the experience as 
follows: 
“Awareness of one or more particular sense impressions grows in intensity until suddenly 
the object of perception and the empirical ego simultaneously seem to cease to exist as 
separate entities, while consciousness seems to transcend subject and object and become 
impregnated by a profound sense of unity, accompanied by the insight that ultimately ‘all 




One may reasonably conjecture that the unitive experience with nature and humanity at least 
partially accounts for psychedelic-assisted increases in compassion, nature-relatedness and 
political activism. 
Importantly, the internal and external unitive experiences are thought to be two sides of 
the same coin: “Although each form of unity occurs in a different manner, the states of 
consciousness ultimately experienced may be identical,” (Pahnke & Richards, 1966, p. 177).  
Notably, in experimental settings, scores of psychedelic-induced unitive experiences correlate 
highly with scores of ego dissolution (Nour et al., 2016).  Carhart-Harris et al. (2018) therefore 
surmise, “One [may] consider the ego [to be] a counterforce to connectedness,” (p. 549). 
Transcendence of Time and Space: Intrinsic to the mystical encounter is a perceived shift 
in the space-time continuum, also described as “a radical change in perspective in which [one] 
suddenly feels…outside of time, in eternity or infinity, beyond both past and future,” (Pahnke & 
Richards, 1966, p. 179).  As Sherwood et al. (1962) further elaborate, “He perceives what he 
may attempt to describe as ‘levels’ of consciousness, as ‘other dimensions’ of space, as 
‘traveling in time’; and yet as he tries to describe these he recognizes the effort to be as doomed 
to partial failure as the effort to describe being in love to someone who has not experienced it,” 
(p. 99). 
Deeply Felt Positive Mood: The mystical encounter also encompasses overwhelming 
feelings of joy, love, blessedness and peace, which may range from “nonsensual feelings of 
ultimate concern for other persons to a state resembling prolonged intense sexual orgasm. The 
latter degree of intensity is generally dissociated from any excitation of the sexual organs, being 
‘spiritual’ rather than ‘erotic’ in nature,” (Pahnke & Richards, 1966, p. 180).  Additionally, 
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feelings of peace “entail not only deep relaxation, but a conviction that ultimately there is no 
ground for anxiety,” (Pahnke & Richards, 1966, p. 180). 
Sense of Sacredness: Deeply felt awe, humility, reverence and “perceived smallness in 
the presence of vastness” also constitute essential components of the mystical encounter (Pahnke 
& Richards, 1966, p. 549).  According to Nour (2017),  
“Awe occurs in response to stimuli that are vast…transcend current frames of reference, 
and… require new schemata to accommodate what is being perceived…[Such] 
experiences…[may] catalyze psychological change within an individual…by shifting 
attention away from one’s individual concerns, and towards the larger entities of which 
an individual is a part.” (p. 22)   
 
Indeed, Carhart-Harris et al. (2018) conjecture that the mystical encounter may prove analogous 
to ‘the overview effect’ experienced by some astronauts when gazing back at earth, whereby 
one’s very self is altered through a transient shift in perspective. 
Noetic Quality: William James assigned the term ‘noetic quality’ to this facet of mystical 
consciousness, whereby the encounter is “intuitively felt to be of a more fundamental form of 
reality than either the phenomena of everyday consciousness or the most vivid of dreams or 
hallucinations,” (Pahnke & Richards, 1966, p. 178-9).  According to Sherwood et al. (1962), “He 
is convinced that, somehow or other, this other realm (which he feels he apprehends directly, in 
contrast to the usual space-time world of practical experience of physics which he perceives with 
physical senses) is ‘really’ there,” (p. 99).  In the words of one research participant, “[The 
mystical experience] left me with a completely unquestioned certainty that there is an 
environment bigger than the one I’m conscious of…[This] went from a theoretical proposition to 
an experiential one,” (Doblin, 1991, p. 14).  As Pahnke & Richards (1966) point out, “Theories 
that dismiss mystical consciousness as ‘mere regression’ or ‘an oceanic feeling of primary 
process’…fail to wrestle with the noetic quality [of the experience],” (p. 201). 
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Paradoxicality: This category reflects “the manner in which significant aspects of 
mystical consciousness are felt by the experiencer to be true in spite of the fact that they violate 
the laws of Aristotelian logic,” (Pahnke & Richards, 1966, p. 181).  For example, an individual 
may report that he “[ceases] to exist, yet obviously continues to exist…[Or] he may [report 
being] ‘out of the body’ while…still [being] ‘in the body,’” (Pahnke & Richards, 1966, p. 181).  
As one participant exclaimed, “I doubt if [any] statement can possibly be made to seem 
meaningful at the ordinary level of consciousness. No wonder the mystics of all faiths teach that 
understanding comes only when logic and intellect are transcended!” (Pahnke & Richards, 1966, 
p. 181). 
Ineffability: According to Pahnke & Richards (1966), “When a subject attempts to 
communicate mystical consciousness verbally to another person, he usually claims that the 
available linguistic symbols – if not the structure of language itself – are inadequate to contain or 
even accurately reflect such experiences,” (p. 181).  In the words of two separate research 
participants: “To seek to condense any of my experiences into words is to distort them,” (Pahnke 
& Richards, 1966, p. 182).   
Transiency: In contrast to everyday consciousness, this category reflects the temporary 
nature of the mystical encounter: “The characteristic of transiency indicates that the mystical 
state of consciousness is not sustained indefinitely and marks one of the important differences 
between it and psychosis,” (Pahnke & Richards, 1966, p. 182). 
Persisting Positive Changes in Attitude and Behavior: According to Pahnke & Richards 
(1966), individuals who experience mystical consciousness also evidence long-term changes in 
attitudes and behaviors toward themselves, others, life, and mystical consciousness itself.  
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Sherwood et al. (1962) summarize the relationship between the mystical encounter and 
personality change in the following way: 
“The subject [discovers] the vast extent of his own being, that he has understanding and 
abilities far greater than he previously imagined…He mentions mystic or oceanic 
experiences so profound as to remove neurotic symptoms forever after. The individual’s 
conviction that he is, in essence, an imperishable self rather than a destructible ego brings 
about the most profound reorientation at the deeper levels of the personality. He 
perceives illimitable worth in this essential self, and it becomes easier to accept the 
previously known self as an imperfect reflection of this. The many conflicts which are 
rooted in lack of self-acceptance are cut off at the source, and the associated neurotic 
behavior patterns begin to die away. Consequently the individual experiences less anxiety 
in connection with situations previously painful. Incapacitating feelings of inadequacy 
and guilt, re-examined in the light of this new self-discovery, seem inappropriate and are 
relinquished.” (p. 107) 
 
Therapist Intervention 
First- and second-wave investigators agree that proper preparation is essential to the 
success of a psychedelic encounter (Chandler & Hartman, 1960; Johnson et al., 2008; Savage et 
al., 1963).  According to the literature, such preparation should include building patient-therapist 
rapport, explaining the range of experiences one might encounter and encouraging the patient to 
mentally surrender during the dosing session, particularly in the face of challenging material 
(Johnson et al., 2008).  According to Chandler & Hartman (1960),  
“Such discussions help to allay the anxiety which the patient might otherwise have when 
confronted with the projections of the unconscious under LSD. The discussion helps to 
support the conscious ego in its reaction to the previously unconscious material now 
elicited under LSD and to encourage tolerance and acceptance of previously unacceptable 
aspects of the unconscious.  We have found that the more the patient understands about 
the procedures, the experience, and the rationale of the process the better is his 
therapeutic response.” (Chandler & Hartman, 1960, p. 65) 
 
There is also widespread agreement that therapists must be available to provide support 
during dosing sessions, particularly in moments of heightened anxiety (Cutner, 1959; Johnson et 
al., 2008; Sherwood et al., 1968).  According to Cutner (1959): 
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“The ego-threshold is rather suddenly lowered and the patient’s defenses against the 
impact of emotional and instinctual or archetypal contents are suddenly weakened, a 
greater amount of anxiety may be engendered than is usual in general analysis. Due to 
this, there is a much greater need for assurance…sometimes by physical touch.” (p. 722) 
 
Beyond the provision of support, there’s disagreement within the literature regarding the 
appropriateness of further therapeutic intervention during a dosing session. According to 
contemporary research guidelines, study participants should be encouraged to “collect 
experiences [while under the influence] to discuss after the drug effects have abated and [are 
discouraged from analyzing] material or [communicating] excessively while the atypical states 
of consciousness are still occurring,” (Johnson et al., 2008, p. 615).  In contrast, first-wave 
investigators are divided over the matter.  Certainly, it’s possible to trace today’s safety 
guidelines to first-wave thinkers, such as Sherwood et al. (1962): 
“It will be noted that an outstanding characteristic of this method of therapy is that it 
places major responsibility clearly on the patient and tends to discourage any sort of long-
term dependency or transference relationship with the therapist. The therapist is not 
called upon to analyze or to interpret except in a most minimal sense. The subject is 
encouraged to discover that his own resources are more than adequate to his needs, and 
the therapist's function is to provide support and guide him toward discovery.” (p. 99)  
 
Nevertheless, first-wave clinicians were more inclined to view psychedelics as an “enhancer of 
skilled psychotherapy,” (Pahnke et al., 1970, p. 1862) and therefore an agent to be incorporated 
into an ongoing traditional psychoanalysis: 
“The ability to make deep interpretations [is] important; the silent or reflective method 
does not take the patient as rapidly as possible to the core of his problems. A fear of 
premature or too penetrating interpretation is minimized by the patient’s ability to view 
himself with detachment. Incorrect or unacceptable interpretations tend to be brushed 
aside.” (Cohen & Eisner, 1958, p. 532)  
 
According to this line of thinking, classic psychedelics potentiate the therapeutic encounter by 
deepening a patient’s access to unconscious material and ability to tolerate challenging 
interpretations.  Additionally, numerous first-wave clinicians link psychedelic exposure to an 
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enhanced capacity to work in the transference (Chandler & Hartman, 1960; Cohen & Eisner, 
1958; Grof, 1967; Schmiege, 1963; Unger, 1963): 
“Transference is more easily analyzed with LSD because of the intensification of affect 
which occurs, so that the patient finds it harder than usual to conceal his feelings toward 
the therapist…Greater availability of early memories and childhood emotions toward the 
parents which so frequently parallel the transference reactions also facilitate analysis of 
the transference. The material produced lends itself to the therapist’s interpretations of 
the nature and operation of the less adaptive defenses. Patients more readily grasp 
interpretations because of their greater capacity for insight.” (Carhart & Hartman, 1960, 
p. 68) 
 
The literature also highlights the relationship between an analyst’s own psychedelic 
psychotherapy and the ability to work ethically with psychedelic-assisted transference: 
“The emotional as well as the technical demands upon the therapist are greater than in 
other forms of therapy because of the greater prominence of the ‘primary process’ type of 
material with which he must deal. The intensification of affect and the fact that the 
impulse life presents itself in much thinner disguise, or as none at all, may touch off 
unconscious problems in the therapist if his own analysis and his exploration of his 
unconscious under LSD had been inadequate. A therapist working with LSD should have 
had extensive personal analysis himself, as well as a series of at least 20 to 40 sessions 
with the drug, to explore all aspects of his unconscious and to become familiar with all 
the typical symbols, identifications, projections, and transference reactions.” (Chandler & 
Hartman, 1960, p. 68) 
 
First- and second-wave investigators are also divided over the importance of long-term 
psychotherapy.  Likely a reflection of methodological considerations, second-wave investigators 
do not study classic psychedelics in the context of long-term treatment but, instead, commonly 
administer 1-2 psychedelic doses in a supportive setting, with the availability of follow-up 
therapeutic supports when necessary.  In contrast, a majority of first-wave investigators 
resoundingly assert the importance of the long-term psychotherapeutic frame (Cohen, 1960; 
Chandler & Hartman, 1960; Pahnke, 1969; Pahnke et al., 1970; Savage et al., 1962; Savage et 
al., 1964; Savage et al., 1966; Schmiege, 1963).  In their words: “The delusion that the drug in 
itself can produce a cure may be a temptation to the immature therapist,” (Schmiege, 1963, p. 
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205).  “The psychedelic experience serves as an opening wedge. It is not nor has it been reported 
to be the entire process,” (Savage et al., 1966, p. 252).  Absent long-term psychotherapeutic 
supports, “the social matrix will remold the patient and the LSD experience will become a 
memory rather than an integral part of the personality,” (Savage et al., 1962, p. 435).  First-wave 
investigators also highlight the phenomenon of “psychedelic afterglow” (Pahnke et al., 1970, p. 
1858), whereby the potency of psychotherapeutic interventions is heightened in the days and 
weeks following a dosing session (Pahnke, 1969; Sherwood et al., 1962).  Importantly, while 
there’s second-wave evidence to support the long-term impact of even a single psychedelic dose 
absent long-term psychotherapy (Bouso et al., 2018; Erritzoe et al., 2018; Griffiths et al., 2011; 
Lyons et al., 2018; Maclean et al., 2011; Schmid & Liechti, 2018), there’s also sound first-wave 
evidence suggesting psychedelic gains may be lost over time if proper psychotherapeutic 
supports are not in place (Mogar et al., 1964; Savage et al., 1966; Savage et al., 1968).  Although 
impossible to conclusively adjudicate as the literature currently stands, first-wave subject pools 
include more severe pathology and psychotherapy may therefore prove more integral to 






To date, no investigator has yet probed the effect of classic psychedelics on personality 
through a contemporary psychodynamic lens.  As these substances are increasingly legalized and 
reintroduced into the psychotherapeutic frame, a deeper understanding of their effect on 
personality and overall wellbeing - as well as their clinical contraindications and potential pitfalls 
- will prove essential.  As a result, this study represents a preliminary investigation into the effect 
of classic psychedelics on psychodynamic constructs that are thought to undergird personality: 
psychiatric symptomatology, attachment style, mentalization, personality organization, prosocial 
behavior and a capacity for flourishing. 
Participants 
Data will be collected through a collaboration with The Psychedelic Society, a non-profit 
organization based in the United Kingdom.  According to the organization’s mission statement:  
“The Psychedelic Society believes the conscious use of psychedelics can help create a 
more compassionate and joyful world through an appreciation of the unity and 
interconnectedness of all things.  Psychedelics have been used by humans for thousands 
of years for healing and spiritual development. After decades of misinformation, and 
outlawing on political as opposed to scientific grounds, the potential of these substances 
is starting to be recognized again. We exist to reinstate the public understanding of and 
access to psychedelics in the UK and beyond.”   
 
As part of their work, The Psychedelic Society facilitates what they call Experience Retreats in 
the Netherlands, where participants ingest psilocybin truffles in a safe, legal and ceremonial 
context, under the guidance of experienced facilitators.  Their rotating team of twelve facilitators 
are trained in a variety of modalities, including psychotherapy, counseling, festival welfare, 
bodywork, Dharma meditation, shamanic practices, sound healing and psychopharmacology.  
According to the Psychedelic Society’s website, “retreats are aimed at people in good mental and 
 
 47 
physical health wanting to explore the nature of reality and the mind.  They are not intended as a 
substitute for medical or psychotherapeutic care.”   
In order to attend a retreat, interested individuals must first apply to the Psychedelic 
Society through an online application, where information is requested regarding personal and 
familial history of mental health difficulty, medication management and exposure to 
psychoactive substances.  Exclusion criteria includes clinically diagnosed and treatment-resistant 
depression and/or anxiety, psychosis (or a first-degree relative with schizophrenia), active PTSD, 
or the following medications: SSRI or SNRI, lithium and benzodiazepines.  Once individuals are 
cleared to participate, they are invited to enroll in Experience Retreats via an online portal.  
These 4-day retreats7 accommodate 10-20 participants at a time, with at least one facilitator per 
every five attendees.  Retreats are offered on a sliding scale basis, ranging from 650 to 2000 
euros per person.  Due to the Schedule 1 classification of psilocybin in the United States and the 
methodological obstacles that ensue, participants of an upcoming Experience Retreat will serve 
as a self-selected convenience sample for this study. 
Set and Setting 
 As set and setting strongly affect the psychedelic experience, a detailed description of the 
Experience Retreat program is provided here.   
 Day 1: Participants meet in Amsterdam to purchase psilocybin together (two 22-gram 
packs per person).  They then travel approximately two hours by bus to the retreat center.  
Accommodations are simple dormitories located in the woods, with approximately 1-2 
participants per room.  Upon arrival, participants are served dinner (all retreat meals are vegan).  
Evening activities begin with an opening circle, where participants introduce themselves and 
 
7 Effective January, 2020, retreats will be 5-6 days in duration, which will slightly shift the schedule of events. 
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ethical guidelines are discussed.  As psilocybin exposure is thought to intensify projections and 
emotional vulnerability, attendees are asked to refrain from sexual activity with one another 
throughout the duration of the retreat and up to one month following.  (These guidelines do not 
apply to preexisting couples who attend the retreat together).  Additionally, participants are also 
asked to turn off electronics in order to support psychological presence and intentionality 
throughout the retreat.  The first evening concludes with a group exercise, which may include 
bodywork, yoga or meditation.  
 Day 2: The day begins with a morning practice (bodywork, yoga or meditation), followed 
by breakfast.  Each participant then meets one-on-one with a designated retreat facilitator to 
discuss the upcoming psilocybin ceremony.  During these freeform conversations, participants 
are invited to explore any lingering questions and concerns.  Additionally, facilitators ask 
participants whether they feel comfortable receiving physical comfort during the psilocybin 
ceremony if necessary and whether they would rather receive such support from a male or 
female facilitator.  Participants are also encouraged to request help during the ceremony when 
needed.  Lastly, psilocybin dose is discussed.  Most participants choose to ingest approximately 
33 grams of psilocybin (1.5 packs), although up to 44 grams (2 packs) are offered depending on 
individual preference.  After one-on-one check-ins, and in advance of the ceremony, participants 
gather together to press the psilocybin truffles into a paste. 
 The five-hour ceremony begins late morning (approximately 11:30 AM) and is held 
indoors in an open room with natural light.  An alter is placed at the center of the room with 
objects that participants handpick from surrounding nature, such as pinecones and flowers.  Each 
participant is provided a mattress (arranged in a circle around the alter), as well as a pillow, 
blanket and eyeshade.  In order to initiate the ceremony, each participant is invited to share his or 
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her intention for the psilocybin experience.  The psilocybin paste is then mixed with hot water 
and ingested as a tea, with most participants drinking two infusions.  (A third infusion is offered 
approximately one hour into the ceremony).  Participants are then invited to lie down, wear their 
eyeshades and psychologically surrender to the experience.  A music playlist accompanies the 
ceremony, curated by Dr. Mendel Kaelen, an ethnomusicologist who arranges soundtracks to 
specifically support the trajectory of psychedelic exposure (for example, music intensifies as 
drug impact peaks).  Although participants are encouraged to quietly tune into themselves and 
limit interaction with others, facilitators are available to escort participants to the bathroom when 
necessary and provide emotional support if needed.  Additionally, approximately four hours into 
the ceremony, light snacks are offered, including sandwiches, dark chocolate and fruit.   
 Following the ceremony’s completion, gentle activities are facilitated (such as walking in 
nature or making art).  Dinner is then served, followed by a brief check-in circle before bed, 
where participants are invited to share initial impressions and feelings.  
 Day 3: Day three of the retreat provides an opportunity for integration - the intentional 
process of incorporating new insights into one’s emotional life and models of the world.  Such 
activities include bodywork, yoga, meditation, journaling, time in nature, the creation of art, song 
and group discussion.  Each participant also attends one-on-one check-ins with his or her 
designated facilitator in order to reflect on the experience and enlist further support.  
 Day 4 and beyond: Following a morning practice (such as bodywork, yoga or 
meditation), as well as breakfast, attendees participate in one final integration circle.  Here, 
participants are given another opportunity to verbally process their experience and share 
reflections with the group.  Additionally, facilitators offer best practices for post-psychedelic 
reintegration into everyday life.  For example, although participants are encouraged to make 
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space and time for deep reflection, they are also discouraged from making any radical life 
changes in the first few weeks following psychedelic exposure.  Participants are also encouraged 
to stay in touch and support one another as the integration process unfolds.   
At approximately 1:30 PM, all participants board a bus back to Amsterdam.  Following 
the retreat, contact information is provided via follow-up email for further psychotherapeutic 
supports in the event that such resources prove necessary.  Additionally, a conference call is held 
three weeks post-retreat, where participants are invited to reconnect and reflect on integration 
experiences together. 
 When compared to first- and second-wave research methodologies, this study most 
closely resembles the contemporary approach.  In contrast to the first wave (where drug 
administration predominantly occurred in the context of long-term psychotherapy with subject 
pools that included severe psychopathology), this study’s participants will skew in a healthier 
direction (due to the implementation of second-wave safety guidelines, such as the exclusion of 
bipolar and psychotic disorders) and the administration of psilocybin will occur in the absence of 
long-term psychotherapy.  Of note, and representing a contrast to the most prevalent first- and 
second-wave approaches, this study will administer psilocybin in a group (as opposed to an 
individual) and ceremonial (as opposed to a clinical) context.   
Measures 
 Participants will complete the following measures the day before drug exposure (via 
hardcopy questionnaire during the bus ride to the retreat center), two days after drug exposure 
(via hardcopy questionnaire during the bus ride back to Amsterdam) and at a one-month follow-
up (via online questionnaire).  Qualitative observations will also be collected and recorded 
throughout the retreat.  All participants will provide informed consent prior to data collection. 
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Brief Symptom Inventory (BSI): The BSI (Derogatis & Melisaratos, 1983) is a 53-item 
self-report inventory covering nine symptom dimensions: somatization (SOM), obsession-
compulsion (O-C), interpersonal sensitivity (I-S), depression (DEP), anxiety (ANX), hostility 
(HOS), phobic anxiety (PHOB), paranoid ideation (PAR) and psychoticism (PSY).  Each item is 
ranked on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely), with rankings 
intended to characterize distress intensity over the prior seven days.  Three global indices of 
distress are also captured: global severity (GSI), positive symptom total (PST) and positive 
symptom distress severity (PSDI).  Several studies have demonstrated the BSI’s adequate 
internal consistency and construct validity, with a nine-factor structure (Derogatis, 1975; Boulet 
& Boss, 1991). 
Experiences in Close Relationships-Revised (ECR-R): The ECR-R (Fraley, Waller & 
Brennan, 2000) is a self-report measure designed to capture adult attachment, with 36 items 
ranked on a 7-point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree).   The 
ECR-R yields two subscale scores: attachment-related anxiety (Ax) (the extent to which 
individuals fear rejection and abandonment) and attachment-related avoidance (Av) (the extent 
to which individuals resist closeness and dependency).  The ECR-R demonstrates adequate 
psychometric properties, with a reliable and replicable dual factor structure and stable test-retest 
reliability estimates of trait attachment (Sibley & Liu, 2004). 
Mentalization Scale (MentS): The MentS (Dimitrijević, Hanak, Dimitrijević & 
Marjanović, 2018) is a 28-item self-report measure of mentalization, defined as “the mental 
process by which an individual implicitly and explicitly interprets the actions of himself and 
others as meaningful on the basis of intentional mental states such as personal desires, needs, 
feelings, beliefs, and reasons,” (Bateman & Fonagy, 2004, p. 21).  Responses are provided on a 
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5-point Likert scale, ranging from 1 (completely disagree) to 5 (completely agree).  Three sub-
scale scores are calculated: self-related mentalization (MentS-S), other-related mentalization 
(MentS-O) and motivation to mentalize (MentS-M) (one’s need to understand the psychic world 
of self and others).  The MentS is a new measure (2018) and preliminarily demonstrates adequate 
psychometric properties (Dimitrijević et al., 2018). 
Inventory of Personality Organization (IPO): The IPO (Lenzenweger, Clarkin, Kernberg 
& Felsch, 2001) is a psychometrically sound, 57-item, self-report measure of personality 
organization.  Responses are ranked on a 5-point Likert-scale ranging from 1 (never true) to 5 
(always true).  Three subscale scores are calculated: identity diffusion (21 items, self-other 
differentiation), primitive defenses (16 items, includes defenses such as projective identification, 
denial, omnipotence and devaluation) and impaired reality testing (20 items, an individual’s 
ability to distinguish the subjective from the objective). 
Pathological Narcissism Inventory (PNI): The PNI (Pincus, Pimentel, Cain, Wright, 
Levy & Ansell, 2009) is a 52-item, self-report inventory, with each item ranked on a 6-point 
scale, ranging from 0 (not at all like me) to 5 (very much like me).  The PNI reliably measures 
seven symptom dimensions of pathological narcissism: contingent self-esteem (CSE) 
(dysregulation in the absence of admiration), exploitativeness (EXP) (manipulative interpersonal 
approach), self-sacrificing self-enhancement (SSSE) (the use of purportedly altruistic acts to 
inflate self-image), hiding the self (HS) (refusal to reveal faults or needs), grandiose fantasy (GF) 
(fantasies of success, admiration, and recognition), devaluing (DEV) (disinterest in those who do 
not provide admiration and feelings of shame when yearning for recognition from rejecting 
others), and entitlement rage (ER) (angry affect following unmet and entitled expectations).  
These subscales also yield three global indices: narcissistic grandiosity (PNI-G) (average of 
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EXP, SSSE, and GF), narcissistic vulnerability (PNI-V) (average of CSE, SSSE, HS, and ER) 
and pathological narcissism (average of PNI-G and PNI-V) (Wright, Lukowitsky, Pincus & 
Conroy, 2010).  Of note, the PNI demonstrates clinical utility and adequate psychometric 
properties (Edershile, Simms, & Wright, 2019; Thomas, Wright, Lukowitsky, Donnellan, & 
Hopwood, 2012). 
Pro-Environmental Behavior (PEB): According to the United Kingdom’s Department for 
Environment, Food and Rural Affairs (DEFRA, 2008), PEB reflects four behavioral domains: 
domestic energy and water use, waste behavior, transport, and eco-friendly shopping.  PEB is 
reliably measured by a 17-item self-report questionnaire (Whitmarsh & O’Neill, 2010; 
Forstmann & Sagioglou, 2017), which asks individuals to indicate how frequently they perform 
certain environmentally considerate actions on a Likert scale ranging from 1 (never) to 4 
(always). 
The Ryff Scale of Psychological Well-Being (Ryff): The Ryff (Ryff, 1989) is a 
psychometrically sound inventory (Ryff, 2014), consisting of 54 self-report items, rated on a 6-
point Likert scale, ranging from 1 (strongly disagree) to 6 (strongly agree).  The Ryff yields 
subscale scores on six dimensions of well-being: autonomy (self-determination and 
independence, ability to resist social pressure), environmental mastery (competence managing 
external environment and surrounding opportunities, ability to create contexts that reflect 
personal needs and values), personal growth (ongoing expansion, movement toward realizing 
potential and self-knowledge over time), positive relations with others (warm, satisfying and 
trusting relationships, capacity for empathy, affection, and intimacy), purpose in life (sense of 
meaning and direction) and self-acceptance (positive attitudes toward self, with an ability to 
accept positive and negative qualities of past and present self). 
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Mystical Experience Questionnaire (MEQ): The MEQ (MacLean, Leoutsakos, Johnson 
& Griffiths, 2012) is a 30-item measure of self-reported mystical experience.  Rankings are 
provided on a six-point Likert scale, ranging from 0 (none, not at all) to 5 (extreme, more than 
ever before in my life).  The MEQ demonstrates adequate validity and reliability, as well as a 
four-factor structure: 1) unity, noetic quality, sacredness, 2) positive mood, 3) transcendence of 
space and time, and 4) ineffability (MacLean et al., 2012).  
Hypotheses 
 This study predicts improvement across all personality-related measures directly 
following drug exposure, as well as maintenance of improvement at a one-month follow-up.  
More specifically, gains will be reflected in the following domains: psychiatric symptomatology 
(measured by the Brief Symptom Inventory, BSI), attachment style (measured by the 
Experiences in Close Relationships-Revised, ECR-R), mentalization (measured by the 
Mentalization Scale, MentS), personality organization (measured by the Inventory of Personality 
Organization, IPO, and the Pathological Narcissism Inventory, PNI), pro-social behavior 
(measured by Pro-Environmental Behavior, PEB), and a capacity for flourishing (measured by 
the Ryff Scale of Psychological Well-Being, Ryff).  It is also hypothesized that mystical 
experience during psilocybin exposure (measured by the Mystical Experience Questionnaire, 
MEQ) will moderate improvement on the aforementioned measures.  
 The subject pool of approximately 60 subjects will likely skew in a psychologically 
healthy direction due to the implementation of relevant exclusion criteria.  As a result of the 
relatively healthy makeup of this subject pool, findings will reflect the effect of classic 
psychedelics on healthy populations and will likely preclude the direct exploration of classic 
psychedelics and their effect on individuals suffering from personality disturbances.  
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Nevertheless, if possible, post-hoc tests will preliminarily explore whether individuals high in 
narcissism experience an exacerbation of narcissistic tendencies following psychedelic exposure 
in the absence of long-term psychotherapy (as indicated by Savage et al., 1962; Chandler & 
Hartman, 1960; Cohen & Eisner, 1958).  If possible, post-hoc tests will also preliminarily 
explore whether individuals organized at the borderline level evidence improvement directly 
following drug exposure, but lose gains at a one-month follow-up in the absence of long-term 
psychotherapy (an arc implied by Chandler & Hartman’s 1960 MMPI research).  
Data Analysis 
Hierarchical Linear Models (HLMs) are the preferred statistical method when estimating 
growth models (estimates of between-person differences in within-person change over time), as 
this approach provides numerous advantages, including an ability to estimate polynomial trends, 
as well as a capacity to handle partially missing data and unequally spaced time points (Kwok, 
Underhill, Berry, Luo, Elliott, & Yoon, 2008; Curran, Obeidat, & Losardo, 2010).  As a result, 
an HLM will be used to analyze the growth curves of within-person change on all measures 
(BSI, ECR-R, MentS, IPO, PNI, PEB, and Ryff) and across three time points (day before drug 
exposure, two days after drug exposure, and at a one-month follow-up).  Additionally, 
psychedelic-assisted mystical experiences (as measured by the MEQ) will be introduced as a 
predictor into a conditional growth model.  Serving as a Time-Invariant Covariate (TIC) (a 
predictor variable that does not change in value as a function of time), it is hypothesized that the 
mystical experience will determine the degree and rate of post-psychedelic change over time.  
As this study’s sample is anticipated to be relatively psychologically healthy, post-hoc 
tests will only preliminarily explore the effect of personality pathology on the aforementioned 
outcome measures.  If numbers allow, descriptive statistics will explore whether trajectories over 
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time trend in the direction of aforementioned hypotheses (individuals high in narcissistic 
pathology will evidence an exacerbation of narcissistic traits and/or individuals organized at the 
borderline level will evidence initial improvement, followed by a regression at two months).  
Alternatively, analysis may need to occur on an individual basis, whereby the trajectory of one 
participant with high levels of personality pathology is analyzed to see whether he or she trends 
in the hypothesized direction. 
Statistical Power and Sample Size 
Power analyses were conducted for linear growth models using a hierarchical mixed 
model approach to repeated measures data (Kreidler, Muller, Grunwald, Ringham, Coker-
Dukowitz, Sakhadeo, Baron, & Glueck, 2013).  The design specified used a baseline assessment, 
post-experience assessment, and follow-up assessment with various measures outlined above.  
The hypotheses predict an improvement from baseline to post-experience assessment, 
maintained at follow-up, and this was the pattern of means used for the power analysis.  A 
change of ½ SD was evaluated, as was a change of ¼ SD.   
There is no available pilot data for the current design, so test-retest correlations were used 
to approximate the intraclass correlation (ICC), which was required by the program.  Test-retest 
correlations were generally high, ranging from .72 (IPO Primitive Defenses) to .90 (BSI Global 
Symptom Index), but reliability information was not available for all measures.  Therefore, an 
ICC value of .8 was assumed for all tests.   
Other assumptions included power of .80, alpha = .05, and mean and variability scale 
factors of 1.  It was also assumed that the correlation between measurements over time 
monotonically decreases with distance or time between repeated measurements. The model has 
two correlation parameters, the base correlation and the decay rate. The base correlation 
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describes the correlation between measurements taken 1 unit apart and this was assumed to be 
.80 as per the test-retest correlations. The decay rate describes the rate of decrease in the base 
correlation as the distance or time between repeated measurements increases, and this was also 
assumed to be .50.  Kreidler et al. (2013) recommend a decay rate of between .05 and .50 for 
behavioral science data and the larger was chosen due to the presumed stability of these 
characteristics and the high test-retest correlations found. 
The results found that to achieve power of .80 to detect a ½ SD change in mean scores 
would require a sample of approximately 19 subjects. For the sample power to detect a smaller, 
¼ SD, change would require approximately 60 subjects.   
Covid-19 Methodology Amendment 
Due to the Covid-19 global pandemic, the Psychedelic Society unexpectedly and 
indefinitely paused all Experience Retreats in March of 2020, which, in turn, prematurely halted 
data collection.  Although the sample size was initially projected to include 60 participants in 
order to achieve statistical power, the sample in its current form includes a total of 21 
participants, many of whom did not complete the entire protocol.  Specifically, there were 8 
participants with completed measures at all three time points, 3 participants with completed 
measures at two time points, 3 participants with completed measures at one time point, and 7 
participants with a partially completed dataset at the first time point.   
In order to allow for the most robust analysis possible in the context of these unexpected 
constraints on sample size, a qualitative and exploratory study design was proposed, with an 
amended methodology detailed below: 
1. Mixed Model Analyses: Though constrained by low power across the board, mixed 
model analyses will assess the data’s preliminary statistical trends.  In this context, 
 
 58 
mixed models remain preferable to ANOVAs, as they optimize data through the 
inclusion of subjects with missing time points.  Specifically, two Hierarchical Linear 
Models (Model 1 and Model 2) with restricted maximum likelihood estimations will 
be conducted for each measure in order to predict outcome scores over time, while 
controlling for Social Desirability (SD).  A random intercept will be included in each 
model to account for varying baselines, with all other effects included as fixed 
effects.  Model 1 will use a Hierarchical Linear Model to test the degree and shape 
(linear vs. curvilinear) of change over time (before psychedelic exposure, after 
psychedelic exposure, and at a one-month follow-up) by including time as both a 
linear effect (Time) and a quadratic effect (Time2).  Additionally, in order to estimate 
effect sizes for this model, a calculation of R2 from Hoffman (2015) will be used. In 
this method, the model’s predicted values of the outcome variable will be correlated 
with the actual values and then the correlation will be squared to obtain the 
percentage of variance explained (small effect size = .02, medium = .09, large = .25).  
Model 2 will examine whether Mystical Experiences (ME) affect trajectory over time 
by conducting a Hierarchical Linear Model with all variables: Time, Time2, SD, ME 
(1=yes, 2=no) and the interaction of ME x Time.  In turn, the difference between the 
effect sizes for Model 1 and Model 2 will indicate the amount of variance explained 
by having had a mystical experience (ME), as well as the interaction of ME and 
Time. 
2. Reliable Change Scores: As stand-ins for historical controls, test-retest reliability 
correlations will determine whether within-person change is sizable enough (reliable 
change scores > ±1.96) to indicate clinical and statistical significance, or whether 
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measurement error provides a more reasonable explanatory framework for 
understanding variations between time points (reliable change scores < ±1.96) 
(Jacobson & Truax, 1991). 
3. Clinical Case Studies: In order to qualitatively explore the effect of psychedelic 
exposure on personality, individual subjects will be selected and their trajectories 
analyzed through a clinical lens in an effort to identify emerging patterns. 
4. Qualitative Data Analysis: All qualitative data collected in response to open-ended 
queries will be thematically analyzed in order to provide an additional framework for 









Sample characteristics are based on the 11 subjects with at least 2 complete datasets (see 
Table 1).  The majority of the sample identified as White (n = 8) and female (n = 7) between the 
ages of 25 and 39 years old (n = 6).  Participants were highly educated, with 100% of subjects 
holding a bachelor’s degree or higher.  The majority of the sample had no prior experience with 
classic psychedelics (n = 7).   
Table 1. 
Demographic characteristics of the sample. 
______________________________________________________________________________ 
Factor         n (%) 
 
Age 
18-24     1 (9%) 
    25-39     6 (55%) 
    40-60     3 (27%) 
    60+     1 (9%) 
Sex 
Female     7 (64%) 
    Male     4 (36%) 
    Other     0 (0%) 
Race/Ethnicity 
White     8 (73%) 
    Black or African American  1 (9%) 
    American Indian or Alaska Native 0 (0%) 
    Asian     1 (9%) 
    Native Hawaiian or Pacific Islander 0 (0%) 
    Hispanic or Latino   2 (18%) 
    Other     1 (9%) 
Highest Education 
    No Formal Education   0 (0%) 
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    Highschool degree   0 (0%) 
    Bachelor’s Degree   4 (36%) 
    Master’s Degree   4 (36%) 
    Doctoral Degree   2 (18%) 
    Other     1 (9%) 
Romantic Partnership 
    Single     5 (46%) 
    Partnered for under 6 months  1 (9%) 
    Partnered 1-3 years   1 (9%) 
    Partnered 3-10 years   3 (27%) 
    Partnered 10+ years   1 (9%) 
Total Household Income 
Under $20,000    4 (36%) 
    $20,001 to $40,000   2 (18%) 
    $40,0001 to $60,000   1 (9%) 
    $60,001 to $80,000   3 (27%) 
    $80,001 to $100,000   0 (0%) 
    $100,001 or more   1 (9%) 
Psychotherapy 
    No therapy past or present  5 (46%) 
    Prior therapy, but not currently  2 (18%) 
    Currently in therapy   4 (36%) 
Prior Psychedelic Experience 
    None     7 (64%) 
    Mescaline / Peyote   0 (0%) 
    Psilocybin / Magic Mushrooms  3 (27%) 
    LSD / Acid    2 (18%) 
    Ayahuasca    0 (0%) 
    DMT     0 (0%) 
    Ibogaine    0 (0%) 
    Other     0 (0%) 
Frequency of Experiences 
    0 experiences    7 (64%) 
1 experience    1 (9%) 
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    2-5 experiences    2 (18%)  
    6-10 experiences   1 (9%) 
    11-20 experiences   0 (0%) 
    More than 20 experiences  0 (0%) 
______________________________________________________________________________ 
 
Of note, t-test analyses comparing the study sample with the 7 participants who dropped 
out midway through baseline revealed no meaningful differences with regard to performance on 
measures (see Table 2) or demographic characteristics (see Table 3). 
Table 2. 
Difference between baseline dropouts and study sample on self-report measures. 
 
    
Dropout Sample 
     ________________________________ 
Variable     M (SD)  M (SD)  t df p 
 
Brief Symptom Inventory       .440      .584  -1.014 19 1.39 
Global Severity Index  
 
Pro-Environmental Behavior     2.343    2.659  -1.544 19 .342 
 
Inventory of Personality Organization  45.800  49.000    -.574 18 .251 
Identity Diffusion  
  
Inventory of Personality Organization  35.600  35.800    -.051 18 .990 
Impaired Reality Testing  
 
Inventory of Personality Organization  26.600  30.667  -1.159 18 .844 
Primitive Defenses  
 















Demographic differences between baseline dropouts and dataset sample. 
____________________________________________________________ 
Variable     x2 df  p 
____________________________________________________________ 
 
Gender      0.175 1 .67 
 
Age      1.330 3 .72 
 
Race/Ethnicity     2.217 4 .70 
 
Romantic Partnership    0.311 1 .58 
 
Highest Level of Education   1.994 3 .57 
 
Psychotherapeutic Treatment   0.543 2 .76 
____________________________________________________________ 
*p < .05. **p < .01 
 
Due to this sample’s small size and, in turn, limited capacity to discern meaningful 
differences among subscales, global indices were chosen to represent each measure where 
possible (see Table 4).  Of note, the rationale for choosing each scale’s summary measure can be 
found in Appendix A.  All relevant scales show acceptable to excellent reliability, with the 
exception of the Inventory of Personality Organization’s Impaired Reality Testing scale at one 
time point (follow-up), which neared the .7 acceptability cut-off, with a .641 alpha coefficient.   
With regard to the Ryff Scale of Psychological Wellbeing, five of eighteen sub-scales 
showed questionable to unacceptable reliability.  As a result, the item-total correlations and alpha 
if item deleted statistics were examined to determine whether particular items were problematic.  
These statistics were both low, indicating an overall problem with the Ryff subscales, rather than 
a problem with one single item.  As a result, all Ryff sub-scales were combined to create one 










Scale     N items  Pre-test  Post-test Follow-up 
 
Brief Symptom Inventory  53  .891  .886  .948 
Global Severity 
 
Experiences in Close Relationships 18  .923  .923  .932 
Attachment-Related Anxiety 
 
Experiences in Close Relationships 18  .850  .951  .941 
Avoidance-Related Anxiety 
 
Mentalization Scale   28  .871  .886  .735 
Global 
 
Pathological Narcissism Inventory 18  .812  .897  .904 
Grandiosity 
 
Pathological Narcissism Inventory 34  .947  .966  .958 
Vulnerability  
 
Pathological Narcissism Inventory 52  .947  .967  .960 
Pathological Narcissism 
 
Pro-Environmental Behavior  17  .750    n/a  .822 
 
Ryff Scale of Psychological Wellbeing    9  .767  .882  .773 
Autonomy 
 
Ryff Scale of Psychological Wellbeing   9  .780  .777  .671 
Environmental Mastery 
 
Ryff Scale of Psychological Wellbeing   9  -.144  .177  .210 
Personal Growth 
 
Ryff Scale of Psychological Wellbeing   9  .771  .845  .905 
Positive Relations with Others 
 
Ryff Scale of Psychological Wellbeing   9  .452  .677  .834 
Purpose in Life 
 
Ryff Scale of Psychological Wellbeing   9  .916  .941  .890 
Self-acceptance 
 
Ryff Scale of Psychological Wellbeing 54  .897  .942  .934 




Inventory of Personality Organization 21  .885  .931  .952 
Identity Diffusion 
 
Inventory of Personality Organization 20  .809  .756  .641 
Impaired Reality Testing 
 
Inventory of Personality Organization 16  .769  .746  .891 
Primitive Defenses 
 
Mystical Experience Questionnaire 30  .962    n/a    n/a 
______________________________________________________________________________ 
 
Correlations between the Marlowe-Crowne Social Desirability (SD) scale and all other 
measures were run in order to assess the potential relationship between self-report items and 
social desirability biases (see Table 5).  Although none of the correlations were statistically 
significant, approximately one-quarter (25.7%) of all effect sizes were in the medium (r ≈.3) to 
large (r ≈.5) range.  As a result, all mixed model analyses (except where noted) controlled for 











Self-report scales correlated with Marlowe-Crowne Social Desirability scale at each time point. 
______________________________________________________________________________ 
 
Scale       r (Pre-test) r (Post-test) r (Follow-up)  
______________________________________________________________________________ 
 
Brief Symptom Inventory    -.510°°  -.038°  -.258  
Global Index 
 
Experiences in Close Relationships   -.264   .013   .227 
Attachment-Related Anxiety          
   
Experiences in Close Relationships   -.073   .172   .019 
Avoidance-Related Anxiety 
 
Mentalization Scale      .265  .453°   .081 
Global Index 
            
Pathological Narcissism Inventory   -.057   .039   .040 
 
Pathological Narcissism Inventory   -.369°  -.081   .057 
Vulnerability  
           
Pathological Narcissism Inventory   -.057   .039   .040 
Grandiosity           
 
Pro-Environmental Behavior     .027     n/a  -.640°°  
       
Ryff Scale of Psychological Wellbeing   .397°   .078   .120 
Overall Wellbeing 
 
Inventory of Personality Organization   -.449°  -.304°  -.140 
Identity Diffusion           
 
Inventory of Personality Organization   -.224  -.352°  -.111 
Impaired Reality Testing          
  
Inventory of Personality Organization   -.196  -.259   .139 
Primitive Defenses            
______________________________________________________________________________ 
°medium effect size (r ≈ .3) 
°°large effect size (r ≈ .5) 
 
Overall, analyses for each measure were based on sample sizes ranging from 9 to 13 
participants. Additionally, and across measures, this study’s sample was highly normative, with 
the majority of participants falling within the normative range at all three time points.  See 
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Appendix B for a closer examination of sample characteristics by measure (including graphs of 
scores over time by subject). 
Hierarchical Linear Models 
 
Though constrained by low power across the board, mixed model analyses assessed the 
data’s preliminary statistical trends.  Specifically, a Hierarchical Linear Model analysis was 
conducted for each measure in order to predict the degree and shape of change over time, while 
controlling for SD.  Additionally, a second Hierarchical Linear Model was conducted for each 
measure with two additional variables: ME (0 = No, 1 = Yes) and the interaction of ME x Time.  
See Table 6 and Table 7 for a summary of all HLM analyses (with significant findings in bold) 
and Appendix C for a more in-depth exploration of all HLM analyses by measure (including 




















Summary of HLM findings for Model 1 by Summary Measure. 
_____________________________________________________ 
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Summary of HLM findings for Model 2 by Summary Measure. 
____________________________________________________________ 
Measure (n) Model 2: 
Effect of ME 
Model 2: 
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Note: ME = Mystical Experience group, Non-ME = Non-Mystical Experience group 
 
 
In sum, twenty-two Hierarchical Linear Models were conducted (two for each of the 
eleven summary measures) and only five models were significant.  With such small sample sizes, 
even statistically significant findings should be interpreted with prudence and viewed as 
provisional.  Within this cautionary context, it’s nevertheless relevant to note the following five 
significant findings: 1) BSI GSI scores evidenced a significant curvilinear pattern over time, with 
scores significantly decreasing (reflecting reduced symptomatology) directly following 
psilocybin exposure and increasing at follow-up (reflecting a return toward baseline after one 
month). 2) IPO-ID scores evidenced a significant curvilinear pattern over time, with a slight 
downward curve (and improved identity diffusion) by the one-month follow-up. 3) IPO-RT 
scores evidenced a significant and curvilinear pattern over time, with a slight downward curve 
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(and improved reality testing) by the one-month follow-up. 4) With regard to IPO-PD scores, the 
interaction for ME x Time was significant, indicating that the non-mystical experience group 
trended toward improved (lower) levels of primitive defenses over time, whereas the mystical-
experience group maintained similar levels of primitive defenses across time points. 5) With 
regard to PNI-G scores, the interaction of ME x Time was significant, indicating that the non-
mystical experience group trended toward improved (lower) levels of grandiosity over time, 
whereas the mystical-experience group maintained similar levels of grandiosity across time 
points.  While attempts to draw specific conclusions from any one particular finding would likely 
prove imprudent, the presence of multiple significant findings that reflect personality-related 
improvement (however nascent) within the context of so few participants suggest the importance 
of future research in this domain. 
Taking a wider view, and while the vast majority of HLMs yielded insignificant findings, 
it’s perhaps still notable that every HLM also yielded large effect sizes when predicting the 
impact of psilocybin exposure on the degree and shape of personality-related change over time 
(while controlling for SD).  While erratic outliers may explain this phenomenon, it’s also 
possible that large effect sizes paradoxically occurring alongside predominantly insignificant 
findings suggest the presence of relationships that would emerge in the context of larger sample 
sizes.  Additionally, and while perhaps less common in clinical research more globally, large 
effect sizes are common in psilocybin research (Bogenschutz, 2015; Carhart-Harris, 2017; Davis, 
Barrett & May, 2020; Griffiths, 2016), which may speak to the watershed experience of 
psychedelic exposure.  
With regard to HLMs analyzing the predictive power of ME and ME x Time, another 
trend emerged.  While only significant for two of the eleven relevant HLMs, seven of the eleven 
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HLMs reveal a consistent trend, whereby the non-mystical experience group averaged greater 
improvement relative to the mystical-experience group.  This preliminary trend is contrary to the 
literature (Doblin, 1991; Griffiths et al., 2008; Grof, 1970; Kurland et al., 1968; Lebedev et al., 
2016; Maclean et al., 2011; Maslow, 1959; Pahnke, 1969; Pahnke et al., 1970; Savage et al., 
1962; Unger, 1963) and also stands in contrast to study predictions, which projected the 
mystical-experience group to demonstrate greater improvement than the non-mystical experience 
group over time.  While this phenomenon may reflect erratic outliers, it may also reflect a novel 
finding that requires future investigation to further clarify.  
Reliable Change Scores 
Reliable change scores allow for the analysis of clinically and statistically significant 
change on the individual level.  With test-retest reliability correlations serving as stand-ins for 
historical controls, reliable change indices were calculated for each subject in order to assess 
within-person change over time.  Specifically, and for every measure, two reliable change scores 
were calculated for each participant: one reliable change score assessed within-person change 
between Timepoints 1 and 2 (directly before and after psilocybin exposure) and one reliable 
change score assessed within-person change between Timepoints 1 and 3 (directly before 
psilocybin exposure and at the one-month follow-up).  (Reliable change scores between 
Timepoints 2 and 3 can be found in Appendix D).  Of note, only one reliable change score was 
calculated for PEB (between Timepoints 1 and 3), as this measure was not administered at 
Timepoint 2.  Taken together, a total of 21 reliable change indices were calculated for each 
participant (two for each measure, except for PEB, where only one was calculated).  Of note, 
reliable change scores greater than ±1.96 indicate statistically significant within-person change 
and reliable change scores less than ±1.96 point to measurement error as a more reasonable 
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explanatory framework for variations between time points (Jacobson & Truax, 1991).  See 
Tables 8, 9 and 10 for reliable change scores for each subject by measure and timepoint (with 
significant scores in bold) and Appendix D for a more in-depth analysis of all reliable change 
score trends by measure.  
Reliable change scores indicate that more significant change may have occurred than 
HLMs were able to detect with such a small sample size.  Although the majority of reliable 
change scores were insignificant, it’s nevertheless notable that, for 12 of 21 measures, 2, 3 or 4 
participants earned significant reliable change scores (20% to 44.4% of subjects with known 
reliable change scores for that measure), indicating either significant improvement, or significant 
deterioration.  Measures with at least two participants with significant reliable change scores 
include the Brief Symptom Inventory’s Global Index (between Timepoints 1 and 2, as well as 
between Timepoints 1 and 3), the Inventory of Personality Organization’s Identity Diffusion 
subscale (between Timepoints 1 and 3) and Reality Testing subscale (between Timepoints 1 and 
3), the Pathological Narcissism Inventory’s Grandiosity subscale (between Timepoints 1 and 3) 
and Vulnerability subscale (between Timepoints 1 and 2, as well as between Timepoints 1 and 
3), the Mentalization Scale’s summary score (between Timepoints 1 and 2), the Experiences in 
Close Relationships-Revised attachment-related Anxiety subscale (between Timepoints 1 and 2, 
as well as Timepoints 1 and 3) and attachment-related Avoidance subscale (between Timepoints 
1 and 2, as well as Timepoints 1 and 3). 
In some cases, it’s possible that HLMs didn’t yield significant findings, as significant 
effects in opposite directions may have canceled each other out, with some individuals 
significantly improving, and others significantly deteriorating.  These findings suggest that 
psychedelic exposure may engender a potent psychological experience capable of catalyzing 
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improvement and deterioration, with an as yet unidentified variable explaining the interaction.  
Overall, and following an intervention that lasted only a few hours, it’s notable that even a few 
participants evidenced significant within-person change (at times sustained at a one-month 
follow-up), as psychological constructs (such as personality organization and attachment style, 
for example) are thought to be deeply entrenched and, in turn, challenging to alter, even under 
the best of psychotherapeutic circumstances.  Future research is warranted to confirm these 
preliminary conjectures and, perhaps most importantly, identify mechanisms that explain for 



























Reliable Change Scores by Subject for BSI GSI and IPO. 
 




T1 to T2 
BSI GSI 


















1 ME 1.51 n/a -0.89 n/a ** -
2.96 
 







0.21 1.27 1.27 *2.12  
3 ME *3.77 1.38 -1.60 1.60 -0.63 0.42 0.64 0.64 
4 ME *4.03 
 
n/a 0.71 n/a 0.21 n/a -0.64 n/a 
5 ME -0.88 0.50 0.53 *2.32 
 
0.85 0.00 -0.21 0.42 
6 Non-
ME 
1.64 0.88 1.07 *3.03 
 
0.42 1.69 1.49 1.91 
7 n/a n/a **-2.01 
 
n/a 1.96 n/a 1.48 n/a 0.42 
8 Non-
ME 
1.38 0.00 -0.71 0.89 -0.63 0.21 -0.42 0.42 
9 Non-
ME 
-1.26 n/a n/a n/a n/a n/a n/a n/a 
10 ME *3.65 
 
n/a 1.96 n/a -0.63 n/a 0.42 n/a 
11 ME -0.01 **-3.90 
 
0.00 -0.36 -0.85 *2.33 
 
1.27 0.64 
12 ME 0.88 0.25 -1.07 -0.71 -1.06 -1.27 -0.42 0.00 
 

























*Significant improvement (reliable change score >1.96) 
**Significant deterioration (reliable change score <-1.96) 
Note: T1 = Timepoint 1, T2 = Timepoint 2, T3 = Timepoint 3. ME = Mystical Experience group, Non-ME 
= Non-Mystical Experience group. BSI GSI = Brief Symptom Inventory Global Scale Index. IPO-ID = 
Inventory of Personality Organization, Identity Diffusion. IPO-RT = Inventory of Personality 







Reliable Change Scores by Subject for PNI, MENT-S, and the Ryff. 
 




T1 to T2 
PNI-G 






















1 ME -1.95 n/a -0.47 n/a 1.36 n/a 0.36 n/a 
2 Non-
ME 
1.27 *2.32  0.19 1.08 0.34 -0.51 0.29 0.76 
3 ME 0.34 -0.35 *3.70 *3.33 
 
-1.19 1.36 0.80 -0.18 
4 ME 0.16 n/a 1.41 n/a -0.17 n/a 0.65 n/a 




1.87 -0.91 0.04 
6 Non-
ME 
*3.62  *5.33  *6.44  
 
*7.83  *2.72  0.51 1.45 -0.40 
7 n/a n/a -0.94 n/a 1.71 n/a n/a n/a n/a 
8 Non-
ME 
-0.73 0.40 -0.60 1.57 -0.34 0.85 -0.36 0.80 
9 Non-
ME 
n/a n/a n/a n/a n/a n/a n/a n/a 
10 ME n/a n/a n/a n/a n/a n/a n/a n/a 
11 ME -0.66 -0.01 -1.34 1.32 -0.34 -0.85 -0.15 -0.33 
12 ME -0.73 -0.12 -0.73 0.70 0.00 -1.36 0.54 -0.58 
 






















*Significant improvement (reliable change score >1.96) 
**Significant deterioration (reliable change score <-1.96) 
Note: T1 = Timepoint 1, T2 = Timepoint 2, T3 = Timepoint 3. ME = Mystical Experience group, Non-ME 
= Non-Mystical Experience group. PNI-G = Pathological Narcissism Inventory, Grandiosity.  PNI-V = 
Pathological Narcissism Inventory, Vulnerability. MentS-T = Mentalization Scale Total.  Ryff-OW = Ryff 







Reliable Change Scores by Subject for ECR-R & PEB. 




T1 to T2 
ECR-R, 
Ax 
T1 to T3 
ECR-R, 
Av 
T1 to T2 
ECR-R, 
Av 
T1 to T3 
PEB 
T1 to T3 
1 ME 0.85 n/a 0.52 n/a 0.45 
 
2 Non-ME 1.09 *2.54 -0.26 0.64 1.13 
 
3 ME 0.61 -0.24 0.67 -0.52 0.23 
 
4 ME *2.54  
 
n/a 1.86 n/a n/a 
5 ME ** 
-2.43  
 
-1.35 -1.57 -1.31 0.23 
6 Non-ME *4.96  *3.50 *3.71  *3.98  -0.68 
 
7 n/a n/a 0.72 n/a 0.29 0.45 
 










9 Non-ME n/a n/a n/a n/a n/a 
 
10 ME n/a n/a n/a n/a n/a 
 







12 ME 0.24 -1.46 0.52 -0.26 0.23 
 






 40% (n=4) 44.4% 
(n=4) 




*Significant improvement (reliable change score >1.96) 
**Significant deterioration (reliable change score <-1.96) 
Note: T1 = Timepoint 1, T2 = Timepoint 2, T3 = Timepoint 3. ME = Mystical Experience group, Non-ME 
= Non-Mystical Experience group. ECR-R Ax = Experiences in Close Relationships, Attachment-Related 






Clinical Case Studies  
In order to more closely examine the potential relationship between pre-psychedelic 
personality organization and post-psychedelic outcome measures, two subjects were selected for 
closer qualitative analysis.  More specifically, the subject with the most personality pathology 
(11) and the subject with the least personality pathology (13) at baseline were selected for 
clinical case studies.  In order to maintain confidentiality, case studies do not include identifiable 
demographic variables or direct quotes from subjects (with self-report and open-ended 
qualitative responses summarized when necessary). 
Subject 11: Subject 11 was selected for a case write-up because s/he evidenced the most 
personality pathology in this study’s sample prior to psychedelic exposure, with the highest (least 
healthy) score on four of five measures of personality organization (PNI Grandiosity, PNI 
Vulnerability, IPO Reality Testing and IPO Primitive Defenses) and the second highest score on 
the fifth measure of personality organization (IPO Identity Diffusion).  Specifically, Subject 11 
evidenced narcissistic grandiosity within one standard deviation above the normative average 
(PNI-G = 2.98, normative average = 2.89 standard deviation = 0.66), narcissistic vulnerability 
between two and three standard deviations above the normative average (PNI-V = 3.74, 
normative average = 2.13, standard deviation = 0.74), identity diffusion within one standard 
deviation above the normative average (IPO-ID = 63, normative average = 51.68, standard 
deviation = 11.35), reality testing within one standard deviation above the normative average 
(IPO-RT = 48, normative average = 38.46, standard deviation = 9.67) and primitive defenses 
between one and two standard deviations above the normative average (IPO-PD = 47, normative 
average = 36.24, standard deviation = 7.91). 
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With regard to reliable change indices, which indicate significant within-person change 
over time, Subject 11 evidenced significantly improved reality testing (IPO-RT) by the one-
month follow-up, alongside significantly deteriorated overall symptomatology by the one-month 
follow-up (GSI BSI) and significantly deteriorated attachment-related anxiety (ECR-R Ax) by 
the one-month follow-up as well.  Subject 11 also evidenced deteriorated attachment-related 
avoidance (ECR-R Av) directly following psilocybin exposure, with a return to baseline by the 
one-month follow-up.  Subject 11 remained statistically unchanged on all other measures. 
Overall, Subject 11 evidenced the least healthy personality organization in the sample 
and also significantly deteriorated in numerous domains by the one-month follow-up.  Subject 11 
also evidenced improved reality testing, which may indicate that greater insight brought greater 
destabilization.  Based on this trajectory, future research should examine whether personality 
pathology is a risk factor for psychological deterioration in the presence of psychedelic exposure, 
and whether appropriate therapeutic interventions are able to capitalize on increased insight in 
order to mitigate deterioration and, in turn, nurture psychological growth in its stead. 
Subject 13: Subject 13 was selected for a case write-up because s/he evidenced the least 
personality pathology in the study’s sample prior to psychedelic exposure, with the lowest 
(healthiest) score on two measures of personality organization (IPO Reality Testing and PNI 
Grandiosity), second lowest score on two measures of personality organization (IPO Identity 
Diffusion and IPO Primitive Defenses) and fourth lowest score on the final measure of 
personality organization (PNI Vulnerability).  Specifically, Subject 13 evidenced reality testing 
between one and two standard deviations below the normative average (IPO-RT = 24, normative 
average = 38.46, standard deviation = 9.67), narcissistic grandiosity between two and three 
standard deviations below the normative average (PNI-G = 1.19, normative average = 2.89, 
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standard deviation = 0.66), identity diffusion between one and two standard deviations below the 
normative average (IPO-ID = 36, normative average = 51.68, standard deviation = 11.35), 
primitive defenses between one and two standard deviations below the normative average (IPO-
PD = 26, normative average = 36.24, standard deviation = 7.91) and narcissistic vulnerability 
within one standard deviation below the normative average (PNI-V = 1.64, normative average = 
2.13, standard deviation = 0.74).  In line with this healthier profile, Subject 13 also evidenced the 
sample’s healthiest attachment-related avoidance, placing within one standard deviation below 
the normative average (ECR-R Av = 2.22, normative average = 2.92, standard deviation = 1.19) 
and the sample’s second healthiest attachment-related anxiety, placing within one and two 
standard deviations below the normative average (ECR-R Ax = 2.28, normative average = 3.56, 
standard deviation = 1.19). 
With regard to reliable change indices, which indicate significant within-person change 
over time, Subject 13 evidenced significantly deteriorated reality testing (IPO-RT) by the one-
month follow-up and remained statistically unchanged on all other measures.  Of note, Subject 
13’s open-ended qualitative responses include a reflection that his/her view of reality shifted in 
profound and positive ways following psychedelic exposure.  This discrepancy between 
deteriorated reality testing (based on the IPO-RT subscale) and improved reality testing (based 
on subjective self-report) raises profound questions regarding the nature of consciousness and 
reality itself.  The IPO-RT subscale includes prompts such as “I know that I cannot tell others 
certain things about the world that I understand but that to others would appear crazy,” and “I 
have seen things which do not exist in reality.”  From the perspective of clinical psychology, 
endorsements of these prompts reflect the deteriorated reality testing of borderline and psychotic 
organizations; conversely, from the perspective of transpersonal psychology (and related 
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theoretical paradigms), endorsements of these prompts may at times reflect an expanded 
understanding of the nature of reality and, in turn, improved reality testing.  Here, Ken Wilber’s 
theory of the pre/trans fallacy (initially explored in this study’s literature review) may prove 
relevant (Wilber, 2000).  According to Wilber’s theoretical model, there are three broad 
developmental stages of consciousness: the pre-personal (pre-egoic, such as the infantile or 
psychotic), the personal (egoic, such as that of the healthy adult) and the trans-personal (trans-
egoic, such as that of the mystic).  According to the pre/trans fallacy, non-rational stages of 
consciousness (which include the pre and trans stages) share certain similarities (such as 
egolessness) and are therefore often confused for one another.  For example, trans-rational states 
(e.g. mystical experiences) are often conflated with pre-rational states (e.g. psychotic breaks), 
and vice versa.  From this perspective, Subject 13 (who evidenced the healthiest personality 
organization and attachment style in the sample prior to the Experience Retreat, and who also 
met criteria for a mystical experience during psychedelic exposure) may be moving from a 
personal to trans-personal state of consciousness as a function of psychedelic exposure.  From 
this theoretical perspective, the IPO-RT (and its a priori assumptions regarding the nature of 
reality and consciousness) might be committing the pre/trans fallacy of conflating evolution with 
devolution.  From this theoretical vantage point, Subject 13’s dearth of significant reliable 
change indices may suggest that self-reported growth is not occurring on the pre-personal or 
personal/egoic levels of consciousness (which this study’s measures are designed to detect) but is 
instead occurring on the transpersonal level of consciousness (which is not recognized by the 
theoretical paradigms underlying this study’s measures and which, in turn, do not detect them).   
In sum, Subject 11 evidenced the unhealthiest personality organization in the sample and 
also significantly deteriorated in numerous domains by the one-month follow-up.  Conversely, 
 
 83 
Subject 13 evidenced the healthiest personality organization in the sample and maintained the 
status quo across post-psychedelic outcome measures (with self-reported improvement with 
regard to awareness of consciousness and the nature of reality).  Future research will be required 
in order to determine whether this relationship between pre-psychedelic personality organization 
and post-psychedelic outcome measures idiosyncratically reflects these two subjects, or whether 
this relationship is maintained in a larger sample and, in turn, informs pre-psychedelic exclusion 
criteria and/or post-psychedelic treatment recommendations. 
Qualitative Data Analysis 
Subjects provided responses to three open-ended questions over the course of data 
collection: before the Experience Retreat (to explore reasons for pursuing psychedelic exposure), 
directly after the Experience Retreat (to assess subjective changes following psychedelic 
exposure) and at the one-month follow-up (to explore the maintenance of subjective changes 
over time).  Qualitative responses are summarized and explored below.  See Appendix F for a 
full compilation of all self-report responses. 
Prior to psychedelic exposure, subjects responded to the following prompt: “In a few 
sentences, please explain why you decided to participate in an Experience Retreat.”  According 
to self-report responses, the most common reason for pursuing psychedelic exposure (endorsed 
by 13 subjects) was a desire to deepen or expand one’s relationship to (and awareness of) self, 
consciousness and reality (e.g., “I’m hoping to get a better insight into my consciousness and 
discover my true nature,” “I want to have a ‘peek to the other side’ and see what else is outside 
of our material world,”).  The second most frequent reason for pursuing psychedelic exposure 
(endorsed by 7 subjects) was a desire to address mental health concerns, including treatment-
resistant depression and sequelae following childhood trauma.  Five subjects also voiced a desire 
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to find purpose, meaning or direction in life (e.g., “I want to understand why I am here and what 
I am doing with my life,” “I feel at a bit of a crossroads in my life and would like to find which 
path to take,”).  Four subjects also indicated a desire to shift problematic thought patterns (e.g., 
“I would like to get past some habitual ways of thinking,”).  Lastly, four subjects hoped for a 
novel or exciting experience (e.g., “Just to do something that seems very exciting,”) and two 
subjects expressed a wish for overall self-improvement (e.g., “I’ve always had an interest in 
personal development,”). 
Following psychedelic exposure, subjects responded to the following prompt: “Do you 
believe that taking psilocybin changed you?  If so, how?”  Of the eleven subjects who provided a 
response at this timepoint, 8 subjects endorsed post-psychedelic change, 2 subjects denied post-
psychedelic change and one subject was unsure.  With regard to post-psychedelic change (and in 
contrast to reliable change indices, which indicated improvement, as well as deterioration) only 
positive changes were self-reported.  The most commonly reported change (endorsed by 4 
subjects) was a deepened or expanded relationship to (and awareness of) self, consciousness and 
reality (e.g., “Opened me to the mysteries of an alternate realm,” “Ultimate reality is not time-
linear, has no sense of good or bad, self or non-self, inside or outside.  It just is, and is not.  So in 
that way it has given ‘me’ a new freedom.  It is not that my self or ego has ceased to exist, but I 
can find space around it, see it as the functional play of existence,”).  Tied for the most 
commonly reported change (also endorsed by 4 subjects) was improved psychological wellbeing 
(e.g., “I was able to release emotional pain and childhood/adolescent trauma that I did not realize 
I was still holding the weight of,”).  Three subjects also endorsed greater acceptance, compassion 
and gratitude, and another three subjects endorsed greater openness.  Of note, two subjects 
endorsed change that cannot be captured with words (e.g., “I feel like I have experienced a 
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profound truth, beyond words…a wisdom beyond concepts,”).  Additionally, one subject 
endorsed shifted cognitions (“Showed me I could be free of self-limiting beliefs,”) and one 
subject endorsed increased nature-relatedness (“Opened me to the wonders of nature,”). 
At the one-month follow-up, subjects responded to the following prompt: “When you 
look back on taking psilocybin, do you think it changed you?  If so, how?”  All nine subjects 
who provided a response at this time point endorsed positive post-psychedelic change, although 
two subjects acknowledged that the effects were starting to wear off.  Here, the most commonly 
reported change (endorsed by 5 subjects) was increased acceptance, compassion and gratitude 
(e.g., “I have a greater reservoir of compassion, both for myself and for challenging dynamics I 
may encounter,” “I feel more forgiving towards myself and others.  I feel I’m able to let difficult 
things be without having a compulsion to solve them or obsess about them; the good and the bad 
can co-exist peacefully,”).  The second most frequent change (endorsed by 3 subjects) was 
improved psychological wellbeing (e.g., “I’m feeling less sad and lonely…I am less fearful of 
the future,” “A lot less brain chatter – mind was generally calmer,”).  Two subjects also endorsed 
a deepened or expanded relationship to (or awareness of) self, consciousness and reality (e.g., “It 
made me feel more definite about the other levels of existence,”).  Increased nature-relatedness 
was also endorsed by two subjects (e.g., “Much more aware and appreciative of plants (trees 
especially),”), as was an improved capacity for meditation (e.g., “I find meditation much easier, 
less irritated and can relax into it much more,”).  Lastly, one participant identified shifts in 
problematic thought patterns (“Some thought habits that often cause me distress have quieted 
down a little, but they are still there, I just feel less frequently restricted by them,”).  
Overall, this study’s self-reported post-psychedelic changes notably mirror those already 
identified by the literature (and detailed in this study’s literature review).  These changes include 
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an altered relationship to (or awareness of) consciousness and reality (e.g. Ditman & Bailey, 
1967; Doblin, 1991; Griffiths et al., 2008; Grof, 1970; Kurland et al., 1968; Lerner & Lyvers, 
2006; Maclean et al., 2011; Pahnke et al., 1970; Unger, 1963), improved mental health and 
psychological wellbeing (e.g. Barbosa et al., 2016; Dos Santos et al., 2016a; Griffiths et al., 
2011; Grof, 1970; Lyons et al., 2018; Mascher, 1967; Rucker et al., 2016; Savage et al., 1962; 
Savage et al., 1964; Savage et al., 1968; Schmid & Liechti, 2018), greater acceptance, 
compassion and gratitude (e.g. Carhart-Harris et al., 2016; Doblin, 1991; Griffiths et al., 2008; 
Griffiths et al., 2011; Grof, 1970; Kavenská et al., 2015; Savage et al., 1964; Savage et al., 1968; 
Schmid & Liechti, 2018; Watts et al., 2017), greater openness (Barbosa et al., 2016; Carhart-
Harris et al., 2016; Erritzoe et al., 2018; Maclean et al., 2011; Nour et al., 2017), and increased 
nature-relatedness (Doblin, 1991; Forstmann & Sagioglou, 2017; Grof, 1970; Lyons & Carhart-
Harris, 2018; Nour et al., 2017).  Of note, these findings also notably mirror the literature in that 
these post-psychedelic changes are almost exclusively positive in nature (and, as a result, stand 
in contrast to reliable change findings, which indicated significant improvement, as well as 
significant deterioration).  At this juncture, it’s currently unknown whether the positive nature of 
self-report findings reflects the overwhelming benefit of psychedelic exposure, the healing nature 
of the Experience Retreat’s set and setting, or a bias embedded within this study’s research 
design (e.g., the self-selecting nature of this sample and, in turn, a potential bias toward reporting 
only positive outcomes).   
From a theoretical perspective, the diversity of self-reported changes lends support to 
theorizers who have characterized the psychedelic encounter as a “catalyzer” (Grof, 1970, p. 73) 
that “enlarges the psychic horizon” (Savage et al., 1964, p. 119), “broadens perception” 
(Winkelman et al., 2007, p. 55), and “expands consciousness” (Sherwood et al., 1968, p. 96).  In 
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this sense, the psychedelic and therapeutic encounters may share a mechanism of action in 
expanded consciousness (or increased awareness of relevant unconscious material), whereby 
idiosyncratic healing reflects the needs of the individual and their unique healing process, as 







Due to the Covid-19 global pandemic, and the premature end to data collection, the 
sample in its current form includes 21 participants, many of whom did not complete the entire 
protocol.  Specifically, there were 8 subjects with completed measures at all three time points, 3 
subjects with completed measures at two time points, 3 participants with completed measures at 
one time point, and 7 participants with a partially completed data set at the first time point.  With 
such a small sample size, definitive conclusions would prove imprudent and even preliminary 
trends are provisional at best.  Nevertheless, a series of datapoints suggest that significant 
findings may prove emergent, warranting future investigation once the circumstances allow.  
Relevant datapoints are included below.  
1) Five of twenty-two Hierarchical Linear Models were significant, indicating post-
psychedelic improvement with regard to overall symptoms (BSI GSI), identity diffusion (IPO-
ID), and reality testing (IPO-RT).  Significant interactions were also found for primitive defenses 
(IPO-PD) and narcissistic grandiosity (PNI-G), with the non-mystical experience group trending 
toward improvement, and the mystical-experience group remaining largely unchanged over time.  
Although constrained by low power across the board, the presence of multiple significant 
findings (however nascent) within the context of so few participants suggests the possibility of 
more robust findings in the context of a larger sample size. 
2) While the vast majority of HLMs yielded insignificant findings, every HLM also 
yielded large effect sizes when predicting the impact of psilocybin exposure on the degree and 
shape of personality-related change over time (while controlling for social desirability).  While 
erratic outliers may explain this phenomenon, it’s also possible that large effect sizes 
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paradoxically occurring alongside predominantly insignificant findings suggests the presence of 
relationships that would emerge in the context of a larger sample size.   
3) Although the majority of reliable change scores were insignificant, it’s nevertheless 
notable that, for 12 of 21 measures, 2, 3 or 4 participants earned significant reliable change 
scores, indicating either significant improvement, or significant deterioration.  (In some cases, 
it’s possible that HLMs didn’t yield significant findings, as significant effects in opposite 
directions may have canceled each other out.)  Following an intervention that lasted only a few 
hours, it’s notable that even a few participants evidenced significant within-person change (at 
times sustained at a one-month follow-up), as psychological constructs (such as personality 
organization and attachment style, for example) are thought to be deeply entrenched and, in turn, 
challenging to alter, even under the best of psychotherapeutic circumstances.  These findings 
suggest that psychedelic exposure may engender a potent psychological experience capable of 
catalyzing improvement and deterioration, with further investigation necessary to clarify the 
nature of this interaction.   
4) With regard to qualitative clinical case studies, the subject with the unhealthiest pre-
psychedelic personality organization significantly deteriorated in numerous domains by the one-
month follow-up, while the subject with the healthiest pre-psychedelic personality organization 
largely maintained the status quo across post-psychedelic outcome measures (with self-reported 
improvement with regard to awareness of consciousness and the nature of reality).  Future 
research is warranted to determine whether this relationship between pre-psychedelic personality 
organization and post-psychedelic outcome measures idiosyncratically reflects these two 
subjects, or whether this relationship is maintained in a larger sample and, in turn, informs 
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important pre-psychedelic exclusion criteria and/or post-psychedelic treatment 
recommendations. 
5) Qualitative analysis of self-report responses to open-ended questions indicates that the 
majority of subjects experienced positive self-improvement directly following psychedelic 
exposure, as well as at the one-month follow-up.  According to self-report, improvement was 
experienced in numerous domains, including improved mental health and psychological 
wellbeing, greater acceptance, compassion, gratitude, and openness, increased nature-relatedness 
and a deepened or expanded relationship to (or awareness of) consciousness and reality.  Of note, 
these findings mirror those already identified by the literature, both with regard to the type of 
post-psychedelic changes reported, as well as the almost exclusively positive nature of these 
subjective changes.   
Of note, this study stands in contrast to both first- and second- wave research designs due 
to the lack of psychotherapeutic supports offered before and after psychedelic exposure.  With 
regard to the first wave, research designs most frequently studied psycholytic psychotherapy, 
whereby psychedelics were intermittently administered in the context of long-term treatment, 
which often lasted months to years.  While the second wave has shifted this paradigm, research 
studies nevertheless commonly offer a handful of therapy sessions before and after psychedelic 
exposure (with more if needed), in order to support pre-psychedelic preparation and post-
psychedelic integration.  In this study, however, participants attended the Psychedelic Society’s 
Experience Retreats, where psilocybin truffles were administered legally in a ceremonial context, 
but which does not provide individual therapy sessions with before and after the experience.  As 
a result, this study examines the potential implications of taking psychedelics outside of a 
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clinical context.  Three notable data points suggest the potential importance of psychotherapeutic 
integration, all of which are explored below. 
1) With regard to HLMs analyzing the main effect of Mystical Experiences, two out of 
eleven relevant HLMs indicated that the mystical experience group evidenced significantly less 
improvement than the non-mystical experience group.  Though not statistically significant, this 
trend was reflected in an additional seven of eleven HLMs.  This finding is notable, as it stands 
in contrast to the literature, which identifies mystical experiences as one of the most potent 
predictors of positive post-psychedelic personality change (Doblin, 1991; Griffiths et al., 2008; 
Grof, 1970; Kurland et al., 1968; Lebedev et al., 2016; Maclean et al., 2011; Maslow, 1959; 
Pahnke, 1969; Pahnke et al., 1970; Savage et al., 1962; Unger, 1963).  Without a therapeutic 
space to integrate such profound insights, it’s possible that mystical experiences were akin to a 
premature interpretation, destabilizing individuals in the face of such an overwhelming and 
reality-shifting experience.  
2) Reliable Change scores also indicate that, while certain participants evidenced 
significant within-person change, other participants evidenced significant within-person 
deterioration across numerous measures.  From a theoretical perspective, it’s possible that 
therapeutic intervention following psychedelic exposure could make the difference for those 
individuals who deteriorated by providing a space to integrate painful insights into the self-
structure. 
3) With regard to case studies, and while both individuals had mystical experiences, the 
individual with the healthiest pre-psychedelic personality organization evidenced emotional 
growth following psychedelic exposure, while the individual with the unhealthiest pre-
psychedelic personality organization evidenced significant deterioration.  Once again, the data 
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preliminarily suggests that some individuals may be more vulnerable in the face of 
overwhelming psychedelic experiences, and would therefore benefit from therapeutic 
intervention following psychedelic exposure. 
With all of this in mind, future studies should seek to clarify whether post-psychedelic 
outcomes differ based on the presence or absence of psychotherapeutic integration following 
psychedelic exposure and, in turn, utilize relevant findings to inform best practices moving 
forward.  
When taken together, these findings indicate that future research is warranted in order to 
further clarify the effect of psychedelic exposure on personality - as well as the effect of 
personality on psychedelic exposure - and the potential mechanisms that explain these dynamic 
relationships.  Once implemented, this research will support the identification of relevant 
exclusion criteria and appropriate treatment recommendations, as psychedelics are increasingly 












Rationale for Chosen Summary Measures 
Brief Symptom Inventory (BSI). The Global Severity Index (GSI) was selected as a 
summary measure for the BSI.  Of note, the GSI is highly correlated at pre-test with the BSI’s 
two other global indices, with Pearson’s coefficients of .92 with the Positive Symptom Total 
subscale (PST) and .78 with the Positive Symptom Distress Severity subscale (PSDI).  As a 
result, the GSI is a strong summary score for the entire BSI scale. 
Inventory of Personality Organization (IPO). The Inventory of Personality Organization 
(IPO) yields three subscale scores: Identity Diffusion (IPO-ID), Primitive Defenses (IPO-PD) 
and Impaired Reality Testing (IPO-RT).  All three subscales will be analyzed, as they represent 
distinct dimensions of personality organization and cannot be meaningfully combined into one 
global score. 
Pathological Narcissism Inventory (PNI). The Pathological Narcissism Inventory (PNI) 
yields three global indices: Narcissistic Grandiosity (PNI-G) (an average of the Exploitativeness, 
Self-Sacrificing Self-Enhancement and Grandiose Fantasy subscales), Narcissistic Vulnerability 
(PNI-V) (an average of the Contingent Self-Esteem, Self-Sacrificing Self-Enhancement, Hiding 
the Self, and Entitlement Rage subscales), and Pathological Narcissism Overall (PNI-O) (an 
average of the PNI-G and PNI-V global indices).  As study predictions sought to assess the 
potential impact of psilocybin on narcissistic grandiosity in particular, the PNI-G and PNI-V will 
be analyzed separately (in lieu of analyzing the PNI-O, which averages the PNI-G and PNI-V 
global indices, and potentially blurs the distinction between these distinct dimensions of 
grandiosity and vulnerability).  
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Mentalization Scale (MentS). The Mentalization Scale (MentS) yields three subscale 
scores and one overall composite score: Mentalization of Self (MentS-S), Mentalization of 
Others (MentS-O), Motivation to Mentalize (MentS-M), and Mentalization Total (MentS-T). As 
the scale’s summary measure, the MentS-T was selected for MentS analyses. 
The Ryff Scale of Psychological Well-Being (Ryff). The Ryff Scale of Psychological 
Well-Being (Ryff) yields subscale scores on six dimensions of wellbeing: autonomy, 
environmental mastery, personal growth, positive relations with others, purpose in life and self-
acceptance.  As previously discussed, nearly a third of Ryff subscales rendered questionable to 
unacceptable reliability scores (see Table 4).  As further investigation indicated a problem with 
subscale measures, as opposed to a problem with one single item, all subscales were averaged to 
create an Overall Wellbeing score (Ryff-OW), which evidenced good to excellent reliability.  As 
a result, the Ryff-OW will be used as a summary score for the entire Ryff scale.   
Experiences in Close Relationships-Revised (ECR-R). The Experiences in Close 
Relationships-Revised (ECR-R) yields two subscale scores: attachment-related anxiety (Ax) and 
attachment-related avoidance (Av).  Both subscales will be analyzed, as they represent distinct 
dimensions of attachment and cannot be meaningfully combined into one global score.   
Pro-Environmental Behavior (PEB). The Pro-Environmental Behavior (PEB) measure 
assesses the frequency with which individuals perform certain environmentally considerate 










Sample Characteristics by Measure 
 
BSI GSI Sample Characteristics: Over the course of data collection, the BSI was 
completed by 21 participants prior to psilocybin exposure, 12 participants following psilocybin 
exposure, and 9 participants at a one-month follow-up.  In order to best understand sample 
characteristics, only the 13 participants who completed the BSI at more than one time point are 
included in the following analyses.   
According to Derogatis and Melisaratos (1983), the non-patient (healthy) average on the 
Global Severity Index (GSI) is .3 (with a standard deviation of .31) and the outpatient average is 
1.32 (with a standard deviation of .72).  As indicated by these norms, higher GSI scores reflect 
worse symptom profiles and, conversely, lower GSI scores reflect healthier symptom profiles.   
Prior to psilocybin exposure, 53.8% (n = 7) of subjects earned a GSI within one standard 
deviation of the non-patient (healthy) average and 46.2% (n = 6) of subjects earned a GSI within 
one standard deviation of the outpatient average.  Following psilocybin exposure, 84.6% (n = 11) 
of subjects earned a GSI within one standard deviation of the non-patient (healthy) average, 
while 7.7% (n = 1) of subjects earned a GSI within one standard deviation of the outpatient 
average.  At the second time point, 7.7% (n = 1) of the sample did not participate in data 
collection.  At the one-month follow-up, 61.5% (n = 8) of participants remained within one 
standard deviation of the non-patient average, while 7.7% (n = 1) of participants earned a GSI 
within one standard deviation of the outpatient average.  At the third time point, 30.8% (n = 4) of 
the sample did not participate in data collection.  In sum, the majority of the sample appeared to 
be within the normal range at all time points, with only one subject approaching the outpatient 




Figure 1. BSI GSI scores over Time by subject. 
Note: BSI = Brief Symptom Inventory. GSI = Global Severity Index. 
 
IPO-ID Sample Characteristics: Over the course of data collection, the IPO was 
completed by 20 participants prior to psilocybin exposure, 11 participants following psilocybin 
exposure, and 9 participants at a one-month follow-up.  In order to best understand sample 
characteristics, only the 12 participants who completed the IPO at more than one time point are 
included in the following analyses.   
According to Lenzenweger et al. (2001), the normative average on the IPO-ID is 51.68 
(with a standard deviation of 11.35), with higher IPO-ID scores indicating higher levels of 
identity diffusion and lower scores indicating lower (healthier) levels of identity diffusion.  With 
regard to this study’s sample, virtually all participants fell within the normative range (or 
healthier) at all three time points, with varying degrees of improvement and deterioration over 





Figure 2. IPO-ID scores over Time by subject. 
Note: IPO-ID = Inventory of Personality Organization, Identity Diffusion subscale. 
 
IPO-RT Sample Characteristics: According to Lenzenweger et al. (2001), the normative 
average on the IPO-RT is 38.46 (with a standard deviation of 9.67), with higher IPO-RT scores 
indicating worse reality testing and lower scores indicating better reality testing.  With regard to 
this study’s sample, the vast majority of participants fell within the normative range (or 
healthier) at all three time points (with varying degrees of improvement and deterioration over 
time), with one participant scoring between 1 and 2 standard deviations above the norm directly 





Figure 3. IPO-RT scores over Time by subject. 
Note: IPO-RT = Inventory of Personality Organization, Reality Testing subscale. 
 
IPO-PD Sample Characteristics: According to Lenzenweger et al. (2001), the normative 
average on the IPO-PD is 36.25 (with a standard deviation of 7.91), with higher IPO-PD scores 
indicating a higher reliance on primitive defenses and lower scores indicating a healthier 
defensive structure.  With regard to this study’s sample, the vast majority of participants fell 
within the normative range (or healthier) at all three time points, with varying degrees of 





Figure 4. IPO-PD scores over Time by subject. 
Note: IPO-PD = Inventory of Personality Organization, Primitive Defenses subscale. 
 
PNI-G Sample Characteristics: Over the course of data collection, the PNI was 
completed by 15 participants prior to psilocybin exposure, 10 participants following psilocybin 
exposure, and 9 participants at a one-month follow-up.  In order to best understand sample 
characteristics, only the 11 participants who completed the PNI at more than one time point are 
included in the following analyses.  
According to Pincus et al. (2009), the non-patient (healthy) average on the PNI-G is 2.89 
(with a standard deviation of 0.66) and the outpatient average is 2.47 (with a standard deviation 
of 0.87), with higher scores indicating higher levels of narcissistic grandiosity.  With regard to 
this study’s sample, all participants fell within the normative range (or healthier) at all three time 





Figure 5. PNI-G scores over Time by subject. 
Note: PNI-G = Pathological Narcissism Inventory, Grandiosity subscale. 
 
PNI-V Sample Characteristics: According to Pincus et al. (2009), the non-patient 
(healthy) average on the PNI-V is 2.13 (with a standard deviation of 0.74) and the outpatient 
average is 2.42 (with a standard deviation of 0.83), with higher scores indicating higher levels of 
narcissistic vulnerability.  With regard to this study’s sample, the vast majority of participants 
fell within the normative range (or healthier) at all three time points (with varying degrees of 
improvement and deterioration over time), with one participant significantly higher than the 






Figure 6. PNI-V scores over Time by subject. 
Note: PNI-V = Pathological Narcissism Inventory, Vulnerability subscale. 
 
MentS-T Sample Characteristics: Over the course of data collection, the MentS was 
completed by 14 participants prior to psilocybin exposure, 10 participants following psilocybin 
exposure and 9 participants at a one-month follow-up.  In order to best understand sample 
characteristics, only the 11 participants who completed the MentS at more than one time point 
are included in the following analyses.   
According to Dimitrijević et al. (2018), the non-patient (healthy) average on the MentS-T 
is 106.29 (with a standard deviation of 11.37) and the clinical average is 100.26 (with a standard 
deviation of 14.02).  As indicated by these norms, higher MentS-T scores indicate stronger 
mentalization capacities, while lower scores indicate relatively weaker mentalization capacities.  
With regard to this study’s sample, virtually all participants fell within the normative range at all 
three time points (with varying degrees of improvement and deterioration over time), with the 
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exception of one participant who fell within the clinical range at time points 1 and 2 (with no 
dataset for time point 3) (see Figure 7). 
 
Figure 7. MentS-T scores over Time by subject. 
 
Ryff Sample Characteristics: Over the course of data collection, the Ryff Scale of 
Psychological Well-Being was completed by 15 participants prior to psilocybin exposure, 10 
participants following psilocybin exposure and 9 participants at a one-month follow-up.  In order 
to best understand sample characteristics, only the 11 participants who completed the Ryff at 
more than one time point are included in the following analyses. 
Although Ryff (1989) provides normative data for the Ryff’s six subscales, the composite 
Ryff-OW score is not traditionally employed by the literature, and normative data is therefore 
not available for comparison purposes.  Of note, higher Ryff-OW scores reflect higher levels of 
well-being and, conversely, lower Ryff-OW scores indicate relatively lower levels of well-being 





Figure 8. RYFF-OW scores over Time by subject. 
 
ECR-R Ax Sample Characteristics: Over the course of data collection, the ECR-R was 
completed by 14 participants prior to psilocybin exposure, 10 participants following psilocybin 
exposure, and 9 participants at a one-month follow-up.  In order to best understand sample 
characteristics, only the 11 participants who completed the ECR-R at more than one time point 
are included in the following analyses.   
According to Fraley et al. (2000), the average norm on the ECR-R Ax is 3.56 (with a 
standard deviation of 1.19), with higher scores indicating worse attachment-related anxiety and 
lower scores indicating relatively healthier levels of attachment-related anxiety.  With regard to 
this study’s sample, virtually all participants fell within the normative range at all three time 
points, with varying degrees of improvement and deterioration over time.  At each time point, 
one or two participants earned scores between 1 and 2 standard deviations above the norm, 






Figure 9. ECR-R Ax scores over Time by subject. 
Note: ECR-R = Experiences in Close Relationships-Revised. 
 
ECR-R Av Sample Characteristics: According to Fraley et al. (2000), the average norm 
on the ECR-R Av is 2.92 (with a standard deviation of 1.19), with higher scores indicating worse 
attachment-related avoidance and lower scores indicating relatively healthier levels of 
attachment-related avoidance.  With regard to this study’s sample, virtually all participants fell 
within the normative range at all three time points, with varying degrees of improvement and 
deterioration over time, with the exception of one participant who earned notably elevated scores 






Figure 10. ECR-R Av scores over Time by subject. 
Note: ECR-R = Experiences in Close Relationships-Revised. 
 
PEB Sample Characteristics: Over the course of data collection, the PEB was completed 
by 21 participants prior to psilocybin exposure and 9 participants at the one-month follow-up.  
(As pro-environmental behavior cannot meaningfully change in the context of a retreat, this 
measure was only collected twice: before psychedelic exposure and at the one-month follow-up, 
once participants had re-entered their everyday life).  In order to best understand sample 
characteristics, only the 9 participants who completed the PEB at both time points are included in 














Hierarchical Linear Model Analyses by Measure 
 
GSI Mixed Model Analysis: A Hierarchical Linear Model analysis was conducted to 
predict the degree and shape of GSI change over time, while controlling for SD.  A first-order 
autoregressive (AR1) covariance structure was the best fit for the data.  The effect of linear Time 
and quadratic Time2 were both significant predictors of GSI scores (see Table 11), indicating that 
scores showed a significant curvilinear trend, with a slight upward curve in change over 
time.  This model predicted 64.8% of the variance in GSI scores (R2 = .648), reflecting a large 
effect size. 
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 = 
No, 1 = Yes) and the interaction of ME x Time.  Of note, neither the main effect of ME nor the 
interaction effect of Time x ME were significant, indicating that mystical experiences were not a 
statistically significant moderator of the effect of GSI scores over time.  With the inclusion of 
predictors ME and ME x Time, the model explained an additional 7.7% of variance (a small to 
medium effect size). 
Figure 12 demonstrates the nature of the effect of the moderator variable.  More 
specifically, and on average, the non-mystical experience group showed greater improvement 
between time points 1 and 2 than the mystical experience group.  Of note, this finding is contrary 
to the study’s original prediction (which projected the mystical-experience group to evidence 
more improvement on the BSI than the non-mystical experience group) and, in fact, appears to 
indicate that the opposite effect may have occurred.  Though not statistically significant, the 






Fixed effects model: Tests of fixed effects predicting BSI GSI scores, controlling for SD. 
 
Source Numerator df Denominator df F Sig. 
Intercept 1 12.772 4.897 .046 
SD 1 12.671 .014 .908 
Time 1 10.346 10.300 .009* 
Time2  1 9.072 7.850 .020* 
ME 1 11.950 .159 .697 
ME x Time 1 11.531 .922 .357 
*Significant (<.05) change 
Note: BSI = Brief Symptom Inventory. GSI = Global Severity Index. SD = Marlow-Crowne Social 




Figure 12. Interaction of ME and Time for BSI GSI scores controlling for SD. 
Note: ME = Mystical Experience. 
 
In sum, there was a significant and curvilinear pattern to change over time, with scores 
decreasing at Time 2 (evidencing improved symptomology on the GSI directly following 
psychedelic exposure) and increasing again at Time 3 (reflecting a return toward baseline after a 
month follow-up period).  Mystical experiences were not a significant moderator of the effect of 
GSI scores over time, although the inclusion of predictors ME and ME x Time explained an 













IPO-ID Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to 
predict the degree and shape of IPO-ID change over time, while controlling for SD.  A first-order 
autoregressive (AR1) covariance structure was the best fit for the data.  The effect of Time2 was 
a significant predictor of IPO-ID scores (see Table 12), indicating that scores showed a 
significant curvilinear trend, with a slight downward curve (and reflecting improved identity 
diffusion) in change over time.  This model predicted 63.6% of the variance in IPO-ID scores (R2 
= 0.636), reflecting a large effect size. 
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 = 
No, 1 = Yes) and the interaction of ME x Time.  Of note, neither the main effect of ME nor the 
interaction effect of Time x ME were significant, indicating that mystical experiences were not a 
statistically significant moderator of the effect of IPO-ID scores over time.  However, with the 
inclusion of the predictors ME and ME x Time, the model explained an additional 24.5% of 
variance (a large effect size). 
Figure 13 demonstrates the nature of this effect.  Specifically, the mystical experience 
group averaged no change directly following psilocybin exposure (followed by improvement at 
the one-month follow-up), whereas the non-mystical experience group averaged slight 
improvement directly following psilocybin exposure (followed by further improvement at the 
one-month follow-up).  Additionally, and while both groups evidenced improved (lower levels 
of) identity diffusion at follow-up, the non-mystical group averaged more improvement relative 
to the mystical experience group.  Of note, this finding is contrary to original study predictions, 
which projected the mystical experience group to evidence greater improvement than the non-






Fixed effects model: Tests of fixed effects predicting IPO-ID scores, controlling for SD. 
 
Source Numerator df Denominator df F Sig. 
Intercept 1 19.150 35.757 .000 
SD 1 20.884 .693 .414 
Time 1 12.960 2.641 .128 
Time2  1 11.018 8.194 .015* 
ME 1 11.990 .052 .824 
ME x Time 1 10.913 1.325 .274 
*Significant (<.05) change 
Note: IPO-ID = Inventory of Personality Organization, Identity Diffusion subscale.  SD = Marlow-
Crowne Social Desirability scale.  ME = Mystical Experience group (0 = No, 1 = Yes). 
 
 
Figure 13. Interaction of ME and Time for IPO-ID scores controlling for SD. 
Note: IPO-ID = Inventory of Personality Organization, Identity Diffusion subscale. 
 
In sum, there was a significant and curvilinear pattern of change in IPO-ID over time, 
with a slight downward curve (and improved identity diffusion) by the one-month follow-up.  
Mystical experiences were not a significant moderator of the effect of IPO-ID over time, 
although inclusion of predictors ME and ME x Time explained an additional 24.5% of variance 
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(a large effect size).  Here, the mystical experience group averaged no change directly following 
psilocybin exposure (followed by improvement at the one-month follow-up), whereas the non-
mystical experience group averaged slight improvement directly following psilocybin exposure 
(followed by even greater improvement at the one-month follow-up relative to the mystical 
experience group). 
IPO-RT Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to 
predict the degree and shape of IPO-RT change over time, while controlling for SD.  An Identity 
covariance structure was the best fit for the data.  The effect of Time2 was a significant predictor 
of IPO-RT scores (see Table 13), indicating that scores showed a significant curvilinear trend, 
with a slight downward curve (and reflecting improved reality testing) in change over time.  This 
model predicted 77% of the variance in IPO-RT scores (R2 = 0.770), reflecting a large effect 
size. 
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 = 
No, 1 = Yes) and the interaction of ME x Time.  Of note, neither the main effect of ME nor the 
interaction effect of ME x Time were significant, indicating that mystical experiences were not a 
statistically significant moderator of the effect of IPO-RT scores over time.  Through the 
inclusion of the predictors ME and ME x Time, the model explained an additional 1.5% of 
variance (nearing a small effect size). 
Figure 14 demonstrates the nature of this effect.  More specifically, the non-mystical 
experience group averaged more improvement relative to the mystical experience group by 
follow-up.  Of note, this finding is contrary to original study predictions, which projected the 
mystical experience group to evidence greater improvement than the non-mystical experience 




Fixed effects model: Tests of fixed effects predicting IPO-RT scores, controlling for SD. 
 
Source Numerator df Denominator df F Sig. 
Intercept 1 15.776 57.046 .000 
SD 1 15.288 1.388 .257 
Time 1 9.115 4.164 .071 
Time2  1 10.642 6.052 .032* 
ME 1 14.392 .003 .957 
ME x Time 1 10.876 .966 .347 
*Significant (<.05) change 
Note: IPO-RT = Inventory of Personality Organization, Reality Testing subscale.  SD = Marlow-Crowne 




Figure 14. Interaction of ME and Time for IPO-RT scores controlling for SD. 
Note: IPO-RT = Inventory of Personality Organization, Reality Testing subscale. 
 
In sum, there was a significant and curvilinear pattern of change in IPO-RT over time, 
with a slight downward curve (and improved reality testing) by the one-month follow-up.  
Mystical Experiences were not a significant moderator of the effect of IPO-RT over time, with 
the inclusion of predictors ME and ME x Time explaining only an additional 1.5% of variance 
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(nearing a small effect size).  Though quite preliminary (in light of statistical insignificance, as 
well as a negligible to small effect size), the non-mystical experience group averaged greater 
improvement relative to the mystical experience group at the one-month follow-up (a trend that 
is contrary to study predictions, which anticipated greater improvement by the mystical-
experience group). 
IPO-PD Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to 
predict the degree and shape of IPO-ID change over time, while controlling for SD.  An Identity 
covariance structure was the best fit for the data.  Neither the effect of Time nor quadratic Time2 
were significant (see Table 14). This model predicted 91.9% of variance in IPO-ID scores (R2 = 
.919), reflecting a large effect size. 
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 = 
No, 1 – Yes) and the interaction of ME x Time.  Although the main effect of ME was 
insignificant, the interaction of ME x Time was a significant predictor of IPO-PD scores, 
indicating mystical experiences were significant predictor of IPO-PD at certain time points.  
With the inclusion of predictors ME and ME x Time, this model explained an additional 2.4% of 
variance (R = .943), indicating a small effect size. 
Figure 15 demonstrates the nature of this effect.  More specifically, and on average, the 
non-mystical experience group tended to evidence reduced levels of primitive defenses over 
time, whereas the mystical-experience group tended to retain consistent levels across time points.  
Of note, this finding is contrary to original study predictions (which projected the mystical 
experience group to evidence greater improvement than the non-mystical experience group over 






Fixed effects model: Tests of fixed effects predicting IPO-PD scores, controlling for SD. 
 
Source Numerator df Denominator df F Sig. 
Intercept 1 20.556 40.187 .000 
SD 1 22.562 .069 .795 
Time 1 11.910 .783 .394 
Time2  1 11.098 .001 .973 
ME 1 11.805 .065 .802 
ME x Time 1 10.449 4.934 .049* 
*Significant (<.05) change 
Note: IPO-PD = Inventory of Personality Organization, Primitive Defenses subscale.  SD = Marlow-





Figure 15. Interaction of ME and Time for IPO-PD scores controlling for SD. 
Note: IPO-PD = Inventory of Personality Organization, Primitive Defenses subscale. 
 
In sum, the effects of linear Time, quadratic Time2 and ME were not significant 
predictors of IPO-PD.  However, the interaction of ME x Time was significant, indicating that 
the non-mystical experience group evidenced improved (lower) levels of primitive defenses over 
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time, whereas the mystical-experience group maintained similar levels of primitive defenses 
across time points.  Of note, these findings stand in contrast to study predictions, which projected 
the mystical-experience group to demonstrate greater improvement than the non-mystical 
experience group over time. 
PNI-G Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to 
predict the degree and shape of PNI-G scores over time, while controlling for SD.  An Identity 
covariance structure was the best fit for the data.  Neither the effect of linear Time nor quadratic 
Time2 were significant (see Table 15).  Additionally, this model predicted 88.3% of variance (R 
= .883), reflecting a large effect size. 
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 = 
No, 1 = Yes) and the interaction of ME x Time.  Although the main effect of ME was 
insignificant, the interaction of ME x Time was a significant predictor of PNI-G scores, 
indicating mystical experiences were a significant predictor of PNI-G scores at certain time 
points.  With the inclusion of predictors ME and ME x Time, this model explained an additional 
7% of variance (R = .883), indicating a small to medium effect size. 
Figure 16 demonstrates the nature of this effect.  More specifically, and on average, the 
non-mystical experience group tended to evidence reduced levels of grandiosity over time, 
whereas the mystical-experience group tended to retain consistent levels across time points.  Of 
note, this finding is contrary to original study predictions (which projected the mystical 
experience group to evidence greater improvement than the non-mystical experience group over 








Fixed effects model: Tests of fixed effects predicting PNI-G scores, controlling for SD. 
 
Source Numerator df Denominator df F Sig. 
Intercept 1 17.148 16.015 .001 
SD 1 18.226 .017 .898 
Time 1 16.620 .013 .910 
Time2  1 17.077 .588 .454 
ME 1 12.255 .212 .653 
ME x Time 1 19.849 8.644 .008* 
*Significant (<.05) change 
Note: PNI-G = Pathological Narcissism Inventory, Grandiosity subscale.  SD = Marlow-Crowne Social 
Desirability scale.  ME = Mystical Experience (0 = No, 1 = Yes). 
 
 
Figure 16. Interaction of ME and Time for PNI-G scores controlling for SD. 
Note: PNI-G = Pathological Narcissism Inventory, Grandiosity subscale. SD = Marlow-Crowne Social 
Desirability scale. 
 
In sum, the effects of linear Time, quadratic Time2 and ME were not significant 
predictors of PNI-G.  However, the interaction of ME x Time was significant, indicating that the 
non-mystical experience group evidenced improved (lower) levels of grandiosity over time, 
whereas the mystical-experience group maintained similar levels of grandiosity across time 
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points.  Of note, these findings stand in contrast to study predictions, which projected the 
mystical-experience group to demonstrate greater improvement than the non-mystical experience 
group over time. 
PNI-V Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to 
predict the degree and shape of PNI-V change over time, while controlling for SD.  A Toeplitz 
(TP) covariance structure was the best fit for the data.  Neither the effect of linear Time nor the 
effect of quadratic Time2 were significant (see Table 16).  Additionally, this model predicted 
85.7% of variance in PNI-V scores (R2 = .857), reflecting a large effect size. 
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 = 
No, 1 = Yes) and the interaction of ME x Time.  Of note, neither the main effect of ME nor the 
interaction effect of Time x ME were significant, indicating that mystical experiences were not a 
statistically significant moderator of PNI-V scores over time.  With the inclusion of predictors 
ME and ME x Time, the model explained an additional .4% of variance (R = .861), reflecting a 
negligible effect size (see Figure 17). 
Table 16. 
Fixed effects model: Tests of fixed effects predicting PNI-V scores, controlling for SD. 
 
Source Numerator df Denominator df F Sig. 
Intercept 1 18.169 17.047 .001 
SD 1 19.181 1.368 .257 
Time 1 15.809 1.811 .197 
Time2  1 11.299 .072 .794 
ME 1 13.334 .042 .840 
ME x Time 1 8.542 .796 .397 
*Significant (<.05) change 
Note: PNI-V = Pathological Narcissism Inventory, Vulnerability subscale.  SD = Marlow-Crowne Social 





Figure 17. Interaction of ME and Time for PNI-V scores controlling for SD. 
Note: PNI-G = Pathological Narcissism Inventory, Vulnerability subscale. SD = Marlow-Crowne Social 
Desirability scale. 
 
In sum, none of the predictors were significantly associated with PNI-V.  Of note, these 
findings stand in contrast to study predictions, which projected reduced levels of narcissistic 
grandiosity over time. 
MentS-T Mixed Model Analysis: A Hierarchical Linear Model analysis was conducted to 
predict the degree and shape of MentS-T change over time, while controlling for SD.  A first-
order autoregressive (AR1) covariance structure was the best fit for the data.  Neither the effect 
of Time nor quadratic Time2 were significant (see Table 17), which likely reflects the limited 
change over time in the sample overall (as reflected in reliable change indices).  This model 
predicted 83.6% of variance in MentS-T scores (R2 = .836), reflecting a large effect size. 
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 = 
No, 1 = Yes) and the interaction of ME x Time.  Of note, neither the main effect of ME nor the 
interaction effect of Time x ME were significant, indicating that mystical experiences were not a 
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statistically significant moderator of the effect of MentS-T scores over time.  However, with the 
inclusion of predictors ME and ME x Time, this model explained an additional 2.8% of variance 
(a small effect size).  Figure 18 demonstrates the nature of the effect of the moderator variable, 
which appears to reflect a regression to the mean. 
Table 17. 
Fixed effects model: Tests of fixed effects predicting MentS-T scores, controlling for SD. 
 
Source Numerator df Denominator df F Sig. 
Intercept 1 16.397 119.166 .000 
SD 1 17.377 .856 .368 
Time 1 10.693 .008 .931 
Time2 1 9.922 .094 .765 
ME 1 11.551 .792 .392 
ME x Time 1 7.321 3.170 .116 
Note: MentS-T = Mentalization Total. SD = Marlow-Crowne Social Desirability scale. ME = Mystical 




Figure 18. Interaction of ME and Time for MentS-T scores controlling for SD. 



















No Mystical Experience Mystical Experience
 
 120 
In sum, and with limited change over time in the sample overall, none of the predictors 
were significantly associated with MentS-T.  Of note, these findings stand in contrast to study 
predictions, which projected improved mentalization skills over time. 
Ryff-OW Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to 
predict the degree and shape of Ryff-OW change over time, while controlling for SD.  An 
Identity covariance structure was the best fit for the data.  Neither the effect of Time nor 
quadratic Time2 were significant (see Table 18), which likely reflects the limited change over 
time in the sample overall (as reflected in reliable change indices).  This model predicted 85.9% 
of variance in Ryff-OW scores R2 = .859), reflecting a large effect size. 
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 = 
No, 1 = Yes) and the interaction of ME x Time.  Of note, neither the main effect of ME nor the 
interaction effect of ME x Time were significant, indicating that mystical experiences were not a 
statistically significant moderator of the effect of Ryff-OW scores over time.  However, with the 
inclusion of predictors ME x and ME x Time, this model explained an additional 4.2% of 
variance (a small to medium effect size).  Figure 19 demonstrates the nature of the effect on the 
moderator variable, with the non-mystical experience group evidencing relatively more 
improvement over time in comparison to the mystical-experience group.  Of note, this trend 
stands in contrast to study predictions, which projected the mystical-experience group to 








Fixed effects model: Tests of fixed effects predicting Ryff-OW score, controlling for SD. 
 
Source Numerator df Denominator df F Sig. 
Intercept 1 17.613 117.303 .000 
SD 1 18.825 .564 .462 
Time 1 12.736 2.887 .114 
Time2  1 10.590 1.034 .332 
ME 1 12.639 .016 .902 
ME x Time 1 6.566 1.429 .273 
*Significant (<.05) change 
Note: Ryff-OW = The Ryff Scale of Psychological Wellbeing, Overall Wellbeing summary score. 
SD = Marlow-Crowne Social Desirability scale.  ME = Mystical Experience group (0 = No, 1 = Yes). 
 
 
Figure 19. Interaction of ME and Time for Ryff-OW scores controlling for SD. 
Note: Ryff-OW = The Ryff Scale of Psychological Wellbeing, Overall Wellbeing summary score. 
 
In sum, and with limited change over time in the sample overall, none of the predictors 
were significantly associated with Ryff-OW.  Of note, these findings stand in contrast to study 
predictions, which projected improved psychological wellbeing over time. 
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ECR-R Ax Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted 
to predict the degree and shape of Ax change over time, while controlling for SD.  A first-order 
autoregressive (AR1) covariance structure was the best fit for the data.  Neither the effect of 
Time nor quadratic Time2 were significant (see Table 19).  In light of the significant 
improvement and deterioration evidenced in this sample overall (as reflected by the 
aforementioned reliable change indices), the insignificant effects of linear and quadratic time 
likely indicate that the sample did not follow a uniform trajectory over time.  This model 
predicted 81.1% of variance in Ax scores (R2 = .811), reflecting a large effect size. 
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 = 
No, 1 = Yes) and the interaction of ME x Time.  Of note, neither the main effect of ME nor the 
interaction effect of Time x ME were significant, indicating that mystical experiences were not a 
statistically significant moderator of the effect of Ax scores over time.  With the inclusion of 
predictors ME and ME x Time, this model explained an additional 2.9% of variance (a small 
effect size).  Figure 20 demonstrates the nature of the effect of the moderator variable.  On 
average, the mystical-experience group deteriorated slightly (higher levels of attachment-related 
anxiety) over time points, while the non-mystical experience group improved slightly (reduced 
levels of attachment-related anxiety) over time.  Of note, this finding is contrary to the study’s 
original prediction (which hypothesized that the mystical experience group would show greater 
improvement than the non-mystical experience group) and in fact preliminarily indicates that the 







Fixed effects model: Tests of fixed effects predicting ECR-R Ax scores, controlling for SD. 
 
Source Numerator df Denominator df F Sig. 
Intercept 1 13.857 14.375 .002 
SD 1 14.337 .002 .965 
Time 1 11.279 1.431 .256 
Time2  1 10.108 1.289 .282 
ME 1 11.173 .531 .481 
ME x Time 1 8.856 1.393 .269 
Note: ECR-R = Experiences in Close Relationships-Revised.  Ax = Anxiety subscale. SD = Marlow-
Crowne Social Desirability scale.  MEG = Mystical Experience (0 = No, 1 = Yes). 
 
 
Figure 20. Interaction of ME and Time for ECR-R Ax scores controlling for SD. 
Note: ECR-R = Experiences in Close Relationships-Revised. 
 
In sum, none of the predictors were significantly associated with Ax.  Of note, this may 
be due in part to the data’s lack of a uniform trajectory: with some individuals improving, and 
others deteriorating (as reflected by reliable change indices), these varied trajectories may be 
canceling each other out.  Nevertheless, the effects of linear and quadratic time explained 81.1% 
of variance (a large effect size), with ME and Time x ME explaining an additional 2.9% of 
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ECR-R Av Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted 
to predict the degree and shape of Av change over time, while controlling for SD.  A Toeplitz 
(TP) covariance structure was the best fit for the data.  Neither the effect of linear Time nor 
quadratic Time2 were significant (see Table 20).  Additionally, this model predicted 85.6% of 
variance in Av scores (R2 = .865), reflecting a large effect size. 
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 = 
No, 1 = Yes) and the interaction of ME x Time.  Of note, neither the main effect of ME nor the 
interaction effect of Time x ME were significant, indicating that mystical experiences were not a 
statistically significant moderator of the effect of Av scores over time.  In fact, with the inclusion 
of predictors ME and ME x Time, this model predicted 7.1% less variance (R = .785) (See 
Figure 21). 
Table 20. 
Fixed effects model: Tests of fixed effects predicting ECR-R Av scores, controlling for SD. 
 
Source Numerator df Denominator df F Sig. 
Intercept 1 12.440 8.344 .013 
SD 1 11.945 .865 .371 
Time 1 17.751 .000 .994 
Time2  1 5.678 .021 .891 
ME 1 14.490 1.291 .274 
ME x Time 1 1.695 .220 .692 
Note: ECR-R = Experiences in Close Relationships-Revised.  Av = Avoidance subscale. SD = Marlow-







Figure 21. Interaction of ME and Time for ECR-R Av scores controlling for SD. 
Note: ECR-R = Experiences in Close Relationships-Revised. SD = Social Desirability. 
 
In sum, none of the predictors were significantly associated with Av change over time 
and the inclusion of ME and ME x Time in fact weakened the percentage of variance explained.  
Of note, these findings stand in contrast to study predictions, which projected improved 
(reduced) attachment-related avoidance over time, with the presence of mystical experiences 
moderating this relationship.  
PEB Mixed Model Analyses: A Hierarchical Linear Model analysis was conducted to 
predict the degree of PEB change over time, while controlling for SD.  (Of note, quadratic Time2 
was not assessed, as PEB was only collected at two time points: before psychedelic exposure and 
at the one-month follow-up). An Identity covariance structure was the best fit for the data.  Of 
note, the effect of Time was not significant (see Table 21), which likely reflects the limited 
change over time in the sample overall (as reflected in reliable change indices).  This model 
predicted 95.4% of variance of PEB scores (R2 = .954), reflecting a large effect size. 
A Hierarchical Linear Model was then conducted with two additional variables: ME (0 = 
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interaction effect of ME x Time were significant, indicating that mystical experiences were not a 
significant moderator of PEB scores over time.  In fact, with the inclusion of predictors ME and 
ME x Time, the model predicted .7% less variance (R2 = .947) (See Figure 22).   
Table 21. 
Fixed effects model: Tests of fixed effects predicting PEB score, controlling for SD. 
 
Source Numerator df Denominator df F Sig. 
Intercept 1 14.378 91.430 .000 
SD 1 14.707 .049 .827 
Time 1 6.558 .056 .821 
ME 1 11.392 .476 .504 
ME x Time 1 9.321 .257 .624 
*Significant (<.05) change 
Note: PEB = Pro-Environmental Behavior summary score. 





Figure 22. Interaction of ME and Time for PEB scores controlling for SD. 




In sum, none of the predictors were significantly associated with PEB change over time 
and the inclusion of ME and ME x Time in fact weakened the percentage of variance explained.  
Of note, these findings stand in contrast to study predictions, which projected improved 
(increased) pro-environmental behavior over time, with the presence of mystical experiences 






Reliable Change Score Analyses by Measure 
 
GSI Reliable Change Scores: According to assessments of reliable change, 61.5% (n = 8) 
of the sample did not evidence significant (>1.96) within-person improvement or deterioration 
on the GSI between time points 1 and 2 (before and after the psychedelic retreat).  In essence, the 
symptom profiles for nearly two thirds of the sample were contrary to predictions and remained 
unchanged directly following psilocybin exposure (see Table 22).   
In contrast, and in alignment with predictions, 30.8% (n = 4) of the sample showed 
reliable change between time points 1 and 2, with all four of these subjects evidencing improved 
symptom profiles and reduced GSI scores by a factor of 3.65 (subject 10), 3.77 (subject 3), 4.03 
(subject 4) and 6.29 (subject 2) standard deviations respectively.  Of note, all four subjects 
earned GSI scores within one standard deviation of the outpatient norm at baseline, and 
subsequently earned GSI scores within one standard deviation of the non-patient norm directly 
following psilocybin exposure.   
Lastly, the trajectory for 7.7% (n = 1) of the sample is unknown, as Subject 7 did not 
complete data entry at time point 2, directly following psilocybin exposure. 
According to reliable change indices assessing within-person change between time points 
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 38.5% (n = 5) 
of participants remained unchanged on the GSI; in other words, approximately one third of the 
sample performed contrary to predictions and were unaffected by psilocybin exposure, earning 
the same GSI score (and, by proxy, the same symptom profile) before and after psilocybin 
exposure, as well as at the one-month follow-up.   
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In contrast, and also contrary to study predictions, 15.4% (n = 2) of the sample 
significantly deteriorated on the GSI at follow-up.  Specifically, Subject 11 (who earned GSI 
scores within one standard deviation of the outpatient norm at all three time points) did not 
significantly change between time points 1 and 2, but significantly deteriorated between time 
points 2 and 3, thus indicating a worsened symptom profile (and an increased GSI score by a 
factor of 3.9 standard deviations when compared to baseline) one month following psilocybin 
exposure.  In comparison to baseline, Subject 7 also deteriorated at the one-month follow-up by a 
factor of 2.01 standard deviations, although this subject earned GSI scores within one standard 
deviation of the non-patient norm at both time points 1 and 3.  (As this subject did not participate 
in data collection at time point 2, it’s unknown whether this deterioration was evident directly 
following psilocybin exposure, or whether it developed during the one-month follow-up period).   
In contrast, and in alignment with study predictions (which anticipated sustained 
improvement on the GSI through follow-up), 7.7% (n = 1) of the sample (subject 2), improved at 
time point 2 (moving from a GSI score within one standard deviation of the outpatient norm at 
baseline to a GSI score within one standard deviation of the non-patient norm in the immediate 
wake of psychedelic exposure) and retained these gains at time point 3 (at the one-month follow-
up).  An additional 7.7% (n = 1) of the sample (subject 3) significantly improved at time point 2 
(directly following psilocybin exposure) but lost these gains by time point 3 (when assessed at 
one month).  Though not indicative of a significant change at follow-up, subject 3 earned a GSI 
score within one standard deviation of the outpatient norm at baseline and GSI scores within one 
standard deviation of the non-patient norm at both time points 2 and 3.   
Lastly, nearly a third of the sample did not participate in data collection at follow-up 
(30.8%, n = 4), leaving their trajectories unknown.  This includes Subject 1 and Subject 9, both 
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of whom remained unchanged on the GSI between time points 1 and 2, as well as Subject 4 and 
Subject 10, both of whom significantly improved between time points 1 and 2. 
In sum, 61.5% (n = 8) of the sample did not evidence significant change (improvement or 
deterioration) directly following psilocybin exposure.  In contrast, 30.8% (n = 4) of the sample 
evidenced significant improvement on the GSI directly following psilocybin exposure. One 
participant did not complete data entry at time point 2, leaving the trajectory for 7.7% of the 
sample unknown directly following psilocybin exposure.  At the one-month follow-up, 46.2% (n 
= 6) of the sample either continued to remain unaffected by psychedelic exposure or lost 
significant gains seen at time point 2, evidencing a return to baseline by the one-month follow-
up.  In contrast, 23.1% (n = 3) of the sample evidenced significant change at follow-up, with 
some evidencing significant improvement, and others evidencing significant deterioration.  
Specifically, 15.4% (n = 2) of the sample evidenced significant deterioration (higher GSI scores) 
by the one-month follow-up, while 7.7% (n = 1) of the sample maintained significant 
improvement (lower GSI scores) at the one-month follow-up.  Of note, nearly a third of the 
sample (30.8%, n = 4) did not participate in data collection at follow-up, leaving their trajectories 
unknown, with two of these subjects (15.4%, n = 2) having previously evidenced no significant 
change directly following psilocybin exposure and the other two subjects (15.4%, n = 2) having 













Reliable change scores on BSI GSI by subject. 
______________________________________________________________________________ 
Subject ID Btwn Timepoints 1 & 2  Btwn Timepoints 2 & 3  Btwn Timepoints 1 & 3 
______________________________________________________________________________ 
1     1.51        n/a      n/a 
2     6.29*      -.75    5.53* 
3     3.77*    -2.39*    1.38 
4     4.03*        n/a      n/a 
5                -0.88      1.38     0.50 
6     1.64     -0.75                 0.88 
7       n/a        n/a               -2.01* 
8     1.38     -1.38    0.00 
9                -1.26        n/a      n/a 
10    3.65*        n/a      n/a 
11              -0.01     -3.77*               -3.90* 
12     0.88     -0.63     0.25 
13     0.63      0.13     0.75 
______________________________________________________________________________ 
*Significant (>1.96) within-person change   
Note: BSI = Brief Symptom Inventory. GSI = Global Severity Index. 
 
IPO-ID Reliable Change Scores: According to assessments of reliable change, 91.6% (n 
= 11) of the sample did not evidence significant (>1.96) within-person improvement or 
deterioration on the IPO-ID between time points 1 and 2 (before and after the psychedelic 
retreat), while the trajectory for the final 8.3% (n = 1) of the sample is unknown, as Subject 7 did 
not complete data entry at time point 2.  In other words, essentially the entire sample performed 
contrary to study predictions, as their identity diffusion remained unchanged directly following 
psilocybin exposure (see Table 23). 
According to reliable change indices assessing within-person change between time points 
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 46.2% (n = 6) 
of participants remained unchanged on the IPO-ID; in other words, nearly one half of the sample 
performed contrary to study predictions and were unaffected by psilocybin exposure, earning the 
same IPO-ID score (and, by proxy, the same degree of identity diffusion) before and after 
psilocybin exposure, as well as at the one-month follow-up. 
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In contrast, and in alignment with study predictions, 23.1% (n = 3) of the sample 
significantly improved on the IPO-ID at the one-month follow-up (evidencing lower levels of 
identity diffusion).  Of note, all three participants (Subject 2, Subject 5, and Subject 6) followed 
the same trajectory, evidencing no change on the IPO-ID directly following psilocybin exposure, 
followed by significant improvement during the one-month follow-up (by a factor of 2.67, 2.32 
and 3.03 standard deviations respectively). 
Lastly, 23.1% (n = 3) of the sample did not participate in data collection at follow-up, 
leaving their trajectories unknown.  This includes Subject 1, Subject 4 and Subject 10, none of 
whom evidenced significant change directly following psilocybin exposure (although Subject 10 
trended toward improvement with a reliable change score of 1.96 between time points 1 and 2, 
which missed the significance cut-off by only .01).  
In sum, 91.6% (n = 11) of the sample did not evidence significant change (improvement 
or deterioration) directly following psilocybin exposure.  One participant did not complete data 
entry at time point 2, leaving the trajectory for 8.3% of the sample unknown.  At the one-month 
follow-up, 46.2% (n = 6) of the sample continued to remain unaffected by psychedelic exposure 
and evidenced no change with regard to degree of identity diffusion.  In contrast, and in 
alignment with study predictions, which projected improved (lower) levels of identity diffusion 
following psychedelic exposure, 23.1% (n = 3) of the sample significantly improved (earning 
lower IPO-ID scores) by the one-month follow-up.  Of note, 23.1% (n = 3) of the sample did not 
participate in data collection at follow-up, leaving their trajectories unknown (none of these 








Reliable change scores on IPO-ID by subject. 
______________________________________________________________________________ 
Subject ID Btwn Timepoints 1 & 2  Btwn Timepoints 2 & 3  Btwn Timepoints 1 & 3 
______________________________________________________________________________ 
 
1              -0.89      n/a      n/a 
2              -0.18    2.67*    2.67*   
3              -1.60    1.60    1.60   
4   0.71      n/a      n/a 
5   0.53    2.32*    2.32*              
6   1.07    3.03*    3.03*  
7     n/a      n/a    1.96   
8              -0.71    0.89    0.89    
10   1.96              n/a      n/a 
11   0.00               -0.36                -0.36 
12              -1.07               -0.71                -0.71   
13              -0.71               -1.43                -1.43               
______________________________________________________________________________ 
*Significant (>1.96) within-person change   
Note: IPO-ID = Inventory of Personality Organization, Identity Diffusion subscale. 
 
IPO-RT Reliable Change Scores: According to assessments of reliable change, 83.3% (n 
= 10) of the sample did not evidence significant (>1.96) within-person improvement or 
deterioration on the IPO-RT between time points 1 and 2 (before and after the psychedelic 
retreat).  In essence, the vast majority of the sample performed contrary to predictions, as their 
reality testing remained unchanged directly following psilocybin exposure (see Table 24). 
Additionally, and also contrary to study predictions (which anticipated improved reality 
testing over time), 8.3% (n = 1) of the sample evidenced significantly worsened reality testing 
directly following psilocybin exposure.  Specifically, Subject 1 earned a higher IPO-RT score 
(reflecting deteriorated reality testing) by a factor of -2.96 standard deviations following 
psilocybin exposure. 
Of note, the trajectory for the final 8.3% (n = 1) of the sample is unknown directly 
following psilocybin exposure, as Subject 7 did not complete data entry at time point 2.   
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According to reliable change indices assessing within-person change between time points 
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 58.3% (n = 7) 
of participants remained unchanged on the IPO-RT; in other words, over half of the sample 
performed contrary to study predictions and were unaffected by psilocybin exposure, earning the 
same IPO-RT score (and, by proxy, the same capacity for reality testing) before and after 
psilocybin exposure, as well as at the one-month follow-up. 
In contrast, and also contrary to study predictions, 8.3% (n = 1) of the sample 
significantly deteriorated on the IPO-RT at the one-month follow-up.  Specifically, Subject 13’s 
reality testing remained unchanged directly following psilocybin exposure, and then significantly 
deteriorated over the course of the follow-up period by a factor of -2.11 standard deviations. 
Only 8.3% (n = 1) of the sample performed in alignment with study predictions and 
evidenced significantly improved reality testing at the one-month follow-up.  Specifically, 
Subject 11, whose reality testing remained unchanged directly following psilocybin exposure, 
evidenced significant improvement in this domain over the course of the follow-up period, 
earning a lower (healthier) IPO-RT score by a factor of 2.33 standard deviations at one month. 
Lastly, 25% (n = 3) of the sample did not participate in data collection at follow-up, 
leaving their trajectories unknown.  This includes Subject 4 and 10, neither of whom evidenced 
significant change directly following psilocybin exposure, as well as Subject 1, whose reality 
testing significantly deteriorated directly following psilocybin exposure by a factor of -2.96 
standard deviations. 
In sum, 83.3% (n = 10) of the sample did not evidence significant change (improvement 
or deterioration) directly following psilocybin exposure.  In contrast, 8.3% (n = 1) evidenced 
significantly deteriorated reality testing directly following psilocybin exposure, while another 
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8.3% (n = 1) of the sample did not complete data entry at time point 2, leaving their trajectory 
unknown directly following psilocybin exposure.  At the one-month follow-up, 58.3 (n = 7) of 
the sample continued to remain unaffected by psychedelic exposure.  In contrast, 16.6% (n = 2) 
of the sample evidenced significant change at follow-up, with 8.3% (n = 1) evidencing a lower 
IPO-RT score (improved reality testing) and 8.3% (n = 1) evidencing a higher IPO-RT score 
(deteriorated reality testing) at the one-month follow-up.  Of note, 25% (n = 3) of the sample did 
not participate in data collection at the one-month follow-up, leaving their trajectories unknown 
(with two of these subjects evidencing no significant change directly following psilocybin 
exposure, and one of these subjects evidencing deteriorated reality testing directly following 
psilocybin exposure). 
Table 24. 
Reliable change scores on IPO-RT by subject. 
______________________________________________________________________________ 
Subject ID Btwn Timepoints 1 & 2  Btwn Timepoints 2 & 3  Btwn Timepoints 1 & 3 
______________________________________________________________________________ 
 
1              -2.96*         n/a      n/a 
2   0.21    1.06    1.27 
3              -0.63    1.06    0.42 
4   0.21      n/a      n/a 
5   0.85                          -0.85    0.00 
6   0.42    1.27    1.69 
7     n/a      n/a    1.48   
8              -0.63    0.85    0.21 
10              -0.63      n/a      n/a 
11              -0.85    3.17*    2.33* 
12              -1.06               -0.21               -1.27 
13              -1.90               -0.21               -2.11*              
______________________________________________________________________________ 
*Significant (>1.96) within-person change   
Note: IPO-RT = Inventory of Personality Organization, Reality Testing subscale. 
 
IPO-PD Reliable Change Scores: According to assessments of reliable change, 91.7% (n 
= 11) of the sample did not evidence significant (>1.96) within-person improvement or 
deterioration on the IPO-PD between time points 1 and 2 (before and after the psychedelic 
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retreat), while the trajectory for the final 8.3% (n = 1) of the sample is unknown, as Subject 7 did 
not complete data entry at time point 2.  In other words, essentially the entire sample performed 
contrary to study predictions and evidenced unchanged defensive structures directly following 
psilocybin exposure (see Table 25). 
According to reliable change indices assessing within-person change between time points 
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 66.7% (n  = 8) 
of participants remained unchanged on the IPO-PD; in other words, approximately two-thirds of 
the sample performed contrary to study predictions and were unaffected by psilocybin exposure, 
earning the same IPO-PD score (and, by proxy, evidencing the same defensive structure) before 
and after psilocybin exposure, as well as at the one-month follow-up. 
In contrast, and in alignment with study predictions, 8.3% (n = 1) of the sample 
performed in alignment with study predictions and significantly improved on the IPO-PD at the 
one-month follow-up (evidencing healthier defenses).  Specifically, Subject 2 did not 
significantly change directly following psilocybin exposure, but gradually improved across the 
follow-up period, earning a significantly lower (healthier) IPO-PD score at the one-month 
follow-up by a factor of 2.12 standard deviations.  
Lastly, 23.1% (n = 3) of the sample did not participate in data collection at follow-up, 
leaving their trajectories unknown.  Of note, none of these subjects evidenced significant change 
directly following psilocybin exposure. 
In sum, 91.7% (n = 11) of the sample did not evidence significant change (improvement 
or deterioration) directly following psilocybin exposure.  One participant did not complete data 
entry at time point 2, leaving the trajectory for 8.3% of the sample unknown.  At the one-month 
follow-up, 66.7% (n = 8) of the sample continued to remain unaffected by psychedelic exposure 
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and evidenced no change with regard to defensive structure.  In contrast, and in alignment with 
study predictions, which projected improved defenses across time points, 8.3% (n = 1) of the 
sample evidenced significant improvement at follow-up on the IPO-PD.  Lastly, 21.3% (n = 3) of 
the sample did not participate in data collection at follow-up, leaving their trajectories unknown.  
Of note, none of these subjects evidenced significant change directly following psilocybin 
exposure. 
Table 25. 
Reliable change scores on IPO-PD by subject. 
______________________________________________________________________________ 
Subject ID Btwn Timepoints 1 & 2  Btwn Timepoints 2 & 3  Btwn Timepoints 1 & 3 
______________________________________________________________________________ 
 
1              -0.42      n/a      n/a 
2   1.27    0.85    2.12* 
3   0.64    0.00    0.64 
4              -0.64      n/a      n/a 
5              -0.21    0.64    0.42 
6   1.49    0.42    1.91 
7     n/a      n/a    0.42   
8              -0.42    0.85    0.42 
10   0.42      n/a      n/a 
11   1.27               -0.64    0.64 
12              -0.42    0.42    0.00 
13               0.00               -0.85               -0.85 
______________________________________________________________________________ 
*Significant (>1.96) within-person change   
Note: IPO-PD = Inventory of Personality Organization, Primitive Defenses subscale. 
 
PNI-G Reliable Change Scores: According to assessments of reliable change, 81.8% (n = 
9) of the sample did not evidence significant (>1.96) within-person improvement or deterioration 
on the PNI-G subscale between time points 1 and 2 (before and after the psychedelic retreat).  In 
essence, the vast majority of the sample performed contrary to predictions, as their levels of 
narcissistic grandiosity remained unchanged directly following psilocybin exposure (see Table 
26).   
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Only 9.1% of the sample (subject 6) performed in alignment with study predictions and 
evidenced significantly reduced narcissistic grandiosity following psilocybin exposure (by a 
factor of 3.62 standard deviations).   
The trajectory for an additional 9.1% of the sample is unknown, as Subject 7 did not 
complete data entry at time point 2, directly following psilocybin exposure.  In sum, and contrary 
to study predictions (which anticipated reduced levels of grandiosity directly following 
psilocybin exposure), the vast majority of the sample remained unchanged directly following 
psilocybin exposure. 
According to reliable change indices assessing within-person change between time points 
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 63.6% (n = 7) 
of participants remained unchanged on the PNI-G subscale; in other words, the vast majority of 
participants performed contrary to predictions and remained unaffected by psilocybin exposure, 
earning the same PNI-G score (and, by proxy, evidencing the same levels of narcissistic 
grandiosity) before and after psilocybin exposure, as well as a one-month follow-up.   
In contrast, only 18.2% (n = 2) of participants (Subject 2 and Subject 6) performed in 
alignment with study predictions and evidenced improved (reduced) levels of narcissistic 
grandiosity by the one-month follow-up.  Specifically, subject 6 improved directly following 
psilocybin exposure (by a factor of 3.62 standard deviations) and continued improving at the 
one-month follow-up (by a factor of 5.33 standard deviations).  Evidencing a slightly different 
trajectory, Subject 2 did not evidence significant change directly following psilocybin exposure, 
but improved more gradually across time points, ultimately evidencing significantly reduced 
levels of grandiosity at one month (by a factor of 2.32 standard deviations).  
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Lastly, 18.2% (n = 2) of participants did not participate in data collection at follow-up, 
leaving their trajectories unknown.  This includes Subject 1 and Subject 4, both of whom 
remained unchanged on the PNI-G between time points 1 and 2. 
In sum, 81.8% (n = 9) of the sample did not evidence significant change (improvement or 
deterioration) directly following psilocybin exposure.  In contrast, 9.1% of the sample (n = 1) 
significantly improved (evidencing reduced grandiosity) directly following psilocybin exposure.  
The trajectory for 9.1% of the sample is unknown directly following psilocybin exposure, as one 
participant did not complete data entry at time point 2.  At the one-month follow-up, 63.6% (n = 
7) of the sample continued to remain unaffected by psilocybin exposure.  In contrast, 18.2% (n = 
2) evidenced significant change at follow-up, with both participants evidencing significant 
improvement (lower levels of grandiosity).  Of note, 18.2% (n = 2) of the sample did not 
participate in data collection at follow-up, leaving their trajectories unknown (this includes two 
subjects, neither of whom evidenced significant change directly following psilocybin exposure). 
Table 26. 
Reliable change scores on PNI-G by subject. 
______________________________________________________________________________ 
Subject ID Btwn Timepoints 1 & 2  Btwn Timepoints 2 & 3  Btwn Timepoints 1 & 3 
______________________________________________________________________________ 
 
1              -1.95      n/a      n/a  
2   1.27    1.04    2.32* 
3   0.34               -0.70              -0.35   
4   0.16      n/a      n/a 
5   0.37    0.51    0.88 
6   3.62*    1.71    5.33* 
7     n/a      n/a               -0.94 
8              -0.73    1.13    0.40 
11              -0.66    1.34               -0.01 
12              -0.73    0.61               -0.12 
13              -0.28               -0.08               -0.36 
    
______________________________________________________________________________ 
*Significant (>1.96) within-person change   




PNI-V Reliable Change Scores: According to assessments of reliable change, 72.7% (n = 
8) of the sample did not evidence significant (>1.96) within-person improvement or deterioration 
on the PNI-V subscale between time points 1 and 2 (before and after the psychedelic retreat).  In 
essence, the vast majority of the sample performed contrary to predictions, as their levels of 
narcissistic vulnerability remained unchanged directly following psilocybin exposure (see Table 
27).   
Only 18.2% (n = 2) of the sample (Subject 3 and Subject 6) performed in alignment with 
study predictions and evidenced significantly improved (reduced) narcissistic vulnerability 
following psilocybin exposure (by a factor of 3.70 and 6.44 standard deviations respectively).   
Lastly, the trajectory of 7.7% (n = 1) of the sample is unknown, as Subject 7 did not 
complete data entry at time point 2, directly following psilocybin exposure. 
According to reliable change indices assessing within-person change between time points 
1 and 3 (before psychedelic exposure and after the one-month follow-up), 54.5% (n = 6) of 
participants remained unchanged on the PNI-V subscale at follow-up; in other words, 
approximately half of participants performed contrary to predictions and remained unaffected by 
psilocybin exposure, earning the same PNI-V score (and, by proxy, evidencing the same levels 
of narcissistic vulnerability) before and after psilocybin exposure, as well as a one-month follow-
up.   
In contrast, 18.2% (n = 2) of participants (Subject 3 and Subject 6) performed in 
alignment with study predictions and evidenced improved (reduced) levels of narcissistic 
vulnerability by the one-month follow-up (by a factor of 3.33 and 7.83 standard deviations 
respectively).   
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Additionally, and contrary to study predictions, 9.1% (n = 1) of the sample (Subject 5) 
evidenced significant deterioration (higher levels of vulnerability) over time by a factor of 2.54 
standard deviations at the one-month follow-up.   
Lastly, the trajectory of 18.2% (n = 2) of the sample is unknown, as Subject 1 and 
Subject 4 did not participate in data collection at follow-up (neither subject evidenced significant 
change directly following psilocybin exposure). 
In sum, 72.7% (n = 8) of the sample did not evidence significant change (improvement or 
deterioration) directly following psilocybin exposure.  In contrast, 18.2% (n = 2) of the sample 
evidenced significant improvement on the PNI-V directly following psilocybin exposure.  One 
participant did not complete data entry at time point 2, leaving the trajectory for 9.1% of the 
sample unknown directly following psilocybin exposure.  At the one-month follow-up, 54.5% (n 
= 6) of the sample continued to remain unaffected by psychedelic exposure.  In contrast, 27.3% 
(n = 3) of the sample evidenced significant change at follow-up, with 18.2% (n = 2) evidencing 
improved (lower) levels of grandiosity, and 9.1% (n = 1) evidencing deteriorated (higher) levels 
of grandiosity at the one-month follow-up.  Of note, 18.2% (n = 2) of the sample did not 
participate in data collection at the one-month follow-up, leaving their trajectories unknown 
















Reliable change scores on PNI-V by subject. 
______________________________________________________________________________ 
Subject ID Btwn Timepoints 1 & 2  Btwn Timepoints 2 & 3  Btwn Timepoints 1 & 3 
______________________________________________________________________________ 
 
1              -0.47      n/a      n/a 
2   0.19    0.89    1.08   
3   3.70*               -0.37    3.33* 
4   1.41      n/a      n/a 
5              -1.64               -0.90               -2.54* 
6   6.44*    1.39    7.83* 
7     n/a      n/a    1.71 
8              -0.60    2.17*    1.57            
11              -1.34    1.99*        1.32         
12              -0.73               -0.35    0.70 
13   1.16               -0.25    0.91 
    
_______________________________________________________ 
*Significant (>1.96) within-person change   
Note: PNI-V = Pathological Narcissism Inventory – Narcissistic Vulnerability index. 
 
MentS-T Reliable Change Scores: According to assessments of reliable change, 72.7% (n 
= 8) of the sample did not evidence significant (>1.96) within-person change on the MentS-T 
between time points 1 and 2 (before and after the psychedelic retreat), while 9.1% (n = 1) of the 
sample (subject 6) evidenced significant improvement on the MentS-T by a factor of 2.72 
standard deviations, and another 9.1% (n = 1) of the sample (subject 5) evidenced significant 
deterioration on the MentS-T by a factor of -3.40 standard deviations (see Table 28).  The 
trajectory for an additional 9.1% (n = 1) of the sample is unknown, as Subject 7 did not complete 
data entry at time point 2, directly following psilocybin exposure.  In sum, and contrary to study 
predictions (which anticipated improved mentalization skills following psilocybin exposure) the 
vast majority of the sample’s mentalization capacities remained unchanged directly following 
psilocybin exposure. 
According to reliable change indices assessing within-person change between time points 
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 63.6% (n = 7) 
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of the sample remained unchanged on the MentS-T; in other words, the majority of the sample 
performed contrary to predictions and were unaffected by psilocybin exposure, earning the same 
MentS-T score (overall capacity for mentalization) before and after psilocybin exposure, as well 
as at a one-month follow-up.  Also contrary to study predictions (which anticipated sustained 
improvement on the MentS-T through follow-up), 9.1% (n = 1) of the sample (subject 5) 
deteriorated at time point 2 (in the immediate wake of psychedelic exposure) but returned to 
baseline at time point 3 (at a one-month follow-up).  In contrast, and in alignment with study 
predictions, 9.1% (n = 1) of the sample (subject 6) improved at time point 2 (in the immediate 
wake of psychedelic exposure) and evidenced even further improvement by time point 3 (at the 
one-month follow-up).  Lastly, 18.2% (n = 2) of the sample did not participate in data collection 
at follow-up, leaving their trajectories unknown.  This includes Subject 1 and Subject 4, both of 
whom remained unchanged on the MentS-T between time points 1 and 2. 
In sum, 72.7% (n = 8) did not evidence significant change (improvement or deterioration) 
directly following psilocybin exposure.  In contrast, 18.2% (n = 2) of the sample evidenced 
significant change, with one participant (Subject 6) evidencing a significantly higher MentS-T 
score (improved mentalization skills) directly following psilocybin exposure and one participant 
(Subject 5) evidencing a significantly lower MentS-T score (deteriorated mentalization skills) 
directly following psilocybin exposure.  One participant did not complete data entry at time point 
2, leaving the trajectory of 9.1% of the sample unknown directly following psilocybin exposure.  
At the one-month follow-up, 72.7% (n = 8) of the sample either continued to remain unaffected 
by psilocybin exposure or returned to baseline following significant change at time point 2.  In 
contrast, 9.1% (n = 1) of the sample evidenced ongoing and significant improvement (higher 
MentS-T score) at the one-month follow-up.  Of note, 18.2% (n = 2) of the sample did not 
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participate in data collection at follow-up, leaving their trajectories unknown (both of these 
subjects remained unchanged on the MentS-T between time points 1 and 2).  
Table 28. 
Reliable change scores on MentS-T by subject. 
______________________________________________________________________________ 
Subject ID Btwn Timepoints 1 & 2  Btwn Timepoints 2 & 3  Btwn Timepoints 1 & 3 
______________________________________________________________________________ 
 
1   1.36      n/a      n/a 
2   0.34               -0.51               -0.17 
3              -1.19    1.36    0.17 
4              -0.17      n/a      n/a 
5              -3.40*    1.87               -1.53 
6   2.72*    0.51    3.23* 
7     n/a      n/a    0.34 
8              -0.34    0.85    0.51   
11              -0.34               -0.85               -1.19 
12   0.00               -1.36               -1.36 
13              -0.34               -0.68               -1.02 
______________________________________________________________________________ 
*Significant (>1.96) within-person change   
Note: MentS-T = Mentalization Total. 
 
Ryff-OW Reliable Change Scores: According to assessments of reliable change, 83.3% (n 
= 10) of the sample did not evidence significant (>1.96) within-person change on the Ryff-OW 
between time points 1 and 2 (before and after the psychedelic retreat) (See Table 29).  The 
trajectory for the additional 16.6% (n = 2) of the sample is unknown, as Subject 7 and Subject 10 
did not complete data collection at time point 2, directly following psilocybin exposure.  Of note, 
these findings are contrary to study predictions, which anticipated improved psychological 
wellbeing following psilocybin exposure. 
According to reliable change indices assessing within-person change between time points 
1 and 3 (before psychedelic exposure and after the one-month follow-up period), 72.7% (n = 8) 
of the sample remained unchanged on the Ryff-OW.  The trajectory for the additional 27.3% (n = 
3) of the sample is unknown, as Subject 1, Subject 4 and Subject 10 did not complete data 
collection at the one-month follow-up.  Of note, these findings are contrary to study predictions, 
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which anticipated improved and sustained psychological wellbeing through the one-month 
follow-up period. 
In sum, 100% of the sample either evidenced no change on the Ryff-OW across time 
points or didn’t earn a reliable change index due to missing data, indicating that psilocybin 
exposure did not meaningfully predict within-person change on the Ryff-OW across time points.  
Table 29. 
Reliable change scores on Ryff-OW by subject. 
______________________________________________________________________________ 
Subject ID Btwn Timepoints 1 & 2  Btwn Timepoints 2 & 3  Btwn Timepoints 1 & 3 
______________________________________________________________________________ 
 
1   0.36      n/a      n/a   
2   0.29    0.76    1.05 
3   0.80               -0.18    0.62 
4   0.65      n/a      n/a              
5              -0.91                0.04               -0.87 
6   1.45               -0.40    1.05 
7     n/a                 n/a               -0.04   
8             -0.36         0.80    0.44        
10     n/a      n/a      n/a   
11              -0.15               -0.33               -0.47  
12   0.54               -0.58               -0.04 
13   0.84                    -0.11    0.73        
______________________________________________________________________________ 
*Significant (>1.96) within-person change   
Note: Ryff-OW = The Ryff Scale of Psychological Wellbeing, Overall Wellbeing summary score. 
 
ECR-R Ax Reliable Change Scores: According to assessments of reliable change, 54.5% 
(n = 6) of the sample did not evidence significant (>1.96) within-person improvement or 
deterioration on the Ax subscale between time points 1 and 2 (before and after the psychedelic 
retreat).  In essence, approximately half of the sample performed contrary to predictions, as their 
attachment-related anxiety remained unchanged directly following psilocybin exposure (see 
Table 30).   
Furthermore, and evidencing the opposite effect of what was hypothesized, 18.2% (n = 2) 
of the sample (subjects 5 and 8) deteriorated following psychedelic exposure, earning 
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significantly increased scores on the Ax subscale (by a factor of -2.43 and -2.54 standard 
deviations respectively).   
Only 18.2% of the sample (subjects 4 and 6) performed in alignment with study 
predictions and evidenced significantly reduced attachment-related anxiety directly following 
psilocybin exposure (by a factor of 2.54 and 4.96 standard deviations respectively).  The 
trajectory of 9.1% (n = 1) of the sample is unknown, as Subject 7 did not complete data entry at 
time point 2, directly following psilocybin exposure. 
According to reliable change indices assessing within-person change between time points 
1 and 3 (before psychedelic exposure and the one-month follow-up period), 36.4% (n = 4) of 
participants remained unchanged on the Ax subscale; in other words, approximately one-third of 
the sample performed contrary to predictions and remained unaffected by psilocybin exposure, 
earning the same Ax score (and, by proxy, evidencing the same levels of attachment-related 
anxiety) before and after psilocybin exposure, as well as at the one-month follow-up.   
Furthermore, and evidencing the opposite effect of what was hypothesized, 18.2% (n = 2) 
of participants evidenced significantly worsened attachment-related anxiety by follow-up.  
Specifically, Subject 8 significantly deteriorated between time points 1 and 2 and maintained this 
deterioration at time point 3 (by a factor of -2.43 standard deviations), while Subject 11 
evidenced no change on the Ax subscale between time points 1 and 2 but deteriorated between 
time points 2 and 3 (by a factor of -4.22 standard deviations).  An additional 9.1% (n = 1) of the 
sample significantly deteriorated between time points 1 and 2 but returned to baseline by 
timepoint 3 (Subject 5).   
In contrast, only 18.2% (n = 2) of participants performed in alignment with study 
predictions and evidenced improved (reduced) attachment-related anxiety by the one-month 
 
 147 
follow-up.  Specifically, Subject 6 significantly improved directly following psilocybin exposure 
and maintained these gains at follow-up (by a factor of 3.5 standard deviations), while Subject 2 
evidenced no change directly following psilocybin exposure but evidenced significant 
improvement at follow-up (by a factor of 2.54 standard deviations).   
Of note, an additional 18.2% (n = 2) of the sample did not participate in data collection at 
follow-up, leaving their trajectories unknown.  This includes Subject 1 (who did not evidence 
significant Ax change directly following psilocybin exposure) and Subject 4 (who evidenced 
significantly improved attachment-related anxiety directly following psilocybin exposure by a 
factor of 2.54 standard deviations). 
In sum, 54.5% (n = 6) did not evidence significant change (improvement or deterioration) 
directly following psilocybin exposure.  In contrast, 36.4% (n = 4) of the sample evidenced 
significant change, with two participants (Subject 5 and Subject 8) evidencing deteriorated 
(higher) levels of attachment-related anxiety and two participants (Subject 4 and Subject 6) 
evidencing improved (lower) levels of attachment-related anxiety directly following psilocybin 
exposure.  One participant did not complete data entry at time point 2, leaving the trajectory of 
9.1% of the sample unknown directly following psilocybin exposure.  At a one-month follow-up, 
45.5% (n = 5) of the sample either continued to remain unaffected by psilocybin exposure or 
returned to baseline following significant change at time point 2.  In contrast, 36.4% (n = 4) of 
the sample evidenced significant change at follow-up, with two participants (Subject 8 and 
Subject 11) evidencing deteriorated (higher) levels of attachment-related anxiety and two 
participants (Subject 6 and Subject 2) evidencing improved (lower) levels of attachment-related 
anxiety at the one-month follow-up.  Of note, 18.2% (n = 2) of the sample did not participate in 
data collection at follow-up, leaving their trajectories unknown (with one of these subjects 
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having evidenced no significant change directly following psilocybin exposure, and the other of 
these subjects having evidenced significant improvement directly following psilocybin 
exposure). 
Table 30. 
Reliable change scores on ECR-R Ax by subject. 
______________________________________________________________________________ 
Subject ID Btwn Timepoints 1 & 2  Btwn Timepoints 2 & 3  Btwn Timepoints 1 & 3 
______________________________________________________________________________ 
 
1   0.85      n/a    n/a 
2   1.09    1.46    2.54* 
3   0.61               -0.85               -0.24 
4   2.54*      n/a    n/a 
5              -2.43*    1.09               -1.35 
6   4.96*               -1.46    3.50* 
7     n/a      n/a    0.72 
8              -2.54*    0.11               -2.43*   
11   0.48               -4.22*               -3.74* 
12   0.24               -1.70               -1.46 
13              -0.61    0.98    0.37 
______________________________________________________________________________ 
*Significant (>1.96) within-person change   
Note: ECR-R Ax = Experiences in Close Relationships-Revised Anxiety subscale. 
 
ECR-R Av Reliable Change Scores: According to assessments of reliable change, 63.6% 
(n = 7) of the sample did not evidence significant (>1.96) within-person improvement or 
deterioration on the Av subscale between time points 1 and 2 (before and after the psychedelic 
retreat).  In essence, approximately two-thirds of the sample performed contrary to predictions, 
as their attachment-related avoidance remained unchanged directly following psilocybin 
exposure (see Table 31).   
Furthermore, and evidencing the opposite effect of what was hypothesized, 18.2% (n = 2) 
of the sample (subjects 8 and 11) deteriorated following psychedelic exposure, earning 
significantly increased scores on the Av subscale (by a factor of -3.31 and -2.79 respectively).   
Only 9.1% (n = 1) of the sample (subject 6) performed in alignment with study 
predictions and evidenced significantly reduced attachment-related avoidance directly following 
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psilocybin exposure (by a factor of 3.71 standard deviations).  The trajectory of 9.1% (n = 1) of 
the sample is unknown, as Subject 7 did not complete data entry at time point 2, directly 
following psilocybin exposure. 
According to reliable change indices assessing within-person change between time points 
1 and 3 (before psychedelic exposure and the one-month follow-up period), 54.5% (n = 6) of 
participants remained unchanged on the Av subscale; in other words, approximately one half of 
the sample performed contrary to predictions and were unaffected by psilocybin exposure, 
earning the same Av score (and, by proxy, evidencing the same level of attachment-related 
avoidance) before and after psilocybin exposure, as well as at a one-month follow-up.   
Furthermore, and evidencing the opposite effect of what was hypothesized, 9.1% (n = 1) 
of the sample (Subject 8) significantly deteriorated (evidencing higher levels of attachment-
related avoidance) between time points 1 and 2 (by a factor of -3.31 standard deviations) and 
maintained this deterioration at time point 3.   
An additional 9.1% (n = 1) of the sample (Subject 11) significantly deteriorated between 
time points 1 and 2 (by a factor of -2.79 standard deviations) but returned to baseline levels of 
attachment-related avoidance by follow-up.   
Of note, only 9.1% (n = 1) of participants performed in alignment with study predictions 
and evidenced improved (reduced) attachment-related avoidance by the one-month follow-up.  
Specifically, Subject 6 significantly improved directly following psilocybin exposure and 
maintained these gains at follow-up (by a factor of 3.98 standard deviations). 
Of note, an additional 18.2% (n = 2) of the sample did not participate in data collection at 
follow-up, leaving their trajectories unknown.  This includes Subject 1 and Subject 4, neither of 
whom evidenced significant change directly following psilocybin exposure. 
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In sum, 63.6% (n = 7) of the sample did not evidence significant change (improvement or 
deterioration) directly following psilocybin exposure.  In contrast, 27.3% (n = 3) of the sample 
evidenced significant change, with two participants (Subject 8 and Subject 11) evidencing 
deteriorated (higher) levels of attachment-related avoidance directly following psilocybin 
exposure and one participant (Subject 6) evidencing significantly improved (lower) attachment-
related avoidance directly following psilocybin exposure.  One participant did not complete data 
entry at time point 2, leaving the trajectory of 9.1% of the sample unknown directly following 
psilocybin exposure.  At a one-month follow-up, 63.6% (n = 7) of the sample either continued to 
remain unaffected by psilocybin exposure or returned to baseline following significant change at 
time point 2.  In contrast, 18.2% (n = 2) of the sample evidenced significant change at follow-up, 
with one participant (Subject 8) evidencing deteriorated (higher) levels of attachment-related 
avoidance and one participant (Subject 6) evidencing improved (lower) levels of attachment-
related avoidance at the one-month follow-up.  Of note, 18.2% (n = 2) of the sample did not 
participate in data collection at follow-up, leaving their trajectories unknown (neither of these 




















Reliable change scores on ECR-R Av by subject. 
______________________________________________________________________________ 
Subject ID Btwn Timepoints 1 & 2  Btwn Timepoints 2 & 3  Btwn Timepoints 1 & 3 
______________________________________________________________________________ 
 
1   0.52      n/a      n/a 
2              -0.26               -1.19    0.64 
3   0.67    0.26               -0.52 
4   1.86      n/a      n/a 
5              -1.57    0.26               -1.31 
6   3.71*    0.26    3.98* 
7     n/a      n/a    0.29 
8              -3.31*    1.07               -2.24* 
11              -2.79*    2.79*    0.00 
12   0.52               -0.79               -0.26 
13   0.52               -0.26    0.26 
______________________________________________________________________________ 
*Significant (>1.96) within-person change   
Note: ECR-R Av = Experiences in Close Relationships-Revised Avoidance subscale. 
 
PEB Reliable Change Scores: According to assessments of reliable change, 100% (n = 9) 
of the sample did not evidence significant (>1.96) within-person change on the PEB between 
time points 1 and 3 (before psychedelic exposure and after the one-month follow-up period) (See 
Table 32).  In sum, psilocybin exposure did not meaningfully predict within-person change on 
the PEB over time.  Of note, these findings stand in contrast to study predictions, which 



















Reliable change scores on PEB by subject. 
___________________________________ 
Subject ID Btwn Timepoints 1 & 3 
___________________________________ 
           
2   0.45  
3   1.13      
5   0.23              
6              -0.68  
7   0.45 
8              -0.45     
11              -0.90              
12   0.23  
13              -0.23    
___________________________________ 
*Significant (>1.96) within-person change   









Summary of Statistical Analyses by Measure 
 
BSI Summary: The Global Severity Index (GSI) was selected as a summary measure for 
the Brief Symptom Inventory (BSI).  A Hierarchical Linear Model was conducted using GSI 
score as the outcome variable and SD as a control.  Additionally, reliable change indices were 
also calculated in order to assess within-person change between time points.  As predicted, both 
types of analyses preliminarily suggest that participants evidence significant improvement on the 
GSI directly following psilocybin exposure.   
Contrary to study predictions, however, which anticipated sustained improvement over 
time, mixed model analyses indicate that the sample, on average, trended back toward baseline at 
follow-up.  With that said, reliable change indices indicate that two separate trajectories may 
have emerged during the follow-up period, which could be cancelling each other out within the 
mixed model analyses.  Specifically, while 23.1% (n = 3) of the sample evidenced significant 
change at follow-up, these participants did not follow a uniform trajectory, with 15.4% (n = 2) 
evidencing significant deterioration (higher GSI scores) and 7.7% (n = 1) evidencing significant 
improvement (lower GSI scores).  It’s possible (though speculative at this juncture) that these 
divergent pathways may be explained by whether or not a given subject had a mystical 
experience: of the four subjects with reliable change at follow-up, the two participants who had a 
mystical experience (Subject 11 and Subject 3) either remained unchanged at time point 2 and 
then deteriorated significantly at time point 3, or improved at time point 2, but then lost these 
gains at time point 3.  In contrast, the participant with no mystical experience (Subject 2) 
sustained significant improvement across time points 2 and 3.  The fourth subject with 
significant change at follow-up has an unknown ME status. 
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A second Hierarchical Linear Model, which included the main effect of ME, as well as 
the interaction effect of Time x ME, provides further preliminary support for this potential 
interaction.  Although neither effect was significant, this model explained an additional 7.7% of 
variance (a small to medium effect size), with the non-mystical experience group showing 
greater improvement between time points 1 and 2 than the mystical experience group (the 
opposite of study predictions, which projected the mystical experience group to evidence greater 
improvement over time).  Overall, these preliminary trends warrant further investigation with a 
larger sample size. 
IPO-ID Summary: A Hierarchical Linear Model was conducted using IPO-ID score as 
the outcome variable and SD as a control.  Additionally, reliable change indices were also 
calculated in order to assess within-person change between time points.  Of note, both types of 
analyses preliminarily suggest that participants remain unchanged directly following psilocybin 
exposure and then evidence significantly improved (lower) levels of identity diffusion at the one-
month follow-up.   
A second Hierarchical Linear Model, which included the main effect of ME, as well as 
the interaction of ME x Time, was not significant, but notably explained an additional 24.5% of 
variance (a large effect size).  On average, the non-mystical experience group evidenced greater 
improvement (less identity diffusion) relative to the mystical-experience group directly following 
psilocybin exposure, as well as at the one-month follow-up (the opposite of study predictions, 
which anticipated the mystical-experience group to improve more over time).  Overall, these 
preliminary trends warrant further investigation with a larger sample size. 
IPO-RT Summary: A Hierarchical Linear Model was conducted using IPO-RT score as 
the outcome variable and SD as a control.  The effect of Time2 was a significant predictor, 
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indicating that IPO-RT scores showed a significant curvilinear trend, with a slight downward 
curve (and reflecting improved reality testing) in change over time.  Reliable change indices, 
which were calculated in order to assess within-person change between time points, indicate less 
significant change overall (with 10 of 11 subjects evidencing insignificant within-person change 
directly following psilocybin exposure and 7 of 9 subjects evidencing insignificant within-person 
change at the one-month follow-up).  As a result, and while Hierarchical Linear Models indicate 
that significant change occurred over time, Reliable Change Indices indicate that this change was 
not clinically significant.  
A second Hierarchical Linear Model, which included the main effect of ME, as well as 
the interaction of ME x Time, was not significant.  It is perhaps relevant to note that both 
subjects who evidenced significant within-person change at the one-month follow-up also met 
criteria for having had a mystical experience, though their pathways diverged, with Subject 11 
evidencing significantly improved reality testing and Subject 13 evidencing significantly 
deteriorated reality testing by the one-month follow-up.   
IPO-PD Summary: Mixed model analyses were conducted using IPO-PD as the outcome 
variable and SD as a control.  Additionally, reliable change indices were also calculated to in 
order to assess within-person change between time points.  The effect of linear Time, quadratic 
Time2 and ME were not significant predictors of IPO-PD.  However, the interaction of ME x 
Time was significant, indicating that the non-mystical experience group evidenced improved 
(lower) levels of primitive defenses over time, whereas the mystical-experience group 
maintained similar levels of primitive defenses across time points.  Reliable change indices 
reflect similar findings. Although the sample was characterized by minimal change overall, the 
participant who earned a significant reliable change score at follow-up did not have a mystical 
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experience during psilocybin exposure and, in turn, evidenced improved (reduced) levels of 
primitive defenses over time.  Of note, these findings stand in contrast to study predictions, 
which projected the mystical-experience group to demonstrate greater improvement than the 
non-mystical experience group over time. 
PNI-G Summary: Mixed model analyses were conducted using PNI-G as the outcome 
variable and SD as a control.  The effects of linear Time, quadratic Time2 and ME were not 
significant predictors of PNI-G.  However, the interaction of ME x Time was significant, 
indicating that the non-mystical experience group evidenced improved (lower) levels of 
grandiosity over time, whereas the mystical-experience group maintained similar levels of 
grandiosity across time points.  Reliable change indices further reflect this finding.  Although the 
sample was characterized by minimal change overall, both participants who earned significant 
reliable change scores at follow-up did not have a mystical experience during psilocybin 
exposure and, in turn, evidenced improved (reduced) levels of grandiosity over time.  Of note, 
these findings stand in contrast to study predictions, which projected the mystical-experience 
group to demonstrate greater improvement than the non-mystical experience group over time. 
PNI-V Summary: A Hierarchical Linear Model analysis was conducted using PNI-V as 
the outcome variable and SD as a control, with predictors including linear Time and quadratic 
Time2, as well as ME and ME x Time.  Contrary to study predictions (which anticipated reduced 
levels of narcissistic vulnerability over time, moderated by mystical experiences) mixed model 
analyses did not meaningfully predict PNI-V.  According to reliable change indices, 18.2% (n = 
2) of the sample evidenced significant within-person change at time point 2 and 27.3% (n = 3) of 
the sample evidenced significant within-person change by time point 3.  As a result, and in the 
context of such a small sample, it is currently unknown whether the absence of significant mixed 
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model findings is due to limited change in the sample overall, or whether divergent pathways 
canceled each other out.  Specifically, of those who evidenced significant within-person change, 
two participants improved directly following psilocybin exposure and maintained these gains at 
the one-month follow-up (evidencing reduced levels of narcissistic vulnerability over time), 
while the third participant did not reliably change between time points 1 and 2, but significantly 
deteriorated by time point 3 (evidencing higher levels of narcissistic vulnerability at one month).  
Overall, further investigation will be required in order to clarify these findings.  
MentS Summary: The Mentalization Total score (MentS-T) was selected as a summary 
measure for the Mentalization Scale (MentS).  Mixed model analyses were conducted using 
MentS-T as the outcome variable and SD as a control, with predictors including linear Time and 
quadratic Time2, as well as ME and ME x Time.  Additionally, reliable change indices were also 
calculated in order to assess within-person change between time points.  Contrary to study 
predictions (which anticipated improved mentalization skills over time), mixed model analyses 
did not meaningfully predict MentS-T.  Reliable change indices support the conclusion that this 
is due to minimal change in the sample overall, as the vast majority of participants remained 
unchanged on the MentS-T (and therefore earned insignificant reliable change scores) across 
time points.  Overall, this data preliminarily supports the conclusion that psilocybin exposure 
does not affect an individual’s capacity for mentalization.  
Ryff-OW Summary: The Ryff’s Overall Wellbeing summary score (Ryff-OW) was 
selected as a summary measure for the entire Ryff Scale of Psychological Wellbeing (the Ryff).  
Mixed model analyses were conducted using Ryff-OW as the outcome variable and SD as a 
control, with predictors including linear Time and quadratic Time2, as well as ME and ME x 
Time.  Additionally, reliable change indices were also calculated in order to assess within-person 
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change between time points.  Contrary to study predictions (which anticipated improved 
psychological wellbeing over time), mixed model analyses did not meaningfully predict Ryff-
OW.  Reliable change indices support the conclusion that this is due to minimal change in the 
sample overall, as the vast majority of participants remained unchanged on the Ryff-OW (and 
therefore earned insignificant reliable change scores) across time points.  Overall, this data 
preliminarily supports the conclusion that psilocybin exposure does not affect an individual’s 
overall psychological wellbeing. 
ECR-R Ax Summary: A Hierarchical Linear Model was conducted using Ax as the 
outcome variable and SD as a control, with predictors including linear Time and quadratic 
Time2.  Although neither of these effects significantly predicted Ax change over time, reliable 
change indices indicate that this may be due to the sample’s lack of a uniform trajectory: with 
some participants significantly improving, and others significantly deteriorating, divergent 
trajectories may be canceling each other out within mixed model analyses.  Specifically, by the 
one-month follow-up, 36.4% (n = 4) of the sample evidenced significant change, with two 
participants evidencing deteriorated (higher) levels of attachment-related anxiety and two 
participants evidencing improved (lower) levels of attachment related-anxiety.  It’s possible 
(though speculative at this juncture) that these divergent pathways may be explained by whether 
or not a given subject had a mystical experience: of the four subjects with reliable change at 
follow-up, the two participants who improved did not have a mystical experience (Subject 6 and 
Subject 2), while the two participants who deteriorated diverged on this variable (Subject 11 had 
a mystical experience, while Subject 8 did not). 
A second Hierarchical Linear Model, which included the main effect of ME, as well as 
the interaction effect of Time x ME, provides further preliminary support for this potential 
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interaction.  Although neither effect was significant, this model explained an additional 2.9% of 
variance (a small effect size), with the mystical-experience group deteriorating slightly, and the 
non-mystical experience group improving slightly (the opposite of study predictions, which 
projected the mystical experience group to evidence stronger improvement over time).  Overall, 
these preliminary trends warrant further investigation with a larger sample size. 
ECR-R Av Summary: Mixed model analyses were conducted using Av as the outcome 
variable and SD as a control, with predictors including linear Time and quadratic Time2, as well 
as ME and ME x Time.  Contrary to study predictions (which anticipated reduced levels of 
attachment-related avoidance over time, moderated by mystical experience) mixed model 
analyses did not meaningfully predict Av (and, in fact, the inclusion of ME and ME x Time 
weakened the percentage of variance explained).  According to reliable change indices, 27.3% (n 
= 3) of the sample evidenced significant within-person change at time point 2 and 18.2% (n = 2) 
of the sample maintained significant within-person change at time point 3.  As a result, and in the 
context of such a small sample, it is currently unknown whether the absence of significant mixed 
model findings is due to limited change in the sample overall, or whether divergent pathways 
canceled each other out.  Specifically, of those who evidenced significant change, two 
participants significantly deteriorated directly following psilocybin exposure (evidencing 
amplified attachment-related avoidance), with one subject maintaining this deterioration at 
follow-up, and another returning to baseline.  In contrast, a third participant significantly 
improved following psilocybin exposure (evidencing reduced levels of attachment-related 
avoidance) and maintained these gains at follow-up.  Overall, further investigation will be 
required in order to clarify these findings.  
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PEB Summary: The Pro-Environmental Behavior (PEB) measure assesses the frequency 
with which individuals perform certain environmentally considerate actions.  This measure 
yields one overall score (PEB), which was used for all analyses.  Mixed model analyses were 
conducted using PEB as the outcome variable and SD as a control, with predictors including 
Time, ME and ME x Time.  (Of note, quadratic Time2 was not assessed, as PEB was only 
collected at two time points: before psychedelic exposure and at the one-month follow-up).  
Additionally, reliable change indices were also calculated in order to assess within-person 
change between time points.  Contrary to study predictions (which anticipated improved PEB 
over time), mixed model analyses did not meaningfully predict PEB.  Reliable change indices 
support the conclusion that this is due to minimal change in the sample overall, as 100% of 
participants remained unchanged on the PEB (and therefore earned insignificant reliable change 
indices) between time points.  Overall, this data preliminarily supports the conclusion that 








Self-Report Responses to Open-Ended Questions 
 
Question 1 (administered before psychedelic exposure): “In a few sentences, please explain 
why you decided to participate in an Experience Retreat?” 
Response Type 1: To deepen or expand relationship to (and awareness of) self, consciousness 
and reality (13 Subjects): 
1. I want to have a 'peek to the other side' and see what else there is outside of our material 
world. 
2. Curiosity about exploring consciousness. 
3. I'm hoping to get a better insight into my consciousness and discover my true nature. 
4. To aim to reach a state of deep connection with the world around me 
5. I would like to deepen my connection with my subconscious, my internal wiring, "bios". 
6. I want to gain new insights into myself and the world. 
7. Understand what is there, at the subconscious level. 
8. I want to explore my subconscious and see what messages and information I will receive 
from it (myself?). 
9. I feel like there is something hidden, that I can almost grab but not quite yet.  
10. I understand it can help with digging deeper into the psyche and becoming more aware in 
general.  
11. I'd imagine the psychedelic-experience could give me a new perspective on some things 
and I hope to learn a few things about myself. 
12. I wanted to understand better myself. 
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13. To explore consciousness in a different way. To explore past unpleasant events that 
negatively affect my life today 
14. I would like to have a bigger perspective on my life. And from what I've been reading, it 
helps with basic existential angst. 
Response Type 2: To address mental health concerns and improve psychological wellbeing (7 
Subjects) 
1. I have been dealing with a trauma from childhood. I want to understand how this 
resonates in my everyday life. I am in a healing process. This method, alternative to other 
that do not seem to fit me, seems to be the best to advance in my life. 
2. Mainly to help improve my mental health. 
3. I have been suffering from depression for many years, and I have been treatment 
resistant. I have been following the recent research about psychedelics and its effect on 
depression, and I want to try it for myself. 
4. I've experienced a depressive episode which prompted me to start psychotherapy. My 
therapist nudged me towards a retreat because she felt it might facilitate the process. I'd 
also independently been thinking about taking psilocybin, just not in a group setting. 
5. Understand what is preventing me from being connected to my emotions and the people 
around me.  
6. To understand why I am constantly wearing armor in an effort to be in control and 
successful. To experience a different way of being that I can strive towards consciously 
following the retreat. 
7. I decided to experience the effects on myself and see if I can overcome some problems I 
have been struggling with. 
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Response Type 3: To find purpose, meaning or direction in life (5 Subjects) 
1. In order to create a more intentional and meaningful life. 
2. I wonder if having this experience will help me to find my way and to understand my 
purpose in life as I am rather disoriented, jumping from one thing to another every few 
months. 
3. I want to understand why I am here and what I am doing with my life. 
4. I want to be guided to find a new personal or professional direction. I feel at a bit of a 
crossroads in my life and would like to find which path to take. 
5. Quite a pivotal time in my life with ending a long-term relationship and leaving my 
business. Intrigued about psychedelics and in the reading what they can offer. 
Response Type 4: Shift problematic thought patterns (4 Subjects) 
1. I also have some limiting beliefs/things that have held me back in my life, that hopefully 
the experience will help me learn from and move past. 
2. I would like to get past some habitual ways of thinking. 
3. I want to break old thinking patterns that I sometimes feel stuck to. 
4. To free myself from some stuck mental patterns. 
Response Type 5: Excitement, novelty, and exploration (4 Subjects) 
1. I want to have a new experience. 
2. Just to do something that seems very exciting. 
3. My constant curiosity to explore my physical as well as psychological boundaries. 
4. I am and always have been a very curious person. Psychedelic substances I think are 
really interesting. I read a lot of publications, watched documentaries, listened to peoples 
reports etc. So for a long time I wanted to try it for myself. 
 
 164 
Response Type 6: Self-improvement (2 Subjects) 
1. I've always had an interest in personal development, meditation and the human condition. 
Having read about the science behind psychedelic use as a therapy, I decided to explore 
this avenue. 
2. After hearing and reading a lot about psychedelics and the positive impact it could have 
on your life…I decided to come to the retreat. 
Question 2 (administered directly after psychedelic exposure): “Do you believe that taking 
psilocybin changed you?  If so, how?” 
Response Type 1: Deepened or expanded relationship to (or awareness of) self, 
consciousness and reality (4 Subjects) 
1. Opened me to the mysteries of an alternate realm. 
2. I think it put me into clear connection with the universe as a source of love, which is 
unforgettable and can be tapped into as and when I need it. 
3. Some of the immediate benefits seem to be understanding self as construct, as merely a 
play of the universe expressing itself through 'me' and translated through the brain as it 
has evolved to constrain 'reality' into workable constructs, to try to create a coherent 
narrative, of a consistent 'self', flowing in time. And the experience allowed me to see / 
experience that all those things are merely the construct of mind. Ultimate reality is not 
time-linear, has no sense of good or bad, self or non-self, inside or outside. It just is, and 
is not. So in that way it has given 'me' a new freedom. It is not that my self or ego has 
ceased to exist, but I can find space around it, see it as the functional play of existence. 
And, currently at least, I can still drop into the non-space where any construct of self, or 
any construct at all ceases to exist as a separate notion. 
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4. I also met several higher entities and had quite long interactions. Those messages are 
firmly in me to guide, drive and inspire me 
Response Type 2: Improved psychological wellbeing (4 Subjects) 
 
1. Have been more attentive, slower and calmer. 
2. I feel less threatened by the outside world and other people.  
3. I was able to release emotional pain and childhood/adolescent trauma that I did not 
realize I was still holding the weight of. It was immensely cathartic and in being able to 
release this emotional pain of the past as myself in the present, I feel I have been able to 
integrate and internalize my resilience as it relates to my trauma recovery much more 
fully than I had prior. 
4. I still feel very much myself but in a way so much more myself than before. 
Response Type 3: Greater acceptance, compassion and gratitude (3 Subjects) 
1. I am finding it easier to accept my self and others just as they are. 
2. I feel self-pride and greater compassion to myself as well as greater radical acceptance 
and peace towards my family trauma. 
3. I feel deep gratitude for my parents who loved me and have given me a good start in life I 
feel touched by all the people who've ever loved me I feel I have a permission to fully 
love myself I have an inexplicable feeling that "I've got it"; nothing in me or my life 
needs changing, and I can handle the challenges life throws in my way - and also accept 
that things aren't perfect and let that go and fade into the background and focus on the 
good I want to say "YESSS!" to life. 
Response Type 4: Greater openness (3 Subjects) 
1. I feel more open. 
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2. More open, aware, trusting. 
3. I feel more open (to experiences, to people). 
Response Type 5: Change that’s beyond words or outside the intellectualized realm (2 
Subjects) 
1. I feel something very deep inside me has been shifted. I haven't quite been able to make 
sense of it intellectually. 
2. I feel like I have experienced a profound truth, beyond words. And it feels to hold so 
much value beyond merely being an 'experience'. There was access to a wisdom beyond 
concepts. 
Response Type 6: Shifted problematic thoughts (1 Subject) 
1. Showed me I could be free of self-limiting beliefs. 
Response Type 7: Improved nature-relatedness (1 Subject) 
1. Opened me to the wonders of nature. 
Question 3 (administered one-month after psychedelic exposure): “When you look back on 
taking psilocybin, do you think it changed you?  If so, how?” 
Response Type 1: Greater acceptance, compassion and gratitude (5 Subjects) 
1. I feel like I have a greater reservoir of compassion, both for myself and for challenging 
dynamics I may encounter. Greater ability to radically accept challenging circumstances. 
2. I have a very great feeling of gratitude and have continued to do a gratitude journal. 
3. More grateful of what I have. 
4. I'd say as a whole I feel more at ease with the way things are in my life right know and 




5. I feel more forgiving towards myself and others. I feel I'm able to let difficult things be 
without having a compulsion to solve them or obsess about them; the good and the bad 
can co-exist peacefully. I'm more thankful for all the good that I have experienced, and 
all the love that I've received. 
Response Type 2: Improved psychological wellbeing (3 Subjects) 
1. After the retreat I had a lot less brain chatter - mind was generally calmer. This is less so 
now, but still a difference from before. 
2. I'm feeling less sad and lonely. I feel more connected with everything around me. I am 
less fearful of the future. 
3. I felt calmer and more present, though I feel the effects are wearing off. 
Response Type 3: Deepened or expanded relationship to (or awareness of) self, 
consciousness and reality (2 Subjects) 
1. It has changed my view on reality and myself, in profound ways that I can't really 
explain. 
2. It made me feel more definite about the other levels of existence. 
Response Type 4: Improved nature-relatedness (2 Subjects) 
1. Can easily tap into peace and comfort in being surrounded by nature, much more aware 
and appreciative of plants (trees especially). 
2. Yes, the connection between me, people and nature. 
Response Type 5: Improved meditation (2 Subjects) 
1. Feel like I have a more defined headspace to work towards when meditating.  
2. I find meditation much easier, less irritated and can relax into it much more. 
Response Type 6: Shifted problematic thoughts (1 Subject) 
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1. Some thought habits that often cause me distress have quieted down a little, but they are 
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